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ABSTRACT
The binding of two covalent minor groove binding ligands to duplex DNA has been 
investigated using high field 1H NMR and NMR/NOE refined molecular modeling 
techniques- Various duplex DNA strands were synthesised and then reacted with the 
covalent minor groove binding drugs SJG-136 and adozelesin. The drug-DNA adducts 
were analysed using 2D NMR techniques and the resulting data used to produce NOE 
distance refined molecular models.
SJG-136 is a synthetic dimeric covalent minor groove binder based on the PBD family 
of antitumour antibiotics. These ligands are isolated from various Streptomyces species 
and exhibit potent in-vitro and in-vivo activity. They are known to form inter-strand 
cross-links with duplex DNA by reaction with the cxo-cyclic NH2 group of guanine. 
Adozelesin is a covalent minor groove binding analogue of the CPI antitumour 
antibiotic (+)-CC-1065. The CPIs are known to alkylate duplex DNA by reaction with 
the N3 position of an adenine base, and owe their biological activity to an ability to 
block DNA replication.
Four novel ligand-DNA adducts have been produced and fully assigned using sequential 
assignment techniques. The NMR data collected has been used to confirm the sites of 
alkylation, orientation of the ligand residue and stereochemistry of the interactions. 
NOE distances are then used to produce accurate NMR refined molecular models of 
each adduct.
The 5W(CICGATCICG)2-SJG-136 adducjt was found to bind covalently to exo-cyclic 
NH2 groups on guanine bases of opposite DNA strands -  forming an inter-strand cross­
link separated by 4 base pairs. Stereochemistry was assigned as ‘S’ at both reaction sites 
and self complementarity and P-helical structure of the DNA duplex was maintained. 
Molecular models show minimal distortion throughout the duplex, with only a small 
localised area of distortion in the central base pairs as a result of drug binding.
The 5’d(CTCATCAC).(GTGATGAG)-SJG-l 36 adduct has been successfully 
produced, with alkylation sites confirmed as the exo-cyclic NH2 groups of two guanine 
bases on the same DNA strand. This represents the first identification of an intra-strand
cross-linked PBD adduct, generating an exciting new possibility involving targeting of 
the human telomere repeat sequence using PBD type ligands. Once again 
stereochemistry at the reaction sites is confirmed to be ‘S’ in both cases and the drug is 
found, as expected, to associate more closely with the modified DNA strand than with 
its complementary sequence.
A 5’</(CGATTAATCG)2-adozelesin mixed adduct has been generated, and found to 
contain a mixture of adducts in an approximately 50/50 ratio. One adduct has retained 
Watson-Crick base pairing within the DNA duplex, while in the second the central AT 
step had adopted a Hoogsteen conformation. In both adducts a significant overlap and 
stacking of the benzofuran subunits is observed. The discovery of novel ‘stacked’ 
adducts for CPI ligands suggests an alternative model for minor groove drug 
interactions and similarities can be drawn between the adozelesin stacked molecules and 
analogous stacking in the non-covalent minor groove binding lexitropsin drugs.
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CHAPTER 1: INTRODUCTION
1.1 Cancer and Chemotherapy
1.1.1: What is Cancer?
Cancer is a broad term encompassing up to 200 neoplastic diseases, and is characterised 
by the presence of malignant cells. It is defined as “any of various malignant neoplasms 
characterized by the proliferation of anaplastic cells that tend to invade surrounding 
tissue and metastasize to distant body sites”.1
In 2002 12.6 % of deaths in World Health Organisation member countries worldwide 
and 19.2 % of deaths in Europe were attributed to malignant neoplasms. As such cancer
n/4is the 2 major cause of death in Europe and throughout the world.
1.1.2: Causes o f Cancer
Many causes of cancer are attributed to the formation of cancerous cells. These include 
the inheritance of faulty genes, exposure to radiation or carcinogenic chemicals, viruses, 
and diet.
Carcinogenic compounds in the environment include asbestos, compounds of beryllium, 
cadmium, chromium, nickel, lead and arsenic, aromatic amines, amino azo-dyes and 
alkylating agents. Carcinogenic chemicals such as diethylamine are found in cigarette 
smoke and the mood altering tetrahydrocannabinol (THC) component of marijuana 
smoke has been found to increase DNA mutations by 300 %.4 Chloroform, a by-product 
of the chlorination of water, is also a carcinogen5,6 and drugs such as oral contraceptives 
have also been shown to increase the risk of breast cancer.7
Links between diet and cancer have been suggested numerous times through the media, 
with varying degrees of scientific evidence. Alcohol and foods contaminated with 
alfatoxins have been established as clear risk factors for some cancer sites. Excessive
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alcohol consumption is known to cause inflammation and cirrhosis of the liver -  leading 
to liver cancer.8 A high intake of red meat has been suggested to lead to an increased 
risk of cancer of the stomach, colon and rectum9 while a diet rich in fresh fruit and 
vegetables is thought to reduce the risk of cancer of the digestive tract and stomach. 
There are various suggestions that the replacement of saturated fats in the diet with 
unsaturated fats or olive oil also reduces the risk of cancer.
Exposure to ionising radiation has been related to the formation of some types of cancer 
and the exposure to UV light is well known to be responsible for a large number of skin
A
cancers, including malignant melanomas and basal cell and squamous carcinomas.
1.1.3: The Treatment o f Cancer
Treatments for cancer include surgery, radiation therapy and cancer chemotherapy.
The surgical procedure involves the removal of the tumour and sometimes the complete 
affected organ. The surgery is followed by treatments such as chemotherapy and 
photoradiation therapy in order to increase chances of survival by shrinking or killing 
any cancer cells that were not able to be removed. Surgery is really only effective when 
a tumour is in its early stages or has not metastasised.
Radiation therapy involves the use of radioisotopes such as cobalt-60 and X-rays to 
destroy solid tumours. Tumours can often be destroyed with little damage to the 
surrounding tissue but the use of the treatment is limited due to the carcinogenic nature 
of the ionising radiation used.
1.1.4: Cancer Chemotherapy
Cancer chemotherapy is available in many forms, including anti-metastatic agents, 
antimitotic agents, antimetabolites, monoclonal antibody therapy, gene therapy, and 
DNA targeted agents such as DNA intercalators and alkylators.
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Metastasis is comprised of growth and detachment from the primary site, local invasion 
and destruction of extra-cellular matrix, intravasation into blood vessels, survival in the 
circulation, extravasation from the vessels into the metastasis site and growth at the 
metastasis site.11,12 Anti-metastatic agents are agents that inhibit enzymes involved in 
these processes in order to prevent tumours from metastasising.
Antimetabolites interfere with cell division and the growth of tumours. An example is 
Methotrexate -  a dihydrofolate reductase (DHFR) inhibitor. DHFR is involved in the 
formation of tetrahydrofolic acid (FH4), which is required for the synthesis of DNA. 
Therefore this antimetabolite can prevent DNA synthesis and so lead to apoptosis.
Antimitotic agents are mainly naturally occurring compounds that prevent cell division 
and are therefore cytotoxic.
Monoclonal antibody therapy (MAB) is the use of highly specific antibodies to target 
cells. The treatment relies upon the stimulation of the patient’s immune system to 
prevent tumour growth by blocking specific cell receptors. Radioactive and chemical 
toxins can also be attached to these antibodies. These are activated at the site of action 
and so affect only tumour cells.10
Gene therapy and antisense technology are promising cancer treatments that act at the 
molecular level. Antisense technology uses oligonucleotide drugs to bind to target RNA 
sequences, blocking the production of specific proteins. Once bound, the antisense 
agent either disables or induces the degradation of the target RNA.13 Gene therapy 
involves the insertion of genes into cells and tissues of a cancer patient. It is possible 
that this could be useful in the reactivation of tumour suppressor genes in cancer cells 
where these genes have been deactivated.
1.1.5: DNA targeted agents
DNA targeted agents are drugs that target DNA in order to suppress or kill cancer cells. 
They include intercalating agents and alkylating agents. Both work by prevention of 
DNA transcription and replication. Examples of intercalating agents include
3
anthracycline antibiotics such as daunorubicin (daunomycin) and doxorubicin 






R = H Daunomycin 
R = OH Adriamycin
Figure 1: Chemical structure of two well-known anthracycline drugs
Alkylating agents are highly electrophilic molecules that react with nucleophilic centres 
of DNA bases -  such as oxygen and nitrogen atoms. The first example of a cancer 
chemotherapy agent was the use of the nitrogen mustard alkylating agents in the 
1940’s.15 An example of a drug with a similar mode of action is cis-platin (Figure 2).
Figure 2: Chemical structure of cis-platin
Although this is not strictly an alkylating agent it cross-links DNA and inhibits DNA 
replication in a similar manner to the alkylating agents. Alkylating agents are the focus
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of this project and so specific agents will be discussed in greater detail in subsequent 
sections.
1.2: Basic DNA Structure
DNA consists of a series of repeating units known as nucleotides. Each nucleotide 
consists of a DNA base (Adenine, Guanine, Cytosine or Thymine) attached to a 5- 
membered ribose sugar and joined to the next unit by a phosphate group. DNA bases 
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DNA backbone
Figure 3: Basic Structure of DNA showing backbone, bases and unique hydrogen bonding
The bases bind specifically (G to C and A to T) by unique hydrogen bonds as shown in 
Figure 3 to form the characteristic DNA double helix, a representation of which is 

















Figure 4: Representation of ^-helical DNA, showing the major and minor grooves
1.3: DNA interactive ligands
There are three possible sites on B-form DNA to which a molecule can bind -  the major 
groove, the minor groove or by intercalation between the bases. The major groove is 
deep and wide, lined with potential hydrogen bond acceptor atoms such as N7 of 
guanine and adenine, 04 of thymine and 06 of guanine. Hydrogen bond donor atoms 
also exist in the major groove in the form of the amino group at C6 of adenine and C4 
of cytosine.16 There are therefore a large number of potential hydrogen bond 
interactions. The major groove is also very accessible due to its width. As such this 
groove is often the site of choice for the interaction of many large proteins (such as 
transcription factors and enzymes). The depth of the major groove is conducive to small 
drugs binding but in practice the width of the site makes it unfavourable to many small 
ligands, particularly those with hydrophobic tendencies, which prefer a tighter fit into 
the DNA minor groove.
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The minor groove of p-helical DNA is deep and narrow, so enabling small drugs to fit 
tightly within the hydrophobic environment. A large surface area is available, with 
opportunities for stabilising hydrogen bonds as well as many Van der Waals forces for 
small planar molecules. Hydrogen bond acceptor molecules of the minor groove consist 
of N3 of adenine and guanine and 02 of cytosine and thymine. A possible hydrogen 
bond donor site is the amino group of guanine.
The most important factor to the achievement of sequence selectivity in the minor 
groove is the topology. “A tracts” in the minor groove give rise to very narrow grooves 
for a close complementary fit with the ligand, while GC regions can accommodate 
bulkier molecules.
Interactions with DNA can be both covalent and non-covalent. Classes of compounds 
reacting with DNA can be split into four main types:
1. Intercalators/6/s-intercalators such as Adriamycin and Z>/s-acridines.
2. Minor groove binders such as cyclopropapyrroloindoles (CPIs), 
pyrrolo[2,1 -c] [ 1,4]benzodiazepines (PBDs) and lexitropsins.
3. Major groove binders including many proteins.
4. DNA cleavage agents - an example of which is bleomycin.
1.4: Minor Groove Binding Agents
Reactions within the minor groove take place primarily by a nucleophilic mechanism. 





S ' (N7.06 bridge)
PBDs eg DSB-120/SJG-136
Figure 5: Schematic showing sites of nucleophilic reaction within the minor groove
Work in this project focuses upon the minor groove binders -  namely PBDs and CPIs, 
with reference to netropsin and the lexitropsins. There follows a review of the history of 
these compounds and their binding to DNA.
1.5: PyrroIo[2,l-c][l,4]benzodiazepines
1.5.1: History
The pyrrolo-[2,1 -c] [ 1,4]benzodiazepine (PBD) family are a series of potent antitumour 
antibiotics produced by various Streptomyces species. They were first discovered in
171965 when an antibiotic was isolated from Streptomyces refuineus, a thermophilic
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actinomycete by Leimgruber et ah18 The actinomycete had been shown two years earlier 
to produce a fermentation broth with antitumour activity.19
When characterised the antibiotic was found to consist of a tricyclic unit comprising a 
benzene ring, a pyrrole ring and a diazepine ring with a C ring substituent. The system 
bears a resemblance to anthranilic acid and so was named anthramycin and the new 
antibiotic group the pyrrolobenzodiazepines (PBDs). The structures of the naturally 
occurring PBDs subsequently discussed can be found in Figure 6.
Anthramycin was found to exhibit a remarkably potent antitumour activity20 and the 
subsequent interest in this class of antibiotics led to the discovery of many more PBDs 
in the following years. In 1972 tomamycin and sibiromycin were isolated from 
Streptomycin achromogenes var. tomamyceticus21 and Streptosporangium sibirium22 
respectively, although the suggested structure of sibiromycin was challenged and a new 
structure suggested in 1988.23
The next PBDs to be isolated were the neothramycins (A and B) in 1976.24 1980 saw 
the discovery of a similar PBD to Anthramycin, named mazethramycin.
Throughout the 1980s several more PBD compounds were isolated and characterised. 
These included prothracarcin,26 DC-81,27 chicamycin,28,29 abbeymycin,30
porothramycin31 and finally DC-102 (sibanomycin).32
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Figure 6: Chemical structures of the naturally occurring PBDs
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1.5.2: Mode of Action
The PBDs are natural antitumour agents, with their biological effectiveness stemming 
from the inhibition of nucleic acid synthesis by covalent attachment to double stranded 
DNA. Binding occurs deep in the narrow minor groove covering a 3 base-pair region 
and requiring duplex DNA and the presence of guanine. Due to the shape of the PBDs 
they cause minimal disruption to the DNA helix. On reaction with PBDs the DNA helix 
becomes less flexible and appears to be stabilised, shown by an increased melting point 
on formation of adducts.33'37
PBDs are named and numbered according to the system designed and utilised by 





Figure 7: Numbering system for the PBD subunit showing the ‘A% ‘B’ and ‘C’ rings19
Reaction with DNA is between the PBD-C11 position of the drug and the exocyclic 
NH2 group of guanine. The reaction site N10-C11 exists as either an imine, 
carbinolamine methyl ether or a carbinolamine form (Figure 8). The three forms are 
interchangeable and exist as a dynamic equilibrium, with the predominant species 
dependent on the compound structure, the synthetic work-up or the method of isolation. 
In a study involving anthramycin, tomamycin and the neothramycins38 the imine 








Figure 8 -  Interchangeable forms of the PBD subunit
1.5.3: Binding o f PBDs to DNA
All forms of the PBD subunit possess the ability to alkylate N2-guanine residues. 
Direct attack on the imine functionality as well as SN2-type mechanisms have been 
suggested for the reaction (Figure 9).39
The SN2 -  type reaction consists of a nucleophilic attack by the NH2 group of guanine 
on the carbinolamine or the methyl ether.40 Alternatively there is a possibility of direct 
attack on the imine species 41 It is however likely that the drug exists in the protonated 
form when present in the human body, so it is possible that the SN2 type reaction would 










Direct attack on imine
Figure 9: Two possible mechanisms for PBD adduct formation40,41
Molecular modeling of the PBD-DNA adducts predicts that the drug is completely 
submerged within the minor groove, following the right-handed contour of the B-DNA 
turn.33
1.5.4: Stereochemistry at the PBD chiral centres
In theory, the cxo-cyclic amino group can attack the PBD-C11 position from either side. 












Figure 10: Representation of the PBD subunit showing ‘R’ and ‘S’ stereochemistry
However, molecular mechanics calculations have predicted that the lowest energy 
conformation is the PBD situated in the minor groove as an 11 ’S’ isomer, with any side 
chain pointing toward the 5’ end of the modified strand.42,43,44 This has been confirmed 
by NMR experiments45 that show the drug to be held strongly in one orientation.
A second chiral centre exists at PBD-C1 la  and all naturally occurring compounds have 
been found to display ‘S’ configuration at this point. This has the effect of giving the 
molecules a right hand twist from the ‘C’ to the ‘A’ ring that allows them to fit snugly 
into the minor groove of right-handed B-form DNA, with racemization at Cl la  
significantly reducing the biological activity.38,46 Previous experimentation has 
predicted that the ‘S’ configuration is probably stabilised by hydrogen bonding 
interactions between the drug and the oligodeoxynucleotide.
1.5.5: Binding site preferences o f the PBDs
Foot printing experiments have shown that drug adducts of PBD compounds span three 
base pairs, with the following sequence preference: 5’Pu-G-Pu > 5’Pu-G-Py or 5’Py-G-
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Pu > 5’Py-G-Py.38,46,47 The rank order of DNA reactivity for natural PBDs is as follows:
iA
sibiromycin > anthramycin > tomamycin > DC-81 > neothramycin.
Although in general the PBDs react similarly with DNA some discrepancies have been 
noted. It was found that with anthramycin and tomamycin for instance, although the two 
drugs share one preferred binding site (-AGA-) they show different preferences when 
binding to other sites such as -GGC-, -GGG-, and -TGC-49 Many sites will bind to one 
drug but not to the other. DNA saturated with anthramycin has also been shown to still 
effectively bind tomamycin. This indicates that these drugs, although overlapping, also 
exhibit specific binding sites. Nearest-neighbour analysis of these adducts indicates that 
bases at the 3’ and 5’ sides of guanine are critical for the anthramycin and tomamycin 
binding process. It was found that G on the 3’ side is least favourable for tomamycin but 
favourable for anthramycin. Therefore there are common factors governing the binding 
of these drugs, but also factors that will affect them differently 49
1.5.6: Anti-tumour Activity
Anti-tumour activity of the PBD family has been shown against transplanted tumours 
including Ehrlich solid carcinoma, sarcoma 180, Human epidermoid carcinoma and 
Leukaemia L1210 cell lines.50,51 In the clinical use of anthramycin and sibiromycin the 
most responsive tumours are gastrointestinal and breast neoplasms, lymphomas and 
sarcomas, with the least responsive ovarian, pancreatic carcinomas and malignant 
melanomas. No evidence for bone marrow depression or gastrointestinal toxicity has 
been found.51 but members of the PBD group have displayed a dose-limiting 
cardiotoxicity similar to that observed with anthracyclines, adriamycin and 
daunomycin.53 It is likely that the mechanism for cardiotoxicity is the same for both 
anthracyclines and the PBD family despite their structural differences, as protective 
therapy used in conjunction with anthracycline treatment is also effective against 
anthramycin-induced cardiotoxicity. Tautomerization or oxidation of the PBD subunit 
as shown in Figure 11 will lead to ortho-quinone products and it is these that are 
thought to be responsible for the observed cardiotoxicity. This is supported by structure- 
activity relationships, as anthramycin and sibiromycin, which both possess oxygen at 




Figure 11: Postulated mechanism for quinoneimine formation39
1.5.7: Ring Substitution
Various studies have been carried out in order to determine the effects of substitution at 
the ‘A’ and ‘C’ rings of the PBD subunit. The importance of the ‘C’ ring for 
cytotoxicity was demonstrated as early as 198554 during an investigation into bicyclic 
analogues with only ‘A’ and ‘B’ rings, while ‘A’ ring substituents have been reviewed 
by Lown et al.55
It is thought that ‘A’ ring substitution (particularly oxy substituents at C8) might be 
involved in non-covalent binding with DNA through hydrogen bonding interactions 
with the minor groove.56 An extensive study into ‘A’ ring modifications was carried out 





Figure 12: Five ‘A’ ring modifications57
This study clearly demonstrated the importance of the ‘C’ ring for cytotoxicity, as none 
of the ‘A’ ring modified compounds containing a saturated and unsubstituted ‘C’ ring 
had cytotoxicities even approaching the level of the three naturally occurring ‘C’ ring 
unsaturated/substituted compounds (Figure 13).
Molecular modeling investigations into the modification of the ‘C’ ring suggested that 
C2 endo or C2 exo unsaturation leads to a flattening of the ‘C’ ring, and hence a more 
comfortable fit in the minor groove.57 From the ‘A’ ring modifications it was found that 
an ‘A’ ring electron donating substituent is not a prerequisite for binding, but can 
influence binding affinity and cytotoxicity. Modeling of dioxazole and dioxazine 
analogues suggests that the extra rigidity introduced by the new rings may cause steric 
interactions with functional groups on the opposite minor groove walls, while C7 
methoxy/C8 hydroxy substitution in DC-81 renders the molecule more flexible and 
allows for more pivoting -  giving a better minor groove fit. Neither aza substitution of 










Figure 13: Three naturally occurring ‘C’ ring unsaturated/substituted compounds
Further investigations into A ring modification were conducted in 2001 when a new 
7,8-methylenedioxy analogue of (+)-porothramycin B and its water soluble sodium 
bisulfite derivative (Figure 14) were shown to exhibit high cytotoxic activities against 
several tumour cell lines.58 Investigation was carried out by Baraldi et al into synthesis 
of a pyrazolo[4,3 -ejpyrrolo[ 1,2-a]diazepinone tricyclic system (Figure 14).59
<
N(Me)-
Methylenedioxy analogue: X=OMe 




Figure 14: Bisulfite derivatives and the pyrazolo [4,3-e]pyrrolo[ 1,2-a]diazepinone tricyclic
system57,59
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The rationale behind this design was to achieve a possibly higher binding affinity and 
modified sequence selectivity from the presence of potential new hydrogen bonds 
between the ‘A’ ring atoms and the DNA bases, as well as reduced cardiotoxicity due to 
the impossibility of the C9-quinone formation suggested to occur in the case of 
anthramycin. The findings from this study suggested that the presence of an 
unsubstituted imine function at N10-C11 is required for cytotoxicity, and for maximum 
cytotoxicity the pyrazole ring should preferably be substituted with a benzyl group at 
N7 and a methyl at C8. However, all of the analogues synthesized were significantly 
less potent than the PBD reference compounds. There was a relative loss of cytotoxicity 
overall when compared with DC-81 and this suggests that this type of modification to 
the ‘A’ ring may not be suitable for the enhancement of cytotoxicity. A significant 
difference in cytotoxicity between DC-81 (IC50 = 0.38mM) and tomamycin methyl 
ether (IC50 = 0.012mM) has also been noted elsewhere59 and this, coupled with earlier 
‘C’ ring observations, suggests that the ‘C’ ring of the PBDs is perhaps more important 
with regards to cytotoxicity.
1.5.8: PBD Dimers
There has been increasing interest in bifunctional alkyating agents, forming inter-strand 
cross-links in the minor groove of DNA. These cross-linking agents are highly 
cytotoxic, possibly due to cross-links challenging cellular repair mechanisms60 or agents 
targeting genes associated with cell growth.61 Molecular modeling has shown covalent 
interaction of dimers within the minor groove to be twice that of the monomers, 
highlighting their difunctional character and the tolerance to the central linker.62
The first cross-linking agent was reported in 1991 by Suggs et a l63 It consisted of two 
unsubstituted PBD units linked through their C7 positions and is shown in Figure 15.
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1st PBD Dimer - Suggs etal, 1991
OMe MeO
DSB-120 - Thurston etal, 1992
SJG-136 - Thurston et al - 2001
Figure 15: PBD Dimers®’64’62
The C7 linked dimer displayed poor DNA cross-linking activity and there was no 
evidence for cytotoxicity. In 1992 a C8 linked dimer of DC-81 known as DSB-120 was 
synthesized by Thurston et al (Figure 15).64,65,66 DSB-120 showed efficient cross- 
linking activity and is a very potent cytotoxic agent. Gel electrophoresis and thermal 
denaturation studies show that DSB-120 has a high affinity for DNA, forming 
irreversible symmetrical inter-strand cross-links between the spatially separated guanine 
N2 atoms on opposite DNA strands.67 Due to the design of the duplex sequences 
however, it was not possible for the PBD to form an intra-strand link and so this 
possibility has not been previously investigated.
Molecular modeling and NMR studies indicate that DSB-120 covers a six base-pair 
region in the minor groove, showing a preference for base sequences 5’-Pu-GATC-py 
or S’-Py-GATC-Pu.67 A two step mechanism for the cross-linking is suggested and is 
shown schematically in Figure 16.67
5'-CICGXXCICG 5'-CICGXXCICG _ , 5'-CICGXXCICG
1 s t arm | 2nd arm |___




Figure 16: Suggested two-step cross-linking mechanism. 
Reproduced from Thurston et o f1
However, although DSB-120 was a very potent cytotoxic agent in vitro, it proved to 
have poor in vivo antitumour activity. Its low therapeutic index was thought to be partly 
due to reaction with molecules containing thiol, causing much reduced reaction at the 
tumour site.69,72 As a result of these problems a new exo-unsaturated analogue called 
SJG-136 was synthesised (Figure 15).62 The design of SJG-136 was based on the fact 
that PBD monomers with unsaturation at the C2 position are known to be more 
biologically potent - possibly a result of the C2-exo unsaturation leading to lower 
electrophilicity at the N10-C11 position.72 SJG-136 has proved to be a highly efficient 
stabilising agent for double stranded calf thymus DNA, proving more than 10-fold more 
efficient than DSB-120. Molecular modeling shows that the SJG-136-DNA adduct 
maintains the B-form structure of the duplex, with little or no disruption of the 
secondary structure. Both SJG-136 and DSB-120 are well accommodated in the minor 
groove, with little exposure beyond the DNA periphery. This leads to the observed 
resistance to repair enzymes, which are thought to be reliant on tracing distortion or 
helical perturbation in DNA. The calculated binding energies showed that PBDs with 
unsaturated ‘C’ rings formed more favourable adducts. Introduction of an exo-cyclic 
methylene at C2 causes stiffening of the ‘C’ ring, making it more planar and providing a 







Figure 17: The fit of a PBD subunit within the minor groove 
Reproduced from Thurston et o f3
The linker itself was also found to make favourable contacts with the floor and walls of 
the minor groove. SJG-136 displays high in vitro cytotoxicity in cis-platin resistant cell 
lines, with an IC50 = 2.25x1 O'5 M. This is the lowest IC50 value for any PBD monomer 
or dimer. The failure of DSB-120, as mentioned, was believed to be due to an 
interaction with glutathione or thiol containing proteins.69 SJG-136 appears unaffected 
by high cellular GSH levels and so is expected to perform better. SJG-136 also exhibits 
a broad spectrum of in vivo antitumour activity, showing high efficacy in tumour 
xenograft models including melanoma, ovarian carcinoma, breast carcinoma or 
melanoma, colon carcinoma, promyelocytic leukaemia, and non-small cell lung 
carcinoma.70 In addition, this versatile dimer, along with several analogues has been 
shown to possess antibacterial activity against MRSA, VRE and mycobacteria, with 
activity thought to stem once again from the covalent cross-linking of the DNA 
duplex.71
1.5.9: Effects o f linker length in PBD dimers
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Studies have been undertaken into the effect of linker length in dimers of both the 
saturated and the unsaturated type.65,73 This involved syntheses of homologous series of 
C8  linked bifunctional DNA alkylating agents with varying linker length, and study of 
their cross-linking efficiency and cytotoxicity (Figure 18).65’73
(CH2) n^  
OMe MeO
3a - 3d n=3-6
4a n=3,4b n=5
Figure 18: Series of C8-linked bifunctional DNA alkylating agents with varying linker
lengths65’73’74
Linkers with an odd number of carbon atoms (n=3, n=5) were found to have a similar 
cross-linking efficiency, while those with an even carbon chain were up to 18-fold less 
efficient. This reflects the difference in ability of the compounds to stabilise the DNA 
double helix coil transitions. In the saturated series 3a-3c the three carbon linker 3a 
(DSB-120) appeared to bind more tightly to double stranded DNA than the five carbon 
(3c) compound. This was in contrast to the unsaturated 4a-4c series, where lengthening 
of the - 0 -(CH2)n-0 - linker from three to five effected an unexpected enhancement of 
DNA reactivity and in vitro cytotoxicity. The cross-link potency is increased around 10- 
fold for 4c relative to 4a, in stark contrast to the 3a-3c series, where the increase of the 
carbon chain from three to five somewhat reduced the cross-linking potency. In vitro 
cytotoxicity was also significantly higher in 4b than for the three-carbon linker 4a. 
Enhancement of activity in individual cell lines ranged from around 30-fold (melanoma) 
to greater than 3000-fold in ovarian cancer cells. This increase in activity was again
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unmarked in the 3a-3c series. Molecular modeling has helped to explain this behaviour 
in terms of a superior isohelical fit of the C2-exo-methylene substituted ‘C’ rings within 
the minor groove, such that the steric crowding between the groove walls and the ring
TXC2 proton of the saturated analogues is avoided.
In a related study a series of radio-labelled oligonucleotides were synthesised to enable 
the comparison of reactivity and cross-linking efficiency within the varying linker 
lengths. 72 The oligonucleotides synthesised are shown in Table 1.
Oligonucleotide Structure General Structure
Oligo-1 5,-(CIC-GATC-ICG) 2 Py-G-Pu
Oligo-2 5,-(CIC-GTAC-ICG) 2 Py-G-Py




Table 1: Series of radio-labelled oligonucleotides synthesised for comparison of reactivity 
and cross-linking efficiency for varying linker lengths74
Denaturing polyacrylmide gel electrophoresis techniques74 showed Oligo 1 to be cross 
linked around 2 fold more efficiently than Oligo 2, and Oligo 3 showed a preference for 
cross-linking greater than Oligo 1 confirming the 5’Pu-G-Pu > 5’-Py-G-Py ranking 
predicted by DNA footprinting and molecular modeling. This behaviour is due to 
favourable hydrogen bonding between the N10-H10 proton of each bound PBD moiety 








Figure 19: Sequence selectivity due to covalent bonds and hydrogen bonds 
Reproduced from Thurston et al73
As in the earlier study, compounds with an odd numbered linker (n=3, n=5) proved to 
have a much greater cross-linking efficiency than the even. There was significant 
correlation between DNA binding affinity, cross-linking efficiency and cytotoxicity, 
and the three carbon linked PBD proved to be 300-fold more efficient at cross-linking 
DNA than the clinically used minor groove binding cross-linking agent melphalan.
It was found that the n = 3 homologue preferred a 5’-GATC- sequence but could not 
tolerate an additional base pair between the two guanines, whereas the n = 5 dimer
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could cross-link both the 5’-GATC- site and the longer 5’-GAATC- site by adoption of 
a folded linker conformation. Molecular modeling showed that only the n=3 and n=5 
dimers were able to form energetically favourable adducts, with the reactivity dictated 
by the spatial distribution of the PBD subunits. In the case of the even homologues the 
unfavourable energy terms are a consequence of poor geometry in the diether linkage, 
leading to a distortion of the host DNA and a poor conformation adopted by the bound 
ligands. 72 Models of the n=5 dimer showed the linker group held snugly against the 
hydrophobic walls of the DNA minor groove in the case of the longer sequence, but 
partly displaced away from the helix and compacted by internal conformational rotation 
to achieve cross-linking with the shorter 5’-GATC- tract.73
As with the mono-alkylating PBDs, it is believed that the stereochemistry at the PBD-
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C ll link preferably exists in the ‘S’ configuration. Attempts at molecular model 
refinement with ‘R’ stereochemistry lead to destabilization of the cross-linked adduct 
resulting in disruption of the base pair associated with the covalently modified guanine. 
This caused the complimentary base cytosine to uncouple from the stacked helix and 
become displaced into the minor groove with an energetically unfavourable distortion of 
the local DNA backbone.67 Modeling with the ‘S,S’ stereochemistry produced stable 
adducts which retained general B-type DNA integrity, and accommodated all NOE data. 
This is reminiscent of the PBD-C11 ‘S’ stereochemistry of a 2:1 anthramycin-DNA 
complex confirmed by X-ray crystallography.41 For this complex, formation of ‘R’ 
stereochemistry again lead to distortion 41
1.5.10: Summary
The PBDs are an interesting and versatile group of DNA alkylating agents with 
relatively simple structures. They react covalently with the NH2 group of a guanine 
DNA base and thereby inhibit DNA transcription. PBD dimers have been well 
researched and are capable of forming inter-strand cross-links with duplex DNA. To 
date no previous evidence has been found for either mono-adducts or for the intra-strand 
cross-linking mechanism discussed in this project.
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1.6: The Cyclopropapyrroloindoles (CPIs)
Cyclopropapyrroloindoles are a class of drugs containing the DNA alkylating 
cyclopropa[c]pyrrolo[3,2-e]-indole-4[5i/]one subunit. The entire class shows 
exceptional antitumour activity, deriving their biological effects through sequence 
selective DNA alkylation. 75' 77
1.6.1: History
(+)-CC-1065 was the first CPI to be discovered, isolated from Streptomyces zelenis by 
the Upjohn Company in 1978.78 It consists of three subunits with the CPI moiety in 






Figure 20: (+)-CC-1065, highlighting the CPI subunit
The curved shape of this drug facilitates association with the minor groove of B-form 
duplex DNA and due to its DNA binding ability it was found to be a potent antitumour
70antibiotic. ’ It was discovered that the CPI subunit alone contained enough 
information to encode for sequence selectivity and produce bending of DNA81 while
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additional substituents on the non-alkylating subunits serve to fine-tune sequence 
selectivity and produce DNA winding.81’82
Despite the high potency of (+)-CC-1065, development of this drug was abruptly 
terminated on the discovery of an unusual hepatoxicity that caused delayed lethality in 
mice at sub-therapeutic doses.83 It was later confirmed that the cause of the delayed 
death was associated with the ethano bridges of the non-alkylating subunits, and these 
were also proposed to be responsible for the winding of the DNA in the drug-DNA 
adducts. 84 Accordingly, new analogues of the drug including adozelesin, bizelesin and 
carzelesin (Figure 21) were synthesised in order to attempt to combat the delayed 
lethality problems associated with (+)-CC-1065.85,86 These compounds will be 
discussed in further detail in a subsequent section.
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Figure 21: Chemical structures of carzelesin, bizelesin and adozelesin
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1.6.2: Mode of Action
In analogy with the DNA minor groove binders netropsin and distamycin, (+)-CC-1065 
exhibits a right handed twist along its axis.87 The hydrophobic groups are situated on the 
concave side of the molecule and experience favourable interactions with the minor 
groove while the hydrophilic groups are found on the convex side of the molecule.
Early research into the sequence specificity and mode of action of (+)-CC-1065 
concluded that cytotoxic effects are mediated via DNA synthesis79 and that the drug 
binds covalently to DNA within the minor groove. 88
(+)-CC-1065 reacts with double stranded DNA through the N3 position of adenine to 
form a covalent adduct that overlaps a five base pair region in the minor groove. 88-90 It 
shows a high sequence selectivity for AT regions, reacting preferably with 5*- 
PuNTTA* and 5’-AAAAA* , 91 and showing an absolute requirement for an adenine at 
the 3’ end.91 The reaction of the drug with DNA is thought to be a multi-step process 
with non-covalent interaction through hydrophobic and Van der Waals forces between 
the ‘B’ and ‘C’ units with the minor groove preceding covalent bonding with the 
alkylating subunit ‘A ’ .92,81
(+)-CC-1065 and adozelesin both exist as cyclopropyl drugs, and the mechanism of 
reaction proceeds via nucleophilic attack on the cyclopropyl ring by the N3 of an 
adenine nucleotide to form a DNA adduct with ‘S’ stereochemistry at the C4a centre, as 
shown in Figure 22. Bizelesin exists in a slightly less active chloro-methane form, 
which requires activation prior to reaction with DNA. Activation proceeds via 
deprotonation of the phenol group in aqueous conditions as shown in Figure 22 and is 
hastened by addition of sodium carbonate. Carzelesin exists as an inactive prodrug as 
shown in Figure 21. Activation is effected by hydrolysis of the phenylurethane 
substituent to a chloromethyl phenol, followed by a ring closing step to produce the 
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Figure 22: Activation of carzelesin and bizelesin followed by general CPI reaction mechanism
Important structural attributes of (+)-CC-1065 were investigated by Warpehoski et a l93 
A series of (+)-CC-1065 analogues were synthesised in order to investigate structure- 
activity relationships and it was found that;
1) An acyl substituent located on the pyrrolidine nitrogen of the CPI optimises 
reactivity to acid catalysed nucleophilic attack,
2) The ring size of the ‘B’ subunit is important for DNA binding -  a five 
membered ring heteroaroyl substituent attached to the CPI permits binding to the 
DNA helix
3) Extension of the amide-linked indole chain enhances DNA interaction.
The delayed hepatotoxicity of (+)-CC-1065 discussed previously is thought to be caused 
by the ethylene bridge moieties of the ‘B’ and ‘C’ subunits, which inhibit helicase- 
mediated unwinding, ultimately causing over-winding of the DNA helix.83,94,75
In order to investigate non-covalent versus covalent interactions, analogues of (+)-CC- 
1065 were synthesised by Hurley et alu  (Figure 23). These were compared to (+)-CC- 
1065 with respect to sequence specificity and biological potency of the covalent and 
non-covalent interactions.
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Figure 23: Analogues of (+)-CC-1065 synthesised by Hurley et a tx
The results of this investigation confirmed that biological potency was linked to the 
alkylation of DNA, It was found that an analogue of (+)-ABC minus the cyclopropyl 
ring did not bind to DNA, therefore implicating the cyclopropyl ring in the binding 
mechanism. Studies using (+)-A and (+)-AB showed that the ‘B’ and ‘C’ subunits 
increased the rate of alkylation at specific adenines. All analogues showed an equal 
sequence specificity in adduct formation, suggesting that it was the DNA base sequence 
that was responsible for the reactivity of adenines to the CPI subunit, as opposed to 
interactions with the ‘B’ and ‘C’ subunits. These subunits were instead suggested to 
have a role in the stabilization of non-covalent bonding and possibly the fine tuning of 
the sequence selectivity prior to alkylation.
This view was challenged in 1990 when Boger and co-workers proved that biological 
activity was not dependent on electrophilic reactivity.95,96,97 It was found in these studies 
that the rate of DNA alkylation and the cytotoxic potency were inverse to the 
electrophilic reactivity. The ‘B’ and ‘C’ subunits were now thought to play a large role
in sequence selectivity through non-covalent binding, preferentially in an AT-rich minor 
groove environment.
Analysis of the 5V(CGCGGAGTTA*GG)-(+)-CC-1065 adduct by NMR98 using 170- 
labelled water and phosphate resulted in the incorporation of two water molecules into 
the alkylation reaction pathway. The first bridges the O-phenolic proton of the CPI 
subunit to the anionic oxygen of the phosphate two bases in the V  direction of the 
thymine residue of the covalently modified base pair. The second is found to be 
hydrogen bonded to the alkylated adenine. Both molecules are thought to be involved in 
the mechanism of covalent bond formation due to their prolonged dwelling times. The 
involvement is thought to involve acid catalysed activation of the CPI subunit in the 
reaction of N3 of adenine.
Studies have been carried out into the extent of drug induced DNA strand damage by 
(+)-CC-1065 using adducts with the Simian virus 40 (SV40) DNA molecule." It was 
thought that the accessibility of cellular DNA to the action of (+)-CC-1065 might be 
limited by the protein components of cellular chromatin, or by other factors such as cell 
and nuclear compartmentalization. It was found that the pattern of (+)-CC-1065 adduct 
formation in SV40 infected BSC-1 cells is almost the same as that observed with the 
purified SV40 DNA molecule. However there is a requirement for higher drug levels in 
the binding to infected cells, and it is thought that uptake parameters may be the reason 
for this reduced efficiency in adduct formation.
In CPI-DNA adducts the DNA duplexes are extremely stable and it was originally 
proposed that due to this stability the adenine existed in a neutral state with the 
possibility that an imine form was present. However, further calculations100 showed that 
a positively charged form could also exist in DNA, and *H and 15N NMR of the (+)-CC- 
1065-(15N6-adenine)-DNA adduct settled upon a final structure in which the adduct 
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Figure 24: Mesomers of adenine in its amino form, showing the major species
1.6.3: Inter-strand cross-links o f (+)-CC-1065
Despite the fact that (+)-CC-1065 is established to be a mono-alkylator hypotheses have 
been formulated around the possibility of enzyme-activated inter-strand cross-link 
formation with this drug. It was thought that the drug might undergo metabolic 
activation by cellular enzymes and so be able to form an additional covalent bond with 
DNA. Experimentation revealed that inter-strand cross-linking was indeed observed for 
(+)-CC-1065 in the cellular system. No cross-linking was seen when the drug was 
added directly to cellular lysates with inactivated enzymes, supporting the theory of 
enzymatic activation. The reactive part of the parent drug is the cyclopropyl ring. This is 
the site of monoalkylation with the second site required for a cross-link generated by 
activation of one of the two available o-methoxy phenol groups. o-Methoxy-phenol 
groups are present in a variety of biologically active compounds and a possible pathway 
of metabolic activation is shown in Figure 25. A second mechanism was also proposed 
in which the activated indole moiety of (+)-CC-1065 reacts with 5,6-dihydroxy or 5,6- 








Figure 25: Possible pathway of metabolic activation for 0-methoxy-phenol groups103
1.6.4: Adozelesin
Adozelesin was the first of the new generation analogues and is shown in Figure 21; 
like (+)-CC-1065 it is overall right-handed and mimics the pitch of B-form DNA. This 
characteristic allows it to fit snugly in the minor groove of DNA with a high recognition 
for its binding site, showing a sequence preference of 5’-Pu,Py/Pu,TTA* (where the 
asterisk shows the site of covalent modification) . 91 The adozelesin duplex adduct was 
reported by Cameron and Thompson; 104 experiments were performed using a single 
palindromic DNA duplex containing two identical adozelesin binding sites, namely 
5,d(C1G?T3A4A 5G6C7G8C?r10T11A 12C13G14)2. The adozelesin residues bound to the 
A12 nucleotide in an edge-on orientation in the minor groove, and traditional Watson- 
Crick base pairing was maintained. Significant hydrogen bonding was found to exist 
between phenolic protons and the phosphate backbone, shown by the chemical shift of 
the phenol of the CPI subunit. 104 A strong hydrogen bond was also formed between the
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NH proton of the amide linker between the indole and benzofuran subunits and a 
thymine (T10) on the modified strand (Figure 26). This hydrogen bonding is much 
stronger than the hydrogen bonding between the phenolic protons and the phosphate 
backbone but surprisingly causes much less detectable distortion throughout the 
molecule. However some distortion was seen around the central guanine (G6 ), which 
appeared to have adopted a less favoured CV-endo conformation whilst the other 13 
base pairs remain in the more commonly observed anti configuration. This provides 
additional hydrogen bonding opportunities between the ligand and the duplex.
As with (+)-CC-1065, adozelesin owes its biological activity to the ability to block 
DNA replication. It has been suggested that this inhibition occurs via a trans-acting 
mechanism through cellular damage response pathways or checkpoints, rather than by 
directly blocking DNA replication, and subsequent experimentation105 has shown that 
the replication is inhibited through the inactivation of human replication protein (RPA) 
-  a major eukaryotic single-strand DNA binding protein required for DNA replication, 
repair and recombination. 106
Adozelesin had high potency and showed good preclinical activity against murine and
107 10fthuman tumour models. ’ As discussed above studies on the 
5 V(CGTAAGCGCTTACG)2-adozelesin adduct104 showed significant hydrogen 
bonding that suggested that the binding mechanism for adozelesin was significantly 
different to (+)-CC-1065, possibly resulting in an inability of adozelesin to overwind 
DNA, and this drug has shown no sign of the delayed toxicity that halted the 
development of (+)-CC-1065. However, in clinical trials the drug proved to have only 
marginal efficacy, showing dose-limiting toxicities of myelosuppression with 
thrombocytopenia and leukopenia. 109
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Figure 26: Schematic representation of adozelesin accommodation in the minor groove of B-form DNA, 
showing potential hydrogen bonds between the drug and the DNA bases.
1.6.5: Bizelesin
Bizelesin is a synthetically derived bifimctional DNA cross-linking agent designed and 
synthesised by Upjohn scientists. 110 It is an analogue of (+)-CC-1065, containing two 
open cyclopropyl ring analogues of the CPI subunit, which are connected by a rigid 
linker consisting of two indole units joined by a ureadiyl linker (see Figure 21). The 
drug once again reacts through the N3 position of adenine in the minor groove, to form 
inter-strand cross-links with adenine residues, generally six base pairs apart. 111 The 
sequence specificity of bizelesin was studied using restriction enzyme fragments. 112 In 
this experiment a higher than expected proportion of cross-linked vs mono-alkylated 
adducts was seen, and this was rationalized on the basis that the thermodynamic 
stability of the cross-linked adduct is higher relative to the mono-alkylated species. 
Bizelesin GC tolerance was also twice as high at the cross-linking sites than for the 
mono-alkylated species. This is due to increased reactivity at normally non-reactive 
sites, caused by covalent immobilisation of the drug leading to close proximity of the 
second alkylation arm. Where bizelesin mono-alkylation occurred the drug appears to 
show an increased sequence selectivity relative to the mono-alkylating analogues. 111 
The most preferred sequence for bizelesin is known to be a six base-pair region -  
5’TAATTA*-3’ , 113,114 mimicking the preference of the mono-alkylating drug (+)-CC- 
1065. On reaction of bizelesin with this sequence two adduct conformations are 
present, both with unusual base pairing within the central AT bases. 115 The adduct exists 
as 40% with base pairs in an open conformation, while the remaining 60% is Hoogsteen 
base-paired as shown in Figure 27. The origin of this unusual base pairing is possibly 
due to low base pair stability in this particular sequence. It is possible that bizelesin 
traps out and stabilises Hoogsteen and open base pairs prior to cross-linking.
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Figure 27: Hoogsteen and Watson-Crick base pairing in DNA bases
The second preferred cross-link sequence is 5’-TTTTTA-3’, and binding of (+)-CC- 
1065 and bizelesin to this sequence was examined by high field NMR and PAGE 
experiments using a 5’J(CGTTTTTACG).5W(CGTAAAAACG) duplex. 1 1 6 " 7 DNA 
containing ‘A’ tracts has been shown by techniques such as gel electrophoresis, electron 
microscopy and X-ray crystallography to contain an unusually narrow minor groove 
which is intrinsically bent. 118' 126 On reaction with (+)-CC-1065 the bent duplex is 
observed. However, on reaction with bizelesin the bending is eliminated. This supports 
the theory for origin of ‘A’ tract bending shown by UV and CD spectroscopy, 127,128 in 
which it is suggested that both straight and bent forms exist in equilibrium, and the 
degree of bending depends on the position of this equilibrium. In this experiment it has 
been observed that (+)-CC-1065 freezes out the bent conformer while bizelesin entraps 
the straight one. On formation of the inter-strand cross-link with bizelesin A8  and A18 
are modified (Figure 28).129 Relative Molecular Dynamics studies performed on the 
linker within the bizelesin-5 ’ -TTTTTA*-3 ’ adduct also show the linker oscillating 
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Figure 28: Formation of inter-strand cross-link via modification of A8 and A18129
As discussed in section 1.2.2, bizelesin is supplied as a less active chloro-methane 
species and undergoes activation prior to reaction with DNA. Post-activation 
modification of the DNA duplex by bizelesin occurs by attachment once again through 
position N3 of adenine and the ligand is again orientated end on in the minor grove. In 
this ‘A’ tract adduct there has been no evidence for unusual conformations - Watson- 
Crick base pairing is maintained throughout. This supports the above-mentioned 
hypothesis for low base pair stability, as the ‘A’ tract sequence is relatively stable 
compared to the 5’-TAATTA- duplex. As noted with (+)-CC-1065, in the case of the 
‘A’ tract sequence both covalently modified adenine residues exist in a doubly 
protonated form. The trapping of straight DNA is potentially useful as a probe to 
evaluate the importance of intrinsic bending or protein induced bending in 
transcriptional or replication elements.
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Molecular modeling and gel electrophoresis experiments have indicated that bizelesin is
• 19Qmost suited to cross linking two adenines spaced six base pairs apart. However, a 
third cross-link type has also been reported in which bizelesin was noted to span a total
• • • 129of seven base pairs, sometimes in preference when a six base-pair site was available. 
Experiments were carried out using both 5’-TTAATTA-3’ and 5’-TTAGTTA-3’ 
sequences, and it is the presence of the -GC- base pairs in the centre of the sequence 
that provide the key to seven base pairing preferences. In the first sequence the six base 
pair site is favoured whereas in the sequence containing the GC base pair, distortion 
around the covalently modified adenine leads to a reduction in distance thus allowing a 
highly favoured seven base pair extended cross-link site. The covalently modified 
adenine is pulled toward the centre of the duplex resulting in a high degree of propeller 
twist and loss of hydrogen bonding into the phosphate backbone. The exocyclic 2-amino 
group of guanine in the minor groove facilitates this distortion by the formation of a 
stable hydrogen bond between the carbonyl of the ureadyl linker and the exo amine 
group of guanine. Replacement of this central guanine group by inosine leads to the 
formation of approximately equal amounts of six and seven base pair links. In view of 
the association of the central guanine with sites on the linker, it would be possible in 
theory to change linkers in order to change sequence specificity and reactivity.
Although bizelesin alkylates DNA with a similar sequence preference to adozelesin, it 
has been shown that different biological responses are affected by this induced 
damage. 130 Both bizelesin and adozelesin inhibit DNA replication but while adozelesin 
induces this affect by a decrease in functional RPA105 bizelesin inhibits replication 
through induction of a replication inhibitor. 131 At equi-toxic concentrations adozelesin 
and bizelesin induce different cellular responses, with adozelesin inducing an ‘S phase’ 
slowdown preceding apoptosis while bizelesin induces cell cycle arrest in the ‘G2-M 
phase’ through activation of p53 and p21 pathways and cellular senescence. These 
differences are thought to be due to the type of lesion and the extent of the damage -  
adozelesin may more extensively damage DNA and cause apoptosis, while the fewer 
but more cytotoxic bizelesin double strand breaks lead to cell cycle arrest. 130
As with (+)-CC-1065 experiments were carried out into the effects of bizelesin on 
genomic DNA of BSC-1 cells as well as intra-cellular and purified Simian virus 40
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(SV40) DNA. 132 It was shown that drug bonding sites were fewer for bizelesin than for 
(+)-CC-106599 but similar regions of the SV40 genome were affected by both drugs. 
Lesions induced by bizelesin also proved 100 times more cytotoxic than those induced 
by (+)-CC-1065. Similar regions of the genome were damaged in both intra-cellular and 
purified SV40 DNA systems, confirming that the chromatin structure of the intra­
cellular DNA does not alter the localization of the bizelesin bonding. Once again 
however, the drug concentrations required to produce damage in the intra-cellular DNA 
are higher than for purified SV40 systems, suggesting as before, a limited accessibility 
into the cell.
Investigation has been carried out into the possibility of region-specific damage to ‘AT
i 'i'5islands’ by bizelesin. Long range in silico analysis shows that at the genomic level 
the bizelesin binding motif is found on average 2.8 times per 250 base pairs. However 
there is a regular occurrence of AT-rich hot spots appearing approximately every 106 
base pairs, in which up to 99 binding sites are found per 250 base pairs. These are 
known as ‘AT islands’ and in models they have proved to be 100-fold more active than 
non-AT islands and relative to these AT rich sites the short AT tracts are unlikely to be 
significant as a bizelesin target. One attribute of an AT island domain is a high Matrix 
Associated Region (MAR) potential. MAR domains are a specialized loci that anchor 
cellular DNA to the nuclear matrix134' 137 and are the site of DNA replication and 
transcription. 134,136"140 Therefore bizelesin-induced damage to MAR-like AT islands 
may explain the observed specific inhibition of replication. 141,131 There are many 
potential therapeutic benefits associated with the targeting of AT islands. Certain 
abnormal AT islands are thought to contribute to tumourigenic phenotypes142 and AT 
island targeting may offer increased selectivity. Also, tumour cells divide rapidly and so 
should be preferentially eliminated by highly localized lesions in replication-related 
regions such as MAR-like AT islands. Adozelesin also shows some preference for AT 
islands but there is substantial binding outside these regions. This shows that sequence 
specificity alone is not sufficient to induce region specificity. The oligopeptide 
antibiotic tallimustine exhibits a preference for 5’- l 11 l ‘GPu-3’ sites, which are 
distributed nearly randomly throughout the genome so the drug displays a lack of region 
specificity. These cases when compared with bizelesin highlight the importance of both 
sequence specificity and genomic regions targeted in the design of anti-cancer drugs 
that limit the adverse effects of current treatments.
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1.6.6: Summary
The CPIs are a family of minor groove binders that alkylate DNA by reaction at the 
CPI-C4 position to form a covalent bond with the N3 of reactive adenine. Various 
analogues exist including (+)-CC-1065, carzelesin, adozelesin and bizelesin. The drugs 
are overall right-handed and mimic the pitch of B-form DNA. They fit snugly into the 
minor groove and show exceptional antitumour activity, mediating their cytotoxic 
effects via DNA replication. A high sequence selectivity for AT regions is shown, with 
a preference for 5’-PuNTTA* and 5’-AAAAA* sequences observed. Formation of a 
5 W(CGTAATTACG)2-bizelesin adduct resulted in two conformations of the DNA 
duplex. The first exhibited open base pairs while in the second adduct the central AT 
step was found to be Hoogsteened. It was thought that bizelesin could trap out and 
stabilise open and Hoogsteen base pairs prior to cross-linking.
1.7: Oligopeptide antibiotics - netropsin, distamycin and the lexitropsins
The lexitropsins (also termed the ‘hair-pin polyamides’) are a class of non-covalent 
minor groove binders that have the ability to sequence selectively ‘read’ DNA. The first 
two examples were the di and tri-peptides distamycin A and netropsin (Figure 29).
nh2
Netropsin Distamycin
Figure 29: Chemical structures of netropsin and distamycin
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Distamycin A and netropsin are naturally occurring peptide antibiotics isolated from 
Streptomyces distallicus and Streptomyces netropsis respectively. 143,144 Their structure 
comprises aromatic rings linked together by amide groups and both drugs display a 
wide range of antiviral, antitumour and antibacterial activities. 145,146
Biological activity is exerted by tight binding to the minor groove of B-form DNA, 
causing interference with replication and transcription. 147,146 The drug molecules show a 
high preference for AT rich sequences, generally binding to clusters of more than four 
AT or IC base pairs, 148 with distamycin A binding preferentially to 5’-AAATT-3,149,15° 
or 5’-AATT-3’ . 151,152 Several studies including footprinting, 153,154 calorimetric, 155 
crystallography156"158 and NMR159' 161 have revealed that netropsin preferentially binds 
to a 5’-ATTT-3’ site, even when other sites with four AT base pairs are available.
Base specificity is thought to have its origins in Van der Waals forces between adenine 
C2 hydrogen atoms and the CH groups on the pyrrole rings of the drug molecule. 156 The 
drug molecule exhibits a small amount of torsional twist; this maximises contacts with 
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Figure 30: Specific hydrogen bonds from lexitropsin compounds to base edges providing
AT specificity162
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There is an additional electrostatic component from the cationic ends, but this is not 
deemed essential146,163,164 and calorimetric studies with 5 W(CGCAAATTTGCG)2 165 
indicate that the process of binding is enthalpy driven with electrostatic interactions not 
dominant. Neither netropsin nor distamycin will attach in GC rich areas due to steric 
hindrance of the guanine NH2 group. 147,166,167 Clashes are thought to occur between the 
NH2 and H atoms of the pyrrole rings. 158 X-ray analysis has shown that the drugs bind 
within the minor groove by displacing the water molecules of the spine of 
hydration. 156,158 Binding occurs through a combination of interactions including 
hydrogen bonding, ionic charge attractions and Van der Waals forces. The drug 
pyrrole rings are hydrophobic and increasing the number of N-methyl-pyrrole- 
carboxamide units appears to stabilize the drug-DNA complex. 163 Stacking interactions 
have been observed between the sugar 0 1  ’ atoms and the three drug pyrrole rings and it 
is thought that this also contributes to the stability of the complex. 152
Although the two naturally occurring oligopeptide antibiotics netropsin and distamycin 
display a marked preference for AT rich regions, it was recognised early on that 
strategic modification of the drugs could render them susceptible to the GC sites also. A 
large number of lexitropsins were synthesised and evaluated in which the pyrrole ring 
was replaced with N-methylimidazole. This resulted in some recognition of GC sites 
but a lack of specificity between these and the AT rich regions, along with reduced 
DNA affinity probably related to the wider GC regions of the minor groove leading to 
weaker Van der Waals interactions. 169
Several binding modes have been observed for distamycin and netropsin. These include 
binding in a 1:1, a 2:1 and even a 4:1 drug-DNA ratio. 171 In 1989 Pelton and 
Wemmer170 used NMR to examine the binding of distamycin A to 
5V(CGCAAATTGGC).5W(GCCAATTTGCG) and observed a concentration 
dependent change in binding modes. At low drug-DNA ratios the 1:1 complex 
dominated, but when drug concentration was increased a 2 : 1  binding mode was 
observed, with a drug binding affinity as high as that for the 1:1 complex. In a simple 
1 :1  binding mode three of the drug amide groups form a bifurcated (or three-centre) 
hydrogen bond between the adjacent adenine N3 or thymine 02 atoms in the A-T base 
pairs at the floor of the minor groove (Figure 31). Due to the narrowness of the AT rich
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minor groove regions the drug sits symmetrically. Its two rings are slightly co-planar so 
that each ring is parallel to the walls of the groove.152
C21





Figure 31: Bifurcating bonds in a distamycin-DNA complex152
The binding of lexitropsins to DNA has been observed to force open the minor groove 
by up to 17 A.171 In a 2:1 binding mode the drug molecules bind side-by-side, 
expanding the minor groove to at least 6.8 A (See Figure 32). An anti-parallel 
orientation is favoured as it reduces charge-charge repulsion between positively charged 
propylamidinium groups.170 Modeling suggests that the distamycin A molecules are 
staggered with respect to one another so that drug-DNA and drug-drug stacking 
interactions can contribute to the complex stability. Molecular modeling has also shown 
that the charged end of the drug is forced deeply into the minor groove where the 
electrostatic potential is larger174 and a favourable contribution to the free energy of 
complex formation can therefore be made. As with the 1:1 complex hydrogen bonds 
between the drug amide and adenine N3 and thymine 02 also stabilize the complex, but 
because in the 2:1 binding mode the drugs are pushed to the walls of the duplex the 
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Figure 32: Schematic view of a side by side dimer, reproduced from reference 162
The 4:1 binding mode has been investigated using NMR and molecular modeling 
studies.171 The DNA duplex accommodates four distamycin molecules bound in a 
tandem anti-parallel manner, existing in solution with free DNA and a 2:1 complex. No 
3:1 or 1:1 complexes are seen in the mixture. The minor groove widens by 16-17 A in 
order to accommodate the stacked drug molecules, an observation supported by 
extensive exchange of the A-T imino protons with the solvent at the binding site. The 




Recent work in the field of the lexitropsins and the PBDs has seen the synthesis and 
evaluation of a number of conjugate molecules of the two classes, displaying the PBD 
subunit linked to a number of combinations of pyrroles and imidazoles. In 2005 Kamal 
et al synthesised a series of PBD conjugates with a view to increasing water solubility 
and combining the effects of both the covalent (PBD) and the non-covalent (azepane) 
moieties (Figure 33A) . 175 Varying linker lengths were evaluated, with one compound 
showing a significantly increased melting temperature when bound to DNA, as opposed 
to only marginal changes for other compounds. This once again highlights the 
importance of linker length in linked compounds designed for the binding of DNA.
Other conjugate molecules include nicotinamide-PBD hybrids (Figure 33B) , 176 all 
showing increased DNA binding relative to DC-81, a series of PBD hybrids linked with 
indole carboxylates (Figure 33C)177-  again all showing potent antitumour activity, with 
hybrids possessing a greater toxicity than DC-81. It is thought that the unity of the two 
drug classes increases recognition for DNA binding sites and hence increased complex 
stability is observed.
C8 -linked PBD-poly(N-methyl pyrrole) conjugates have also been reported (Figure
1751 *33D). These compounds show an increase in DNA binding affinity that is more than 
50-fold greater than the individual PBD and pyrrole components. All of the conjugates 
studied appeared to take on the properties of both component fragments, showing 
sequence-selective DNA binding with high affinity, as well as an ability to block RNA 
transcription.
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Figure 33: PBD conjugates synthesized in recent years175-178
1.9: Aim of this project
1.9.1: Synthesis and analysis o f  drug-DNA adducts with SJG-136
As discussed previously, synthetic cross-linking PBD dimers such as DSB-120 and 
SJG-136 are designed to be inter-strand cross-linkers. However, work carried out by 
Cameron and Thompson179,180 suggested the possibility of an intra-strand cross-link. 
This work involved the reaction of DSB-120 with a 5W(CTCATCAC).(GTGATGAG) 
sequence, chosen due to the possibility of an intra-strand cross-link site utilising 
covalent modification of G11 and G14 on the same strand.
This work was not taken to completion due to the degradation of the PBD dimer, but on 
reaction with the drug a broad hump appeared at 8.70 ppm in the !H NMR spectrum of 
the drug-DNA adduct (See Figure 34).
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Mountzouris et alm  had noted a similar peak in 90 % D2 O at 9.10 ppm in a 
5 W(CICGATCICG)2 -DSB-120 inter-strand cross-linked adduct. This was thought to be 
due to the NH proton of guanine N2, which is covalently bound to DSB-120 at DSB- 
C ll via an aminal linkage. The presence of this peak in the spectrum produced by 
Cameron and Thompson supported the covalent modification of the duplex by DSB- 
120, though it was not possible on the strength of the data to determine whether the drug 
had bound at both G11 and G14, or just at one.
Aminal Peak
F I
Figure 34: *H NMR of DSB-120-5’</(CTCATCAC).5W(GTGATGAG) adduct
(Cameron and Thompson)179
It was proposed during this project to synthesize the 5 V(CTCATCAC).(GTGATGAG) 
duplex for reaction with SJG-136, in order to investigate further the possibility of the 
intra-strand cross-link and to compare the drug-DNA adduct with that of the inter-strand 
linked DNA formed with DSB-120.
1.9.2: Synthesis and analysis o f further drug-DNA adducts with adozelesin
Previous investigation of a 5’d(CGTAAGCGCTTACG)2-adozelesin adduct by high 
field NMR saw evidence suggestive of an overlap of the ends of the two adozelesin 
molecules in the fo's-adduct.179,180 Molecular modeling studies as a result of NMR data
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were performed on one half of the symmetrical 6 /s-adduct, and showed slight distortion 
at the ends of the molecule, with the benzofuran ’C’ subunit exhibiting a slight ‘fish- 
tailing’ effect. It is possible that this ‘fish-tailing’ could be the result of a stacking 
interaction between the aromatic rings of the benzofuran subunit, as shown in Figure 
35.
5 1- C - G - T - A - A - G - C - G - C - T - T - A - C - G - 3 '
CHj
HX
3 1- G - C - A - T - T - C - G - C - G - A - A - T - C - G - 5 '
Figure 35: Suggested overlap of benzofuran subunits in the 5V(CGTAAGCGCTTACG)2-
adozelesin adduct
Incidences of molecular ‘stacking’ have been discussed previously in conjunction with 
the lexitropsins, and a comparison of the adozelesin molecule with this class of drug 










Figure 36: Comparison of the molecular structures of netropsin and adozelesin
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It can be seen that both drugs contain planar units linked by flexible linkers, which 
allow the drugs to bend with the turn of the DNA helix. As stated previously, 
lexitropsins are accommodated in the minor groove by the utilisation of hydrogen 
bonding and Van der Waals forces. Conversely adozelesin forms a covalent attachment, 
although hydrogen-bonding interactions are also noted between the ‘B’ and ‘C’ subunits 
and the DNA duplex. Due to the shape of the drug and the fact that it is held in place by 
a covalent bond it is suggested that it may be possible for this molecule to at least 
partially ‘stack’ in a similar manner to the lexitropsins.
It was proposed during this project that a shorter DNA duplex would be synthesized in 
the form of 5 V(CGATTAATCG)2 . This duplex is 4 base pairs shorter than that 
previously used to bind adozelesin, and so in theory could produce significant overlap 
of the drug molecules.
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CHAPTER 2 -  EXPERIMENTAL PROCEDURES
2.1: Laboratory reagents -  sources
P-Cyanoethyl phosphoramidites (deoxy: adenine, thymine, guanine, cytosine and
inosine ie dA, dT, dG, dC and dl) — Cruachem
Iodine (oxidising agent) -  Cruachem
Trichloroacetic acid (TCA), (deblok) -  Cruachem
Acetic Anhydride (Cap A) -  Cruachem
4-(Dimethylamino) pyridine (DMAP), (Cap B) -  Cruachem
Tetrazole (Activator) -  Cruachem
Aqueous ammonia (NH4OH) -  Sigma 35% NH3
Ammonium acetate (NH4OAC)- Sigma anal, grade 99%
Acetic acid (CH3COOH) -  Fisons HPLC grade 
Acetonitrile (CH3CN) -  Fisons HPLC grade 
Controlled pore glass (CPG) support -  Cruachem 
Deuterium oxide (D2O) - Sigma
Disodium hydrogen orthophosphate (Na2HP0 4 .2 H2 0 ) -  Fisons anal, grade, 98 -  100% 
Sodium dihydrogen orthophosphate (NaH2PC>4 .2 H2 0 ) -  Fisons anal, grade, 98 -  100% 
Sodium Chloride (NaCl) -  Sigma, 99.9%
Methanol (CH3OH) -  Fisons HPLC grade 
Dimethylformamide-d7 — Sigma
Adozelesin -  A gift from the former Upjohn Company, Kalamazoo, Michigan 49001, 
USA
SJG-136 -  A gift from IPSEN, France
2.2: Synthesis of DNA
2.2.1: Preparation
p-Cyanoethyl phosphoramidite bases were dissolved in HPLC grade acetonitrile (ACN) 
as shown in Table 2.
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Base Weight (g) Vol of ACN (mL) Molarity
Adenine 1 1 1 . 2 0 . 1
Guanine 1 1 1 . 6 0 . 1
Cytosine 1 1 1 . 8 0 .1
Thymine 1 13.2 0 . 1
Table 2: Dissolving of bases in acetonitrile
2.2.2 Synthesis
The required DNA monomer (15pm) was synthesised using phosphoramidite chemistry 
on an Applied Biosystems 381A DNA Synthesiser. The synthesiser was programmed to 
synthesise “trityl-on” DNA to enable subsequent purification of the sample using 
HPLC. The deprotection step was monitored by UV spectroscopy (A, = 497) in order to 
check that the coupling efficiency was satisfactory. The four stages of oligonucleotide 
synthesis are shown in Figures 37-40:182
A. Detritylation (Figure 37)
In this step the dimethoxytrityl protecting group is removed from the 5’-OH of the 
nucleoside anchored to the column. The deprotecting agent used is trichloroacetic acid 
(TCA) (obtained from Cruachem under the name “Deblok”).
5* DMTrIo
0  Base (C.GAT.I)
0J
0 = P -O M e1O
H+
from TCA

















Figure 37: Removal of dimethoxytrityl group
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B. Addition (Figure 38)
In the addition step a 5’ to 3’ inter-nucleotide linkage is formed between the first and 
second nucleotide in the sequence via a trivalent phosphorous. Tetrazole is added to the 
column simultaneously with the nucleoside derivative. The tetrazole protonates the 
nitrogen of the diisopropylamine group on the 3’ phosphorus, rendering it susceptible to 





















C. Capping (Figure 39)
The coupling reaction has an efficiency of 98 - 100 %. However, some chains will not 
undergo addition and a capping step is necessary to terminate these in order to limit the 
lengths of any impurities and enable separation after synthesis. Unreacted chains will all 
have a free 5’-OH, whereas in the reacted chains this will be blocked with a 
dimethoxytrityl group. The free -OH groups are capped using an acetylating agent
55












Acetic anhydride M e th y l amlnopyrldlne
Figure 39: Capping reaction
D. Oxidation (Figure 40)
The trivalent phosphorus (phosphite) triester linkage formed in the coupling reaction is 
unstable and susceptible to acid and base cleavage. To combat this problem conversion 
to a more stable pentavalent phosphate triester is performed immediately after the 
capping step. This also helps to avoid the formation of acetic acid around the 
oligonucleotides (caused by water from the oxidising solution mixing with acetic 
anhydride). The oxidising solution is a basic lutidine/THF solution, in which iodine acts 
as the oxidising agent and water the oxygen donor. An iodine lutidine complex is 
formed with the trivalent phosphorus, this is then displaced by water to form a 
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Figure 40: Oxidation
These four steps are repeated for each nucleoside addition. The end result is an 
oligonucleotide strand attached to the CPG column at the 3 * terminal and protected by a 
dimethoxytrityl at the 5’ terminal. This strand is now removed from the CPG support 
and then requires purification before it can be used for drug addition.
2.3: Stages in the Purification and Annealing of DNA
2.3.1. Removal o f DNA from the CPG Support
The DNA sample was removed from the CPG support following instructions given in 
the Biosystems manual. Two syringes were connected to either end of the column and 
5mL of concentrated ammonia (35 %) was flushed back and forth across the column 
several times to ensure that the packing was thoroughly wet. The column was then left 
with the syringes depressed half-way for half an hour. This was repeated twice, after
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which the column was repeatedly flushed with further aliquots of ammonia. The total 
ammonia used was around 50 mL.
During this step the DNA sample is cleaved from the column and the (3-cyanoethyl 
protecting groups are removed (Figure 41). This step was monitored by UV 




O 2. Removal of protecting
n c (c h ,)2o  - p  =o  0POUp from basea
IO1b. Removal i
protecting group \ /












A d e n o s in e  A 62
Benzoyl
Cytosine CBz
Figure 41: Removal of DNA from support and deprotection
2.3.2: Deprotection o f the Bases
Bases are protected using isobutyryl and benzoyl groups as shown in Figure 41. 
Deprotection of bases was achieved by heating of the DNA sample in concentrated 
ammonia for 16 hours at 55°C. This was done overnight, by heating the ammonia 
sample in a sealed, Schott bottle in a water-bath thermostatted at 55 °C.
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2.3.3: Purification by HPLC
Purification of the single-stranded DNA was carried out using reverse phase HPLC with 
a Dynamax-300A, C l8 (20mm x 200m) preparative HPLC column. The failed 
syntheses were separated from the pure DNA strand using an HPLC linear gradient 
system from 0.1M ammonium acetate to 40 % v/v acetonitrile (HPLC grade) in 0.1M 
ammonium acetate over a period of 90 minutes. HPLC conditions are given in Table 3.
GRADIENT (% V/V) 0-40
Total Time (mins) 90
Wavelength (nm) 254
Flowrate (mL/min) 10
Recorder sensitivity (dual recorder) lOmv (red), 2V (black)
Recorder speed mm/min 10
Table 3: HPLC conditions for DNA purification
HPLC of the tritylated sample produced a characteristic trace, independent of the 
sequence of bases. (See Figure 42).
FT
J
17-20% ACN 4-7% ACN
Figure 42: Characteristic HPLC trace showing separation between failed syntheses and 
pure DNA. Right hand peaks = eluted first.
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The failed syntheses contain no trityl group, and consequently elute at between 4% and 
7% acetonitrile as a series of sharp off-scale peaks, corresponding to capped strands of 
increasing molecular weight. The pure strand of DNA is eluted last at about 17 % -  20 
% acetonitrile. There is a large gap between failed and complete synthesis connected to 
the polarity of the molecules. The capping reaction results in failed syntheses having an 
acetylated 5’-OH instead of a dimethoxytrityl group (See Figure 43). The smaller acetyl 
group is more polar than the dimethoxytrityl group and thus acetylated strands are 













Figure 43: Diagram showing capping procedure -  resulting in only pure DNA strand
having DMTr group
The DNA containing fraction was collected and concentrated to around 5 mL using a 
rotary evaporator. The sample was then dialysed against 1.5 L Milli Q water for 16 
hours using dialysis membrane (MWCO = 1000) in order to remove the salt. The water 
was once again removed by rotary evaporation.
2.3.4: Detritylation
The DNA strand was detritylated by treatment with 50 % v/v glacial acetic acid (dilute 
in Milli Q) for 20 minutes. A transient pink colour was observed. Acid was then
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removed by rotary evaporation and the sample dialysed in 1.5 L MilliQ water, in order 
to remove the cleaved trityl groups. The quality of the sample was then checked using 
ID proton NMR.
If at this point further purification was required a second HPLC step was then 
performed as before, but with a gradient of 0-10 % v/V acetonitrile in ammonium acetate 
over a period of one hour. The collected DNA peak eluted at around 5 % acetonitrile 
and was concentrated and dialysed as before.
2.3.5: Examination by NMR
Prior to annealing it was necessary to add 0.6 mL of NMR buffer to each 
oligonucleotide strand. This is important as salt concentration has a significant effect on 
spectral resolution, and also helps to sustain the three-dimensional duplex structure of 
the DNA, thus avoiding formation of hairpins at low ionic strengths. NMR buffer was 
prepared by mixing 0.01M NaH2P0 4  and 0.01M Na2HPC>4 (made up in 0.1M NaCl) 
until they reached pH 6.85. This phosphate buffer will maintain pH, but its own protons 
are likely to be responsible for additional peaks in the NMR spectrum. This problem 
was addressed using exchange of these protons by redissolution in D2O. The DNA 
sample was first dissolved in 0.6mL NMR buffer, then evaporated to dryness, dissolved 
in 1 mL D2O, freeze dried again, and finally taken up in 0.6 mL D2O. *H NMR was 
used to examine the samples, and if clean enough they were ready to be annealed into a 
duplex. Examples of satisfactory *H proton NMR of a DNA strand before and after 
purification are shown in Figure 44.
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Unpurified 5W(GTGATGAG) on removal from CPG support
5 W(GTGATGAG) after HPLC, dialysis and detritylation steps
Figure 44: Comparison of DNA duplex strands before and after purification by HPLC
2.3.6: Annealing
For non-palindromic sequences such as 5’d(CTCATCAC).(GTGATGAG) it was 
necessary to anneal the samples by mixing equal quantities of each complementary 
strand. Quantities of DNA were determined using absolute signal to noise measurement 
in the NMR spectrum. Each strand was dissolved in 0.3 mL 100 atom % D2 O and the 
two were mixed together in an NMR tube. The mixed strands were then heated to 
around 70°C by immersion of the NMR reaction tube in hot water in a flask and 
allowed to cool over 3-5 hours. As the samples are heated the DNA melts (midpoint 
melting temperature is ca. 69°C16) and reforms as duplex DNA as the sample cools 
down. For palindromic sequences such as 5’J(CGATTAATCG)2 the process involves 
simply dissolving the strand in 0.6 mL 100 atom % D2 O and heating as before.
2.4: DNA adduct formation
On production of a pure DNA duplex the DNA was treated with a drug in order to 
produce a covalently bound drug-DNA adduct.
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2.4.1: Reaction o f 5 ’d(CTCATCAC).(GTGATGAG) and5’d(CICGATClCG) 2  with SJG- 
136
101
The method for drug addition to DNA outlined by Mountzouris et al was followed:
The duplex in question was freeze-dried from double-strength NMR buffer (as outlined 
in section 2.3.5). It was then taken up in 0.6 mL D2O, with the addition of 0.2 mL 
deuterated methanol (100% atom) to aid solubility of the drug. The duplex was then 
added to 5 mg of SJG-136 -  constituting a large drug excess. The mixture was stirred 
for 16 hours at room temperature in the absence of light.
On reaction of the drug (confirmed by NMR) the reaction mixture was filtered and 
excess drug removed. The resulting adduct was then subjected to further NMR 
experiments as outlined in section 2.4.3.
2.4.2: Reaction o f 5 ,d(CGATTAATCG) 2  with Adozelesin
The duplex was freeze-dried from double-strength NMR buffer as outlined in section 
2.3.5 and taken up in 0.6 mL D2O. The duplex was added to 4 mg of adozelesin 
dissolved in 0.4 mL deuterated DMF (constituting a large excess of drug). The mixture 
was initially stirred for 48 hours in the absence of light. On assessment of the NMR 
spectrum it was ascertained that the reaction had not proceeded to completion and so the 
mixture was allowed to continue reacting for a further 10 days. At this point NMR 
was utilised to confirm completion of the reaction and the excess drug was filtered from 
the mixture. The resulting adduct was subjected to further NMR experiments as detailed 
in section 2.4.3.
2.4.3: NMR Conditions
All NMR experiments were carried out in double-strength NMR buffer as detailed in 
section 2.2.5. One and two-dimensional 400 and 600 MHz NMR data sets were 
recorded in H2O and D2O on Varian 400 and 600 spectrometers. Proton signals were
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recorded in parts per million (ppm) and referenced relative to the residual water signal 
at 4.71 ppm.
Phase-sensitive NOESY spectra (600 MHz) were obtained for mixing times 200 and 
300 ms. Spectra were recorded with 32 scans at each of 1024 t] values at a spectral 
width of 10.002 ppm at a relaxation delay of 2 s between scans. Two-dimensional NOE 
spectra in 90 % H2O at 150 ms mixing time were recorded using water suppression by 
pre-saturation with a 2 s repetition delay and a sweep width of 25.025 ppm.
DQF-COSY spectra were also recorded on the Varian 600 MHz spectrometer and were 
used to confirm assignments made in the NOESY spectra. The 5 V(CGATTAATCG)2- 
adozelesin adduct was also subjected to ROESY experiments in order to rule out any 
conformational exchange within the duplex.
2.5: NMR Experiments
2.5.1: Basic NMR Spectroscopy184-186
The first successful NMR experiment was demonstrated in 1946, and since then the 
technique has become an indispensable research tool. The use of NMR for studies of 
drug-DNA interactions carries a distinct advantage in that samples are in solution. This 
means that important parameters such as pH, temperature and ionic strength can be 
varied in order to mimic the conditions experienced in a biological system.
NMR spectroscopy is based on the fact that nuclei that contain an odd number of 
protons or neutrons possess a magnetic moment. When an external magnetic field is 
applied the magnetic moment becomes aligned either parallel or opposed to the 
direction of the applied field. In the case of the hydrogen atom, *H, this corresponds to 
the two spin states + V2 and -  V2 . The two spin states have different energies, and an 
exact amount of energy is required to ‘flip’ the magnet from one position to the other. 
This amount of energy, AE, is related to the magnetic moment of the proton, p, the 
applied field strength, Bq and the frequency, v, as shown in Equation 1.
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AE=hv=2]iB0
Equation 1: Equation relating amount of energy AE to change the spin state of a proton 
with magnetic moment |i, applied field strength B0 and frequency v.
Early NMR experiments were carried out by keeping a constant frequency and varying 
the magnetic field in order to determine the point where the magnetic moment flipped. 
Modem spectrometers however, work by irradiating the sample with a short pulse of 
electromagnetic radiation, hence delivering a range of frequencies simultaneously to the 
sample while keeping the applied magnetic field constant. The !H nuclei are excited, 
and as they relax back to equilibrium conditions a signal relating to each excited 
frequency can be detected. A technique known as Fourier Transform is then employed 
to convert the signals detected into the final spectrum, where protons appear as 
resonances at different chemical shifts according to their environment.
2.5.2: The Nuclear Overhauser Effect
The Nuclear Overhauser Effect (NOE) is due to a transfer of magnetisation between two 
spins that are in close spatial proximity. If two spins, A and B, are within 5 A of each 
other magnetisation is transferred between them by through-space cross relaxation. This 
means that irradiation of one nucleus at its resonance frequency affects the strength of 
the signal arising from the second nucleus -  it is either strengthened (Nuclear 
Overhauser Enhancement) or weakened. This means that it is possible to gain a wealth 
of information on the spatial locations of protons within a molecule.
It is possible to illustrate the theory behind NOE using a molecule containing two 
inequivalent protons, I and S, that are not scalar coupled. Figure 45 A shows the energy 
level diagram for these protons, as well as their equilibrium population distribution. As 
shown, there are six relaxation pathways possible. Four of the relaxation pathways
T n
correspond to single spin flipping, and are denoted Wj and W) , where ‘W’ denotes the 
probability of a single quantum transition, while the subscript gives the change in
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quantum number. The remaining relaxation pathways are due to cross-relaxation, when
TC TO
the I and S protons relax together. These are denoted Wo and W2 . If the sample is 
irradiated at the frequency of the ‘S’ proton the ‘S’ spin becomes saturated and the 
population distribution is that shown in Figure 45 B. It is now possible for cross-
TO TO tn
relaxation to occur via the W2 and Wo pathways. If relaxation occurs via W2 the 
population of levels will be that shown in Figure 45 C, and will therefore result in an 
enhancement of the I signal. If the WoIS pathway is utilised then there is a decrease in 
signal as shown in Figure 45 D.
NOE experiments are not always an accurate measure of distance as there are problems 
that can arise. Low sensitivity (a low signal to noise ratio) can render integral 
calculations difficult, and problems can occur with larger molecules. A large molecule 
rotates slower than its smaller counterpart, and this can lead to spin-diffusion pathways
c T
(Wi and W i) becoming as prominent as the cross-relaxation pathways. This changes 
peak intensities and complicates interpretation of distances. An increased mixing time 
can be used to make longer range NOEs easier to observe, but this will also make the 
spin-diffiision pathways more prominent in the shorter range couplings.
2.5.3: Two-dimensional Nuclear Magnetic Resonance
Conventional NMR spectroscopy results in spectra, which are a plot of intensity against 
frequency. For coupling nuclei however, such as H-H, the interactions are also a 
function of time. By sampling at a range of times therefore, it is possible to separate 
interactions in order to establish which nuclei are coupled. Two frequency axes are 
involved, and so the process is known as two-dimensional NMR spectroscopy. There 
are many different 2D-NMR experiments, but several are of particular use in the NMR 
of DNA, and will therefore be introduced.
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enhancement o f ‘I’ signal weakening of T  signal
Figure 45: Energy levels, relaxation pathways and population distributions of two dipolar 
coupled protons, I and S. Adapted from reference 184
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2.5.4: Correlated Spectroscopy (COSY)
Through-bond coupling is known as scalar coupling; protons within three bonds of each 
other will exhibit 3Jhh scalar coupling. The COSY experiment is used to collect 
information on protons that are scalar coupled. A spectrum is produced with the original 
1D resonances pictured as a diagonal from comer to comer. Any scalar coupled protons 
will exhibit an off-diagonal cross-peak as shown in Figure 46.
ProtoiCross-peak AB
Cross-peak A
Figure 46: Cross-peaks shown by two scalar coupled protons, A and B, in a COSY
experiment
The strength of the coupling observed is affected by several factors including the 
electronegativity of attached substituents and the dihedral angle. The effect of the 
dihedral angle is of particular importance in the NMR of DNA as this can cause the 
absence of expected COSY cross-peaks, making assignment of DNA by NMR more 
difficult.
The effect of the dihedral angle on the vicinal coupling constant can be effectively 
predicted using Karplus’s equations (Equation 2).
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The effect can be more readily visualized when the equation is expressed graphically as 
in Figure 47. It can be seen that the largest vicinal couplings arise when the dihedral 
angle is 0° or 180°. Protons at 90° to each other give rise to very small couplings and in 
this situation the expected COSY cross-peaks may be entirely absent.
J  = A + B cos 0  + C cos 20
Equation 2: Karpins equation187 relating coupling constant, J  to dihedral angle, o
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Figure 47: Graphical representation of Karplus equation188
2.5.5: Nuclear Overhauser Enhancement Spectroscopy (NOESY)
NOESY experiments are used to detect protons that are dipolar coupled, and are 
therefore useful in detecting protons that are close together in space. The NOE 
experiment works on the basis of the NOE theory discussed previously, and once again 
produces a two-dimensional spectrum in which the 1D spectrum is present as a central 
diagonal. Any protons within a spatial proximity of 5 A will produce off-diagonal cross­
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peaks similar to those seen in the COSY experiment. An estimate can be made as to the 
distance between the protons in question based on the intensity of the cross-peak 
observed.
2.5.6: Rotating Frame Overhauser Spectroscopy (ROESY)
ROESY is a similar experiment to NOESY -  detecting through space couplings by use 
of NOE effects. However, in addition the ROESY spectrum provides information on 
conformational exchange. If exchange takes place during the NMR timescale peaks are 
visualised as opposite sign (ie positive peaks become negative). This is useful in 
detection of phenomena such as base ring opening or open duplex conformations in a 
DNA molecule.
2.6: NMR studies on DNA duplexes
There are several stages in the sequential assignment procedure for nucleic acids, which 
have been well documented. 189’192 For the purpose of discussion the 
5’J(CTCATCAC).(GTGATGAG) duplex will be used for an in depth account of these 
stages.
2.6.1: The one-dimensional ]H  NMR spectrum
On collection of NMR data it is important to assign all non-exchangable protons before 
drug addition to the duplex, to enable a comparison to take place on addition of the 
drug. A diagram showing the numbering system for the duplex is shown in Figure 48.
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Figure 48: Diagram showing numbering system of 5V(CTCATCAC).(GTGATGAG)
duplex for NMR assignment purposes
The one dimensional (ID) spectrum is of limited use in the assignment of protons in 
DNA, due to the large incidence of overlaid peaks, making it impossible to distinguish 
one proton from another in much of the spectrum. The ID spectrum therefore, is mainly 
used for quality control. An indication of sample purity can be obtained, with impure 
samples showing obvious impurities, line broadening and a low signal to noise ratio. 
These are all indications of the sample needing further purification or re-synthesis. It is 
also possible to determine whether correct nucleotide components are present, even if it 
is not possible to decipher their order. For this the base protons of each nucleotide are 
used, these appear in the aromatic region and are usually fairly well defined. Peaks due 
to protons of the DNA sugar backbone however cover two thirds of the spectrum and 
are greatly overlaid. It is not possible to do more than relate each spectral region to its 
respective deoxyribose proton in these regions (See Figure 49).
The Pu-H8 , Py-H6  and A-H2 protons appear in the aromatic region due to a pseudo 
aromatic effect created by lone pairs of electrons on the nitrogen atoms of the DNA 
bases. The purines guanine and adenine produce one and two singlets respectively, with 
the second adenine singlet due to the A-H2 proton. The pyrimidines are slightly more 
complicated with cytosine producing doublets in the aromatic region and the HI ’ region 
(5.5 ppm - 6.5 ppm). These are due to scalar coupling between C-H6  (‘aromatic’ 
proton) and C-H5. Thymine produces a singlet in the aromatic region, as well as a 
methyl peak appearing between 1 - 2  ppm.
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Figure 49: Numbering system for NMR and chemical shift values of deoxyribonucleotide
base and sugar protons.
The one dimensional NMR spectrum of the 5’J(CTCATCAC).(GTGATGAG) duplex is 
shown in Figure 50. On obtaining the ]H spectrum it is often possible to estimate the 
number of peaks in the aromatic region. For this duplex 24 peaks should be present 
(Gx4, Tx4, Ax8, Cx8), with the proton count integrating for 20 protons. In actual fact 
the peaks in this area are too overlaid to allow an accurate peak count, but the proton 
count integrates for 20 and is in a 1:1 ratio with the sugar H I’ region, as expected. Four 
methyl peaks can also be seen between 1-2 ppm, indicating the presence of four 
thymine bases as expected. The spectrum is sharp, with a high signal to noise ratio, and 
no obvious impurities, and on the basis of this evidence it was possible to obtain 2D 
NOESY spectra in order to assign all protons.
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Figure 50: One dimensional Varian 400 MHz *H NMR spectrum of
5’</(CTCATCAC).(GTGATGAG)
2.6.2: The two-dimensional 1H NOESY spectrum o f the
5 d(CTCATCAC).5 ’d(GTGATGAG) duplex
In order to model a drug-DNA adduct it is necessary to use NOE methods to work out 
the distances between protons in the molecule. These distance restraints are then entered 
into molecular modeling programmes in order to work out the most likely orientation of 
the drug in the minor groove.
A diagram of the sequential connectivities between two DNA nucleotides can be found 
in Figure 51. Due to the orientation of bases in the DNA double helix any particular 
base can only ‘see’ into the 5’ direction. That is to say that a base will display 
connectivities between its own protons, and also to the protons of its 5’ neighbour, but 
will not ‘see’ back into its 3’ neighbour. This means that a 5’ terminal base will form 
connectivities only with its own protons, as it has no further 5’ neighbour. This is 













Figure 51: Diagram showing connectivities for two consecutive DNA bases
The entire 2D NOESY spectrum for the 5’</(CTCATCAC).(GTGATGAG) duplex is 
shown in Figure 52. It produced a set of well-resolved NOE off-diagonal peaks, with 
adequate signal to noise ratio for sequential assignment to begin. Each dimension of the 
spectrum was referenced to the H2 O peak at 4.71 ppm. In order for observable NOE 
peaks to be present in the spectrum the maximum 'H-lH distance must be within 5 A. 
This means that only NOEs between protons within a nucleotide (intra-nucleotide) or 
between neighbouring nucleotides in the same strand (inter-nucleotide) are close enough 
to result in observable NOEs. Therefore each oligonucleotide strand gives rise to a 
cross-connectivity network between ribose and base protons of the constituent 
nucleotides. If sequences are self-complementary the cross-connectivity networks are 
superimposed upon each other and the spectrum is greatly simplified due to its 
symmetry. In this case the sequence was non-complementary however, so the proton 
resonances are different for each strand. The intense diagonal line of resonances across 
the spectrum is a projection of the one-dimensional spectrum previously discussed. On 
each side of the diagonal is a symmetrical arrangement of cross peaks resulting from 
dipole-dipole induced cross-relaxation. An NOE between two protons close in space 
will result in a contoured peak, the x and y coordinates of which indicate the chemical
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shifts of the protons. In order to assign the NOESY spectrum a combination of 
techniques were used, all of which have been previously documented.189'192
F2
(ppm)
H8/H6 - H27H2"/T-CH3 region j
H8/H6 - H4' region
H8/H6 - H3' region
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Figure 52: Full NOESY Spectrum for 5W(CTCATCAC).(GTGATGAG)
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2.6.3: Cytosine H5 protons (C-H5) (Figure 53)
Cytosine H5 protons are in such close proximity to the C-H6  protons that they produce 
extremely intense cross peaks in the NOESY spectrum, as well as COSY peaks in the 
COSY spectrum. This immediately provides a location for the C-H6  proton resonances 
and makes a good starting point in the assignment procedure. As shown in the ID 
spectrum, C-H5 protons are found in the region of 5-6 ppm. When the H6 /H8  -  H I7 
region of the 2D NOESY spectrum (Figure 53) is studied it is possible to identify four 
extremely intense cross peaks at 5.20 ppm, 5.46 ppm, 5.56 ppm and 5.76 ppm in the F2 
dimension that correspond to the C-H5 protons of the four cytosines in the 
oligonucleotide sequence. In addition to the COSY resonance produced by the coupling 
of C-H5 to C-H6  each C-H5 peak correlates directly into its own C-Hl’ and C-H6  
protons in the F2 dimension. At 3.9 A the C-H5 is also close enough to the aromatic 
base proton on the 5’ side to produce an NOE connectivity in the FI direction, thereby 
identifying the chemical shift of the aromatic base proton of the 5’ flanking neighbour. 
At this stage it is not possible to identify which resonance belongs to which cytosine.
2.6.4: Thymine CH3  protons (Figure 54)
The methyl protons of thymine produce a set of characteristic intense cross-peaks in the 
far up-field region of 1-2 ppm. If this region is examined in the 2D NOESY spectrum 
four intense pairs of peaks can be seen along the F2 dimension at 1.18 ppm, 1.20 ppm, 
1.22 ppm, and 1.46 ppm. The most intense of each pair of peaks corresponds to the 
strong interaction (distance 2.9A) between T-CH3 and T-H6  of the same base. Therefore 
the T-H6  shifts of the four thymines in the sequence can be assigned as 6 . 8 6  ppm, 7.19 
ppm, 7.00 ppm and 7.48 ppm respectively. The less intense peaks are due to an NOE 
between the T-CH3 and the 5’ flanking aromatic base proton. It is therefore possible to 
assign the four flanking bases’ H8 /H6  chemical shifts as 8.04 ppm, 7.77 ppm, 8.18ppm 
and 7.70 ppm. The two most down-field shifts correspond to adenine bases, which 
appear the most down-field due to increased ring-current effects. The further up-field 
peaks are due to guanine or cytosine bases. On examination of the DNA sequence it can 
be seen that there are indeed two incidences of thymines flanked by adenine bases (T5 
and T13) while T2 and T10 are flanked by cytosine and guanine respectively. Peaks
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from T-CH3 to flanking aromatic protons are less intense due to the greater distance 
between these protons (3.8 A). In this case, as with the cytosine H5 protons, it is not 
possible to further distinguish which thymine is which from this information.
2.6.5: The H8 /H6  to HI ’ deoxyribose proton region. (Figure 53)
This region overlaps with the cytosine H5 region, spanning around 1.5 ppm from 5.1- 
6.3 ppm. Resonances in this region are due to the inter- and intra-nucleotide interaction 
between each aromatic H6  or H8  protons with the HI ’ proton of its own sugar, and also 
with that of its 5’ flanking neighbour. The H8 /H6  chemical shifts of the four cytosines 
and the four thymines are already known from examination of the cytosine H5 and 
thymine CH3 regions. It is now possible to examine the connectivities of these protons 
with their neighbours in order to determine which resonance belongs to which base.
To begin with the thymine resonances at 7.00 ppm it can be seen that at this chemical 
shift there are a pair of peaks (5.66 ppm and 6.05 ppm) that line up in the vertical 
direction. These are due to the thymine H6  interaction with its own HI ’ proton and that 
of its 5’ flanking neighbour. Looking horizontally along the FI dimension from each of 
these resonances they are found to line up with two peaks at 7.35 ppm and 8.18 ppm. 
From examination of the cytosine H5 region and the thymine CH3 region it is already 
known that these peaks correspond to a cytosine and an adenine respectively. The 
thymine in question then, is flanked by a cytosine and an adenine and can only be T5. 
The cytosine and adenine resonances can similarly be attributed to C6  and A4. Hence 
the H6 /H8  and H I’ resonances for A4 and T5 are now known. The C6  resonance is 
found to line up with another peak in the F2 dimension at 5.37 ppm, and this can 
therefore be assigned to the C6 -H r  resonance. A chain of connectivity now exists from 
C6-T5-A4. It is now possible to continue to “walk” from resonance-resonance in this 
manner in both directions thereby identifying the other protons in the 5’d(CTCATCAC) 
strand. When Cl is reached it is important to note that this resonance has no other 
connectivity in the F2 dimension. This is because the Cl residue is at the 5’ terminal 
and therefore can see only its own HI ’ sugar proton, as it has no 5’ flanking neighbour.
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The 5’J(GTGATGAG) strand can be assigned in the same manner, but is slightly more 
difficult due to the presence of overlying signals, namely G9-H1’ and C1-H5. The 
chemical shift of G9-H8 is known from identification of T10 in the thymine CH3 region 
(discussed previously). It is evident from the size of peaks and the number of contours 
that some peaks are overlaid, and using the information discussed as well as 
conformation from other regions of the NOESY spectrum (to follow) it is possible to 
tentatively identify H6 /H8  and HI ’ resonances for all bases (See Table 4).
Cl T2 C3 A4 T5 C6 A7 C8
H6 /H8 7.70 7.48 7.42 8.18 7.00 7.35 8.10 7.19
HF 5.67 5.96 5.34 6.05 5.66 5.37 6.03 5.86 j
Table 4: Chemical shifts in ppm for aromatic and HI* protons for the duplex 
5V(CTCATCAC).(GTGATGAG), C strand
G9 T10 Gil A12 T13 G14 A15 G16 I
H6/H8 7.77 7.19 7.73 8.04 6.86 7.66 7.92 7.44 I
HF 5.80 5.64 5.48 6.01 5.46 5.19 5.92 5.78 I
Table 5: showing chemical shifts in ppm for aromatic and HI’ protons for the duplex 
5W(CTCATCAC).(GTGATGAG), G strand
As discussed previously, this region is also home to adenine H2 resonances. The 
position of adenine H2 protons in the centre of the minor groove allows close contact 
with protons within its own strand, and also NOE inter-strand connectivities. Each A- 
H2 can ‘see’ into its own deoxyribose H I’ proton, into the thymine HI* proton to which 
it is Watson-Crick base paired, and also into the H F proton of the 3’ neighbour of that 
thymine. In this duplex the A-H2 cross peaks are very weak, but they will be discussed 
further in section 2.7.1.
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2.6 .6 : The H6 /H8  to H2 ’ and H2 ’ ’ region. (Figure 54)
This region spans from 1.8 -  3.0 ppm. It is used to confirm shifts assigned in the H8 /H6  
to H I’ region, and clear up discrepancies regarding any overlaid peaks. As H6 /H8  shifts 
have been suggested for all bases at this point it is possible to find all peaks coupling to 
each ‘aromatic’ base proton at any given chemical shift. At each H6 /H8  shift four peaks 
should be present in the H2’ and H2” region, two of these correspond to the interaction 
between the base H6 /H8  proton with its own H2’ and H2” , while the other two are due 
to the interaction of the H6 /H8  proton with the H2’ and H2” protons of its 5’ flanking 
neighbour. As with the aromatic to HI ’ region, the number of peaks at the terminal base 
is halved due to the fact that this base can only interact with its own protons, as it has no 
5’ flanking neighbour.
To assign this region a pair of parallel lines are drawn from the H6 /H8  resonances, in 
the FI direction. These lines should intersect another pair of peaks at the chemical shift 
of the 5’ flanking neighbour. These are due to the interaction of the H2’ and H2” of the 
first base with the H8 /H6  proton of the neighbour. A clear example of this is shown 
between T5 and A4 in the region in question. From the assignment of the aromatic to 
H I’ region it can be seen that the H8  resonance of the T5 base is at 7.12 ppm. At this 
resonance in the H2’ and H2” region four clear peaks can be seen. Parallel lines drawn 
along the FI direction connect these peaks to four more peaks -  one pair at the A4 
chemical shift, and one pair corresponding to the shift value for C6 . This confirms the 
H6 /H8  proton assignments for these bases and also allows assignment of the T5-H2’, 
H2” and the A4-H2’, H2” peaks. These are assigned chemical shifts of 1.99 ppm, 2.38 
ppm and 2.66 ppm, 2.90 ppm.
The H2’ and H2” can be distinguished between owing to the size of the NOE cross­
peak with their own H8 /H6  proton. The H2’ proton is situated approximately 2.3A from 
the ‘aromatic’ proton whereas the H2 ” proton is further away at approximately 3.6 A 
(distances based on UCSF-Chimera molecular models) . 193 The H2’-H8/H6 cross-peak 
therefore is more intense than the H2” -H8/H6. In addition it is generally found that the 
H2’ resonates down-field of the H2” . In this manner the H2 proton peaks are assigned 
for both strands (See Tables 6  and 7).
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Cl T2 C3 A4 T5 C6 A7 C8
H2’ 2.38 2.40 2.26 2.74 2.24 2.18 2.66 2.64
H2” 2.04 2.04 1.98 2.47 1.84 1.86 2.46 1.90
Table 6: Chemical shifts (ppm) for the sugar H2' and H2” protons in the 
5W(CTCATCAC).(GTGATGAG) duplex, C strand
G9 T10 G il A12 T13 G14 A15 G16
H2’ 2.60 2.32 2.62 2.70 2.04 2.44 2.68 2.38
H2” 2.05 1.98 2.51 2.41 1.68 2.32 2.44 2.16
Table 7: Chemical shifts (ppm) for the sugar H2’ and H2” protons in the 
5V(CTCATCAC).(GTGATGAG) duplex, G strand
2.6 .7; The H8 /H6  to H3 ’ region. (Figure 55)
This region is typically quite weak and full proton walks are rarely achieved. Due to 
water suppression in this region some cross peaks are also lost under the water 
suppression band. It is possible however, to confirm locations of some of the previously 
assigned peaks. For the duplex in question it was possible to confirm a fairly strong 
walk for the G strand, while several short chains of connectivity were discovered for the 
C strand. Missing chemical shifts were discovered using other regions of the spectrum 
and a tentative assignment was made for each proton. The data agreed with those 
assigned in previous regions and is shown in Tables 8  and 9.
Cl T2 C3 A4 T5 C6 A7 C8
H r 4.46 4.70 4.40 4.83 4.64 4.64 4.83 4.60
Table 8: Chemical shifts in ppm for H3’ protons for the duplex 
5W(CTCATCAC).(GTGATGAG), C strand
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G9 T10 G il A12 T13 G14 A15 G16
H3’ 4.77 4.70 4.83 4.76 4.83 4.62 4.76 4.82
Table 9: Chemical shifts in ppm for H3’ protons for the duplex 
5 V(CTCATCAC).(GTGATGAG), G strand
2.6.8: The H8/H6 to H4 ’ region
This region is home to connectivities between ‘aromatic’ and H4’ protons. Each 
aromatic proton shows an NOE into its own H4’ proton. This area is often heavily 
overlaid and unambiguous assignment of peaks is difficult.
2.6.9: TheH8/H6 toH8/H6region.
The H8 /H6  -  H8 /H6  region is used to confirm locations of ‘aromatic’ protons and 
adenine H2 protons. Each Pu-H8  and Py-H6  proton correlates into the H8  or H6  proton 
of both its 3’ and 5’ neighbour. In the case of the 5 V(CTCATCAC).(GTGATGAG) 
duplex this region was too greatly ridged to be of much use. It will however, be 
discussed in relation to the 5 ’J(CGATTAATCG) 2  duplex.
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Figure 53: 2D NOESY Varian 600 MHz spectrum of 5’tf(CTCATCAC).(GTGATGAG), 
mixing time 200ms. C-H5 and H8/H6 — H I’ region
82
* y? c&o-'o & #  A?
FI (ppm)
Figure 54: 2D NOESY Varian 600 MHz spectrum of 5W(CTCATCAC).(GTGATGAG), 
mixing time 200ms. Thymine methyls (blue) and H8/H6 to sugar H2’ and H2” walk, C

















Figure 55: 2D NOESY Varian 600 MHz spectrum of 5W(CTCATCAC).(GTGATGAG), 
mixing time 200ms. The H8/H6 to sugar H3’ walk. C strand = green, G strand = red
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2.7: 2D NMR spectrum of the 5’d(CGATTAATCG)2 duplex
The 2D NOESY spectra were assigned in a similar manner to that of the previous 
duplex, and so will not be discussed in depth here. It is evident that, as discussed, the 
spectrum is a lot less complicated and the assignments more clear in most regions. 
There are however, one or two areas that would benefit from further explanation.
2.7.1: Adenine-H2 assignment.
As previously discussed, A-H2 proton resonances are found at around 6.50 -  8.50 ppm 
in the aromatic region. They display connectivities to H I’ resonances and therefore 
cross-peaks can be identified in the H6 /H8  to H I’ region of the spectrum (Figure 57). 
In the case of the palindromic duplex discussed here the simplification of the spectrum 
allows relatively easy assignment of these protons. Obvious peaks can be seen at 7.65 
ppm that have not been included in the aromatic to H I’ walk. If this chemical shift is 
studied in the H8 /H6  to H2’ and H2” region (Figure 58) it can be observed that there 
are no cross-peaks in this region. The resonances seen at 7.65 ppm can therefore be 
attributed to the interaction of an A-H2 proton with sugar H I’ protons. Other A-H2 
resonances can be seen in the H6 /H8  to H I’ region underneath the A6-H8/A3-H8 
chemical shift at 8.11 ppm. This is supported by the ID spectrum (Figure 56), in which 
the peak seen at 8.11 ppm integrates for not two but three protons. Observation of the 
ID spectrum also provides the clue for the location of the third A-H2 proton resonance, 
where an extra sharp singlet can be seen at 7.41 ppm - very close to the Cl resonance. 
This indicates that the third A-H2 resonance is probably situated underneath the ridged 
area around the Cl region of the 2D spectrum. To assign which A-H2 is which it is 
necessary to study their connectivities with other protons. As discussed earlier each A- 
H2 can ‘see’ into its own HI ’ proton, into its Watson-Crick paired thymine, and into the 
3’ neighbour of that thymine. In some cases a connectivity to the H I’ proton of the 3’ 
neighbour of the adenine H2 can also be observed. As the NOE peaks at 7.65 ppm in the 
FI direction are the most clear these were studied first. These peaks display 
connectivities into A3-H1’, T4-H1’, T8 -HF and C9-H1’ and the resonances are 
therefore due to A3-H2. The other peaks are heavily overlaid so are more difficult to 
assign. However, a clear resonance can be seen at 7.41 ppm in the FI direction, which
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shows clearly into the A7-H1’ resonance at 5.96 ppm. This peak therefore can only be 
due to A7-H2, and the remaining resonances at 8.11 ppm can be assigned to A6-H2 by 
default, supported by the fact that underlying peaks can be observed at 5.52ppm, 
showing a connectivity into T5-H1’.
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Figure 56: ‘H 600 MHz spectrum of 5V(CGATTAATCG)2
2.7.2: The H8/H6 to H8/H6 region
In this case the aromatic to aromatic region was much clearer than in the previous 
duplex, and it was possible to find correlations to back up earlier assignments in this 
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Figure 57: 2D NOESY Varian 600 MHz spectrum of 5’</(CGATTAATCG)2 mixing time
200ms H6/H8 to H I’ region.
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Figure 58: 2D NOESY Varian 600 MHz spectrum of 5’*f(CGATTAATCG)2 mixing time
200ms H6/H8 to H2’ and H2” region
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Figure 59: 2D NOESY Varian 600 MHz spectrum of 5W(CGATTAATCG)2 mixing time
200ms. H6/H8 to H6/H8 region
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H8/H6 H2/H5/CH3 H r H2’l H2’2 H3’ H4’
Cl 7.70 5.76 5.67 2.38 2.04 4.46 3.90
T2 7.48 1.50 5.96 2.40 2.04 4.70 4.05
C3 7.42 5.56 5.34 2.26 1.98 4.40 3.96
A4 8.18 7.45 6.05 2.74 2.47 4.83 3.96
T5 7.00 1.24 5.66 2.24 1.84 4.64 3.96
C6 7.35 5.46 5.37 2.18 1.86 4.64 3.90
A7 8.10 7.67 6.03 2.66 2.46 4.83 3.96
C8 7.19 5.20 5.86 2.64 1.90 4.60 4.27
G9 7.77 - 5.80 2.60 2.05 4.77 3.90
T10 7.19 1.20 5.64 2.32 1.98 4.70 4.03
G il 7.73 - 5.48 2.62 2.51 4.83 4.16
A12 8.04 7.60 6.01 2.70 2.41 4.76 4.26
T13 6.86 1.19 5.46 2.04 1.68 4.83 3.89
G14 7.66 - 5.19 2.44 2.32 4.62 4.10
A15 7.92 7.60 5.92 2.68 2.44 4.76 4.23
G16 7.44 - 5.78 2.38 2.16 4.82 *
Table 10: Completed proton assignments for 5’*/(CTCATCAC).(GTGATGAG). *=peak
not found
H8/H6 H2/H5/CH3 HI’ H2’ H2” H3’ H4’
Cl 7.40 5.67 5.47 2.16 1.65 4.51 3.52
G2 7.80 - 5.36 2.66 2.55 4.83 4.17
A3 8.10 7.40 6.13 2.78 2.54 4.89 4.00
T4 7.00 1.17 5.71 2.32 1.79 4.71* 4.00
T5 7.16 1.43 5.52 2.28 1.93 4.71* 3.96
A6 8.10 8.11 5.76 2.74 2.58 4.33 4.28
A7 7.97 7.65 5.96 2.71 2.36 4.82 4.00
T8 6.94 1.09 5.70 2.22 1.78 4.90 3.96
C9 7.28 5.43 5.53 2.18 1.83 4.71* 3.90
G10 7.75 - 5.94 2.44 2.18 4.51 3.9°
Table 11: Completed proton assignments for 5 W(CGATTAATCG)2. *= peak not found 
hence assumed underwater suppression band at 4.71ppm
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2.8: Assignment of Drog-DNA Adduct spectra
After assignment of the duplex spectrum, a DNA duplex can be allowed to react with 
the DNA-binding drug. The resulting adduct is then subjected to further ID and 2D 
NMR analysis. For the purpose of drug-DNA adduct assignment explanation the 
5’d(CICGATCICG)2-SJG-i36 adduct will be considered. Being a self-complementary 
sequence of only 1 0  base pairs this adduct provides a relatively simple spectrum for the 
purposes of an assignment explanation. Figure 60 shows the numbering system of the 
duplex and the drug for the purposes of NMR assignment.
, ^1 2 3 4 5 6 7 8 9 10. ,
5 ' - C - I - C - G - A - T - C - I - C - G - 3
„  ,  _10 _9  _8 _ 7  _ 6  _5 _4 _ 3  _2 ^1 -  .
3 ' - G - C - I - C - T - A - G - C - I - C - 5 '
Figure 60: Numbering system for the 5V(CICGATCICG)2 duplex
2.8.1: The ]H  NMR spectrum
The lH NMR spectra of both the duplex and the adduct can be seen in Figure 61. These 
spectra are used to confirm that a reaction between the drug and the DNA has taken 
place. When the spectra are compared it is evident that different resonances are present 
in the adduct spectrum. As expected, the same regions of the spectrum are densely 
populated, but in particular new peaks can be observed at 1.80 ppm, 5.20 ppm and 6.60 
ppm whilst peaks present in the duplex spectrum at 4.90 ppm, 7.50 ppm and 8.10 ppm 
are no longer present. This supports a drug-DNA reaction and suggests that no duplex 
DNA remains in the reaction mixture. Sharp singlets between 3 and 4 ppm are possibly 
due to the drug methyl group (SJG-H14). The adduct spectrum is also clean and well- 
resolved and so is deemed of a quality to allow 2D NMR experiments to take place.
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Figure 61: 600 MHz Varian ‘H NMR spectra of the 5W(CICGATCICG)2 duplex and the 
5 V(CICGATCICG)2-SJG-136 adduct. The duplex spectrum is shown in black while the
adduct is superimposed in red
2.8.2: The 2D NOESY and COSY spectra o f the 5 ’d(CICGATCICG)2-SJG-136 adduct
The NOESY and COSY spectra for the 5’J(CICGATCICG)2-SJG-136 adduct showing 
all drug resonances can be found in Figure 65. On comparison of the 2D NOESY 
spectrum of this adduct with that of the 5’c/(CICGATCICG)2 duplex it is confirmed that 
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Figure 62: 600 MHz NOESY spectra of the 5V(CICGATCICG)2 duplex and the 
5W(CICGATCICG)2-SJG-136 adduct, H8/H6-H1’ region. The duplex spectrum is shown 
in black while the adduct spectrum is superimposed in red.
The sequential assignment procedure for the drug-DNA adduct begins in the same 
fashion as for the duplex, with assignment of the duplex protons based on the same 
connectivities as discussed in sections 2.5 and 2.6. It is usual to begin with the H6/H8 to 
H I’ region and successful assignment of a complete ‘walk’ in this region confirms that 
the DNA has retained B-form character. The 2D NOESY expansion of this region fiilly 

















F I  (ppm)
Figure 63: 2D NOESY spectrum of the 5’tf(CICGATCICG)2-SJG-136 adduct, H8/H6-H1’
region 600 MHz, 300ms mixing time
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The presence of only one walk in this region confirms that the duplex has also 
maintained self-complementarity, and that only one adduct is present in the reaction 
mixture.
2.8.3: Assignment o f drug resonances
Drug protons are found using intra-drug connectivities, which provide a ‘walk’ across 










Figure 64: Pictorial representation of one end of the symmetrical covalent minor groove 
binder, SJG-136. The numbering system is shown as well as useful connectivities within 
the drug. COSY (scalar) couplings are shown in red with NOESY (dipolar) couplings
represented in black
The assignment procedure for the drug protons of the 5V(CICGATCICG)2-SJG-136 
adduct began with the SJG-H11 and SJG-Hlla protons. These protons are 3Jhh scalar 
coupled and so exhibit a strong COSY cross-peak. When the 2D COSY spectrum is 
examined a COSY peak can be observed in the H I’ -  H4’ region (Peak A, Figure 65).
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As H I’ -  H4’ connectivities do not result in COSY interactions this peak can only be 
attributed to a drug interaction. Previous work on the similar 5 ’ c/(CICGATCICG)2- 
DSB-120 adduct181 located the SJG-H11 and SJG-Hlla protons at a chemical shift of 
5.75 ppm and 3.83 ppm respectively so it is likely that the COSY peak in question is the 
result of the SJG-Hll-Hlla interaction and as a result these protons are tentatively 
assigned chemical shifts of 5.54 ppm and 3.59 ppm respectively.
From the SJG-Hlla resonance at 3.59 ppm it is possible to identify the SJG-Hla and 
SJG-Hlb proton shifts by virtue of a COSY connectivity with SJG-Hlla. In practise 
although both SJG-Hla and SJG-Hlb are 3Jhh scalar coupled to SJG-Hlla only one 
COSY cross-peak is found. This is due to the dihedral angle between the two coupled 
protons. As discussed in section 2.4.4, if the angle is close to 90° the coupling constant 
becomes very small. In the case of the SJG-Hlla-SJG-Hla/b connectivity the coupling 
between SJG-Hlla — SJG-Hlb would be expected to produce a COSY cross-peak, 
whereas the SJG-Hlla -  SJG-Hla coupling might not. If a line is drawn in the FI 
direction from the HI la  chemical shift of 3.59 ppm it bisects a strong COSY peak at
3.04 ppm (Figure 65, Peak B), thereby identifying SJG-Hla/b. The second SJG-H1 
proton can be found by a COSY connectivity between SJG-Hla and SJG-Hlb (Figure 
65, Peak C) and is assigned a chemical shift of 2.51 ppm.
When vertical lines are traced in the F2 direction from the chemical shifts of SJG-Hla 
and SJG-Hlb as expected they bisect a pair of NOESY cross-peaks at the SJG-H11 
resonance of 5.54 ppm (Figure 65, Peaks E & F). At this point it is possible to 
tentatively distinguish between SJG-Hla and SJG-Hlb on the basis of the strength of 
the interaction with SJG-H11. There is a slight difference in the distance of SJG-Hla to 
SJG-H11 (approximately 2.3 A) and the longer distance between SJG-Hlb and SJG- 
H ll (approximately 2.9 A). This results in a slightly stronger NOESY cross-peak 
between SJG-Hla and SJG-H11, and therefore SJG-Hla and SJG-Hlb are assigned 
chemical shifts of 2.51 ppm and 3.04 ppm respectively. These assignments are 
supported by the presence of the COSY connectivity from SJG-Hlla -  SJG-Hla/b, 
which as expected, occurs as a result of the connectivity of SJG-H1 la  with SJG-Hlb.
Continuance of the SJG-Hla and SJG-Hlb lines in the F2 direction sees them bisect 
another pair of NOESY resonances at a chemical shift of 5.58 ppm (Figure 65, Peaks
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G&H). This resonance can be assigned as SJG-H2a/b, and the lack of any other pairs of 
NOESY peaks in this region as well as a lack of any COSY connectivity that could be 
attributed to a correlation between the SJG-H2 peaks suggests that in this case SJG-H2a 
and SJG-H2b are overlaid.
Scanning of the SJG-H2a/b chemical shift in the FI direction results in the observance 
of a pair of peaks at 4.00 ppm and 4.09 ppm (Figure 65, Peak pair I). These can be 
attributed to SJG-H3a and SJG-H3b although due to a lack of clear NOE resonances to 
surrounding DNA protons and the similarity in chemical shift of the two it is not 
possible to distinguish between the pair. This almost completes the assignment of the 
PBD subunit protons, leaving only SJG-H9 and the protons of the linker unit 
unassigned.
The SJG-H9 proton provides a lead into the linker protons by virtue of its connectivity 
with SJG-H12 and SJG-H14, and can be easily found due to its close proximity to the 
A5-H2 proton of the DNA duplex. When connectivities to the A5-H2 proton at 8.10 
ppm are examined a large NOESY connectivity is observed at 6.55 ppm that is not due 
to a DNA connectivity (Figure 65, Peak J). This cross-peak can be attributed to the 
interaction of SJG-H9 and A5-H2 and hence the SJG-H9 proton is assigned a chemical 
shift of 6.55 ppm.
From the SJG-H9 resonance it is possible to identify SJG-H12a/b (both at the same 
chemical shift) by a NOESY cross-peak at 4.20 ppm (Figure 65, Peak K). SJG-H12a/b 
is 3Jhh scalar coupled to SJG-H13a/b and so the connectivity results in a COSY 
interaction. The COSY cross-peak can be found at 2.30 ppm (Figure 65, Peak L), 
hence confirming the chemical shift of SJG-H13a/b. The lack of any other significant 
NOESY or COSY cross-peaks at the SJG-H12 chemical shift in this region leads to the 
conclusion that SJG-H13a and SJG-H13b are also found at the same chemical shift.
There now remain only two proton resonances to identify -  SJG-H6  and SJG-H14. The 
connectivity between these would be expected to produce a large NOESY cross-peak in 
the DNA H8 /H6  to H3’ or H4’ region. Such a cross-peak can be seen at coordinates
7.05 ppm/3.80 ppm and hence the SJG-H6  and SJG-H14 protons can be assigned shifts 
of 7.05 ppm and 3.80 ppm respectively.
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Figure 65: 600 MHz NOESY spectrum of the 5W(CICGATCICG)2-SJG-136 adduct
200 ms mixing time
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On completion of assignment of drug protons in this way it is possible to confirm some 
assignments using NOE connectivities into the DNA duplex. Many of the drug-DNA 
connectivities are discussed in Chapter 3.
2.8.4: Assignment o f drug protons in the 5 ’d(CGATTAATCG)2-Adozelesin Adduct
As with the 5’d(CICGATCICG)2 -SJG-136 adduct, after ascertaining that the drug has 
reacted with the DNA and that there are no remaining duplex signals the first step in 
assigning the DNA-adozelesin adduct is to identify and assign all resonances belonging 
to the DNA. The drug proton walks are then identified in a similar manner using 
connectivities within the drug, as well as NOE connectivities to nearby DNA protons. 








Figure 66: Pictorial representation of the covalent minor groove binder, adozelesin. The 
numbering system is shown as well as useful connectivities within the drug. COSY (scalar) 
couplings are shown in red with NOESY (dipolar) couplings represented in black
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In the assignment of the 5 ’d(CGATTAATCG)2-adozelesin adduct the drug methyl 
groups provided a good starting point due to the two large and fairly obvious NOESY 
cross-peaks in the aromatic-methyl region at 2.70 ppm and 2.85 ppm (Figure 67, Peaks 
A & B) corresponding to the interaction of the adozelesin methyl groups with the H6  
proton. The Ado-H6  and Ado-methyl resonances were hence assigned shifts of 8.30 
ppm and 2.85 ppm respectively (adduct 1), 8.30 ppm and 2.70 ppm (adduct 2). From the 
methyl proton in each case a cross-peak can be found in the F2 dimension 
corresponding to the interaction of this proton with the Ado-H8 a/b protons (Figure 67, 
Peaks C & D). The Ado-H8 a and Ado-H8 b protons were found to be overlaid in both 
adducts, as only one cross-peak with the drug methyl group was observed for each 
adduct.
Ado-H8A2 was found in both adducts owing to a large NOE with Ado-H8 a/b (Figure 
67, Peaks E & F). There was no evidence of the expected COSY peak resulting from 
this interaction in either adduct, suggesting that in both cases the dihedral angle was 
close to 90°. Ado-H8A2 then provides a lead into the chemical shift of the Ado-Hla and 
Ado-Hlb protons by way of a COSY connectivity with these (Figure 67, Peaks G & 
H). Once again, the presence of only one such COSY peak for each adduct confirms 
that, as with the Ado-H8 a/b protons, the Ado-Hla and Ado-Hlb protons are overlaid in 
both cases. The Ado-Hla/b protons then provide a connectivity with the Ado-H3’l 
proton in the DNA H8 /H6  -  H4’ region of the spectrum. The Ado-H3’l proton 
chemical shift can be supported in the DNA H8 /H6  - H8 /H6  region of the spectrum by 
its connectivity with Ado-H4’l. However, care must be taken when confirming the 
location of Ado-H3’ 1 in this manner as there are many peaks present in this area.
The protons of the benzofuran tail and the H6’l-H7’l vicinal coupling are found by 
virtue of strong COSY peaks in the DNA H8 /H6  -  H8 /H6  region. There are no DNA 
protons that give rise to COSY peaks in this area, hence any COSY peaks detected can 
be safely attributed to drug protons. The Ado-H6 ’l -  Ado-H7’l is an isolated spin 
system and so can usually be attributed to any peak that does not align with any others, 
while the remaining vicinal couplings around the benzofuran tail give rise to a 
connectivity network. In the case of the 5 W(CGATTAATCG)2-adozelesin adducts 
assignment of this region was difficult owing to overcrowding. In addition many 
protons were situated at very similar chemical shifts -  leading to the COSY cross-peak
1 0 0
being situated on the diagonal. The protons were assigned using a mixture of techniques 
including connectivities with DNA protons such as the adenine H2 protons and 
connectivities with thymine and adenine exchangeable amino H3 protons, seen only on 
acquisition of additional 2D spectra in a water solvent. The assigned region can be seen 
in Figure 6 8 .
Differentiation between the two adducts was based on connectivities into the DNA 
backbone. From these it is possible to link the drug walk into a distinct DNA walk. 
Evidence for the Hoogsteen or Watson-Crick nature of each adduct will be subsequently 
discussed in Chapter 5.
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Figure 67: 600 MHz 2D NOESY and COSY spectra of the 5V(CGATTAATCG)2-adozelesin 
mixed adduct. NOESY mixing time 200ms. Black=NOESY, blue = COSY.
Green lines = Watson-Crick assignments, red lines = Hoogsteen assignments
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Figure 68: 600 MHz 2D NOESY and COSY spectra of the 5V(CGATTAATCG)2-adozelesin mixed 
adduct. Black = NOESY, Blue= COSY. NOESY mixing time 200ms. Expansion of the H6/H8-H6/H8 
region. Green lines = Watson-Crick assignments, Red lines = Hoogsteen assignments
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CHAPTER 3: RESULTS AND DISCUSSION
THE 5’</(CICGATCICG)2-SJG-136 INTER-STRAND ADDUCT
As discussed in Chapter 1, SJG-136 (Figure 69) is an exo unsaturated PBD dimer, 
linked through the C8  positions of the PBD subunits by a flexible propyl chain. It was 
designed to form inter-strand cross-links with B-form DNA. It was postulated that the 
drug would react similarly to DSB-120 (Figure 69) but with increased potency, as it 










Figure 69: Structures of SJG-136, DSB-120 and tomamycin
The increased potency of the monomers is thought to be a result of lower 
electrophilicity at the N10-C11 position. On a concentration basis SJG-136 was found 
to show a 10-fold greater efficiency than DSB-120. Molecular modeling has shown an 
SJG-136 adduct to maintain the structure of B-form DNA and both SJG-136 and DSB- 
120 are easily accommodated in the minor groove. The lack of exposure beyond the
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DNA periphery leads to an observed resistance to DNA repair enzymes, which function
77by tracing helical perturbation or distortion in DNA. Calculated binding energies 
suggest that SJG-136 should form a more favourable adduct than DSB-120 as 
introduction of an exocyclic methylene at C2 causes the C ring to stiffen and become
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more planar and hence a better fit in the minor groove. In this study an SJG-136
adduct has been formed and compared with an identical duplex sequence which had
1formed adducts with DSB-120 and tomamycin in an earlier study.
3.1: Design of Duplex
The 5 W(CICGATCICG) 2  duplex was synthesized using standard methods and was 
allowed to react for 16 hours with 5 mg of SJG-136 as detailed in Chapter 2. The 
duplex was identical to the duplex used in the study of DSB-120, in order to allow a 
direct comparison to be made. From the ID !H NMR spectrum it was deduced that the 
reaction had proceeded to completion and 2D COSY and NOESY experiments were 
performed on the resulting adduct. Prior to performing molecular modeling experiments 
on the adduct it was necessary to determine the complexity of the cross-linked species 
formed, identify the sites of covalent linkage between SJG-136 and DNA and determine 
the stereochemistry and orientation of the drug within the DNA duplex.
3.2: Symmetry of the 5’rf(CICGATCICG)2-SJG-136 adduct
The one-dimensional JH-NMR non-exchangeable spectra for both the duplex and the 
adduct can be seen in Figures 70 & 71. The spectrum was clean with well-resolved 
signals. The resonances have been assigned by two-dimensional NMR spectra 
employing through-bond COSY and through-space NOESY connectivities. The 
chemical shift assignments for the nucleotide and drug protons in the duplex and the 
adduct are listed in Tables 12 & 13. There were no duplex resonances remaining after 
reaction with SJG-136 confirming that the reaction has proceeded to completion. The 
complete 2D NOESY and COSY spectra with drug resonances assigned can be seen in 
Figure 72, while an expansion of the H6 /H8  -  H I’ region of the adduct NOESY and 
COSY spectra can be seen in Figure 73. Four strong COSY peaks can be identified
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(Peaks A, B, C and D) concurrent with the C-H5-C-H6 interaction of the four cytosine 
peaks. This suggests that the self-complementarity of the duplex has been retained, an 
observation that is supported by the presence of a single proton walk in this region. It is 
therefore confirmed that a single bis-adduct has been formed.
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Figure 70: 600 MHz ID 'H NMR spectrum of the 5’</(CICGATCICG)2 duplex
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Figure 71: 600 MHz lU NMR spectrum of the 5V(CICGATCICG)2-SJG-136 adduct
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Table 12: Chemical Shifts (ppm) of 5V(CICGATCICG)2 and 5V(CICGATCICG)2-SJG-136 adduct DNA Protons o
Base H8/H6 H I’ H2’ H2” H3’ H4’ H5/CH3/H2
Cl 7.69 7.60 0.09 5.56 5.52 0.04 1.90 1.82 0.02 2.30 2.28 0.02 4.63 4.61 0.02 3.64 3.63 0.01 5.85 5.80 0.05
12 8.39 8.28 0,11 6.11 6.15 0.04 2.71 2.66 0.05 2.82 2.82 0.00 4.95 4.91 0.04 4.34 4.32 0.02 7.92 7.82 0.10
C3 7.28 7.34 0.06 5.70 5.47 0.23 1.68 1.86 0.18 2.23 2.27 0.04 4.75 4.92 0.17 4.03 4.06 0.03 5.24 5.26 0.02
G4 7.94 7.80 0.14 5.49 6.08 0.06 2.66 2.66 0.00 2.71 2.94 0.23 4.93 4.95 0.02 4.30 4.06 0.24 - - -
A5 8.20 8.15 0.05 6.14 6.30 0.16 2.71 2.46 QJA 2.84 2.66 0.18 4.90 4.88 0.02 4.16 3.94 0.22 7.76 8.11 0J5
T6 7.17 7.05 0.12 5.80 5.71 0.09 1.94 1.94 0.00 2.37 2.17 0.20 4.77 4.55 0.22 4.20 3.98 0.22 1.23 1.20 0.02
C7 7.53 7.14 0.39 5.48 5.44 0.04 2.00 2.09 0.09 2.32 1.65 0.67 4.95 4.71 0.24 4.05 4.02 0.03 5.52 5.26 0.26
18 8.33 8.12 0.21 6.08 5.84 0.24 2.64 2.57 0.07 2.80 2.10 0.70 494 4.83 0.11 406 3.82 0.24 7.72 7.38 0.34
C9 7.28 7.20 0.08 5.76 5.77 0.02 1.58 1.46 0.12 2.15 2.13 0.02 4.92 4.71 0.21 3.99 3.94 0.05 5.30 5.26 0.04
G10 7.96 7.90 0.06 6.05 6.06 0.01 2.28 2.26 0.02 2.58 2.55 0.03 4.60 4.58 0.02 4.10 3.96 0.14 - - -
Key: B lue = duplex shift (ppm ), B lack =  adduct shift (ppm ) G reen =  + /- D ifference (ppm ) U nderlined = greater than 0.25 ppm
Table 13: Chemical shifts of adduct drug protons
Drug Hla Hlb H2a/b H3a/b H6 H9 HI 1 H lla H12a H13 H14
Shift (ppm) 2.55 3.21 5.84 4.02/4.06 7.05 6.53 5.64 3.92 4.24 2.28 3.83
Table 14: Comparison of chemical shifts (ppm) 5V(CICGATCICG)2-SJG-136 and 5W(CICGATCICG)2-DSB-120 adducts
H8/H6 H I’ H2’ H2” H3’ H4’ H5/CH3/H2
Cl 7.60 7.72 0.12 5.52 5.74 0J2 1.82 1.92 0.10 2.28 2.38 0.10 4.61 4.62 0.01 3.63 3.98 OJA 5.80 5.93 0.13
12 8.28 8.26 0.02 6.15 6.21 0.06 2.66 2.81 0.15 2.82 2.81 0.01 4.91 4.94 0.03 4.32 4.37 0.05 7.82 7.93 0.11
C3 7.34 7.50 0.16 5.47 5.43 0.04 1.86 2.05 0.19 2.27 2.30 0.03 4.92 4.82 0.10 4.06 4.10 0.04 5.26 5.52 0.26
G4 7.80 7.92 0.12 6.08 6.16 0.08 2.66 2.71 0.05 2.94 3.05 0.11 4.95 5.06 0.11 4.06 4.12 0.06 - -
A5 8.15 8.26 0.11 6.30 6.44 0.14 2.46 2.60 0.14 2.66 2.75 0.09 4.88 4.98 0.10 3.94 4.15 Q Jl 8.11 8.16 0.05
T6 7.05 7.07 0.02 5.71 5.78 0.07 1.94 2.03 0.09 2.17 2.19 0.02 4.55 4.62 0.07 3.98 2.61 IJ7 1.20 1.27 0.07
C7 7.14 7.17 0.03 5.44 5.48 0.04 1.65 1.65 0.00 2.09 2.15 0.06 4.71 4.72 0.01 4.02 4.07 0.05 5.26 5.31 0.05
18 8.12 8.05 0.07 5.84 5.86 0.02 2.57 2.73 0.16 2.10 2.56 0.46 4.83 4.89 0.06 3.82 3.79 0.03 7.38 7.54 0.16
C9 7.20 7.44 0.24 5.77 5.83 0.06 1.46 1.82 0.36 2.13 2.34 0.21 4.71 4.72 0.01 3.94 4.08 0.14 5.26 5.52 0.26
G10 7.90 7.89 0.01 6.06 6.12 0.06 2.55 2.64 0.09 2.26 2.34 0.08 4.58 4.65 0.07 3.96 4.15 0.19 -
B lack =  SJG -136 adduct (ppm ), Red =  D SB-120 adduct (ppm ), G reen =  difference (+ /-)(ppm ) U nderlined =  greater than 0.20 ppm
F2
( p p m )
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Figure72: 600 MHz 2D NOESY and COSY spectra of the 5V(CICGATCICG)2-SJG-136 adduct 
Black= NOESY, Blue = COSY, NOESY mixing time 200 ms. Complete drug assignments are shown
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Figure 73: 600 MHz NOESY spectrum of the 5W(CICGATCICG)2-SJG-136 adduct 
Mixing time = 200 ms, H6/H8-H1’ region. A, B, C and D show C-H5 to C-H6 cross-peaks
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3.3: Identification of the Covalent Linkage Site
PBD ligands are known to react with the exo-cyclic NH2 group of a guanine base via 
either direct attack on the imine species or by an SN2 type mechanism as shown in 





Direct attack on imine
SN2 - type reaction with 
carbinolamine species
Sugar
Figure 74: General reaction of a PBD with a guanine base. An equilibrium exists between 
the imine and carbinolamine species, resulting in possible direct imine attack or SN2 type
reactions
Connectivities between SJG-136 and the duplex are listed in Table 15. These, along 
with the large changes in shift value throughout the central bases of the adduct when 
compared with the duplex (see Table 12) confirm the presence of the drug in the minor 
groove as depicted in Figure 75.
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A5-H4’ M(o) B B
A5-H3’ M
T6-H4’ W/M B B
T6-H5’ W
T6-H5” w
T6-H1’ M M M(o)
C7-H1’ W W W(o) MAV M(o) W
C7-H4’ W B S(o) B
I8-H3’ M(o) MAV
I8-H2 M M W(o) W M
I8-H4’ B B B
I8-H1’ W(o) M(o)
C9-H4’ M(o) B B
C9-H1’ W
Table 15: NOE connectivities between SJG-136 protons and the 5V(CICGATCICG)2 
duplex. S = strong, M = medium, W = weak, (o) = overlaid, B = buried
Furthermore similar shift changes have been previously reported for the reaction of
1 fi 1DSB-120 (Table 14) with an identical duplex sequence. In light of this evidence the 
covalent linkage site is identified as G4, supported by large changes in the chemical 
shift of the opposite base (C7) as well as 18.
3.4: Stereochemistry and Orientation
As discussed in Chapter 1, it is possible in theory for either ‘S’ or ‘R’ stereochemistry 
to exist at the covalent linkage site Cl 1 in PBD-DNA adducts (See Figure 76).
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Figure 76: R and S stereochemistry in the PBD subunit
Previous studies have shown that, for the tomamycin (Figure 69) */(ATGCAT) 2  adduct 
the PBD -ll’R’ and PBD-11* S’ stereoisomers exist in approximately equal 
proportions. 194 However molecular mechanics calculations predict that the lowest 
energy conformation is an IT S ’ isomer42,43,44 and other studies have shown the ‘S’ 
isomer to be predominant for this class of drugs. 181,195 The proton attached at the PBD- 
C ll covalent linkage site has proved to be a useful diagnostic probe for determination 
of the stereochemistry at this site. It has been stated that in an adduct with ‘S’ 
stereochemistry at the PBD-C11 point PBD-H11 will be directed towards the 3’ side of 
the covalently modified guanine, whereas for an ‘R’ isomer the situation is reversed
1 fitwith PBD-H11 closer in space to the 5’ side. A pictorial representation of this can be 
seen in Figure 77. In the case of the 5W(CICGATCICG)2-SJG-136 adduct a strong 
NOE between SJG-H11 and A5-H1’ (Figure 78) confirms that the ‘S’ isomer is 
present. This is supported by the absence of any cross-peak between SJG-H11 and the 
cytosine to the 5’ side of G4 (C3). The orientation of the aromatic rings in the SJG-136 
adduct is fixed in a head to head orientation by the methylene linker unit.
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Figure 77: Representation of the central region of the 5V(CICGATCICG)2-SJG-136 
adduct, with 11’S’ stereochemistry, showing the proximity of A5-H1’ to SJG-H11
6 . 5  6 . 0  5 . 5  5 . 0
PI (ppm)
Figure 78: 600 MHz NOESY expansion showing NOEs between SJG-H11 and A5-
H l’ & G4-H1’, mixing time = 200ms
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3.5: Nucleic Acid Proton Chemical Shifts
A comparison of the 5 W(CICGATCICG)2-DSB-120 adduct181 with the 
5’d(CICGATCICG)2-SJG-136 adduct shows a very similar two dimensional NOESY 
spectrum (see Table 14). However, some marked differences were observed. Although 
the chemical shift values for the two adducts were generally similar there was a marked 
up-field shift in many of the DNA-C9 base protons in the SJG-136 adduct when 
compared with the DSB-120 adduct. This, along with changes in the relative shift of 
DNA-C1 and DNA-I8  protons can be attributed to the shielding effect of the 
introduction of the ethylene group.
3.5.1: Relative chemical shifts o f the DNA-H2 ’ and H2 ’ *protons
As discussed in Chapter 2, chemical shifts of H2’ and H2” proton resonances are 
usually seen between 1.5 ppm and 3.0 ppm. The H l’-H2’ coupling is invariably more 
intense than the H r-H 2” as a result of the greater inter-proton distance in the latter 
case and typically the H2’ protons resonate up-field of the H2” protons within the same 
nucleotide sequence. 196 For the 18 nucleotide in the SJG-136 adduct however, there is a 
reversal of the general pattern and the HI ’-H2” resonance is found up-field of the HI 
H 2\ This feature was also noted in the study of the DSB-120 adduct and is indicative of 
a conformational change within the internal nucleotide. It suggests that, as with DSB- 
120, SJG-136 induces an additional perturbation in the structure of the C7 nucleotide 
facing the covalently modified G4 in the minor groove.
3.5.2: Chemical shift changes in the 5 id(CICGATCICG)2 -SJG-l36 adduct relative to 
duplex DNA
Chemical shifts for oligonucleotide proton resonance signals of the SJG-136 adduct 
relative to the duplex are shown in Table 12. There are up-field chemical shifts of 0.39 
ppm and 0.26 ppm for C7-H6 and C7-H5 respectively, which mirror shift changes seen 
when the same duplex sequence was reacted with DSB-120. In addition large shift 
changes can be seen for C7-H2’/H2” and C7-H3’ protons. These chemical shift
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changes suggest an increase in stacking of the T6-C7 step. However studies of the 
DSB-120 adduct revealed probable de-stacking of the I2-C3 step, deduced from 
downfleld shifts for C3-H6 and C3-H5. These shifts are absent in the SJG-136 adduct 
spectrum, suggesting that the aforementioned de-stacking does not occur in this case. 
The I8-H2 resonance of the SJG-136 adduct undergoes a 0.34 ppm up-field shift. 
Similar observations have been noted in the relative chemical shifts of I8-H2 when the 
duplex sequence was reacted with tomamycin. A large up-field shift of the I8-H2 
relative to the duplex was attributed to the shielding effect of the ethylidene
m i
functionality of the drug in this case. This shift is not seen in the DSB-120 adduct due 
to the absence of the ethylidene group and in the case of SJG-136 it would appear that 
the introduction of the ethylene functionality produces a similar effect to the former 
drug. The 0.34 ppm downfield shift of the A5-H5 resonance has been seen in both the 
DSB-120 and tomamycin adducts also, and can be attributed to de-shielding effects of 
the aromatic ring of the covalently attached drug. Other chemical shift changes within 
the adduct relative to the duplex, as seen with DSB-120, are mainly protons in 
proximity to the attached drug and most are attributable to drug shielding and de­
shielding effects.
The previous studies on DSB-120 and tomamycin highlighted a dramatic difference 
between the chemical shift changes of T6-H4’ in each case. This proton is shielded by 
the drug aromatic rings in both cases but the resulting up-field shift was dramatically 
attenuated in the case of DSB-120. It is suggested that the structure of the inter-strand 
cross-linking via tethered DNA reactive units in this case causes the DSB aromatic ring 
to be partially averted from the wall of the groove, greatly reducing the level of 
shielding experienced. In the case of SJG-136 only a 0.22 ppm up-field shift is observed 
compared with 1.65 ppm in the case of DSB-120. This suggests that in this case the 
aromatic rings of the drug are averted still further, causing the shielding to be much 
reduced relative to that felt by DSB-120. Molecular modeling of this area is shown in 
section 3.7.
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3.6: Intermolecular Drug-DNA Contacts
The proton resonances for SJG-136 have been identified and assigned using analysis of 
the NOESY and COSY spectra as discussed in Chapter 2. Contacts have been found 
between SJG-136 protons and G4, A5, T6 , C7,18 and C9 bases and are shown in Table 
15 as well as pictorially in Figure79. The presence of this network of NOE contacts 
from SJG-136 to specific DNA protons locates the drug indisputably in the minor 
groove. As seen in studies of the DSB-120 adduct, SJG-H11 shows a strong cross-peak 
to A5-H1 ’ and a moderate cross-peak to G4-H1 ’ (Figure 78). In the case of DSB-120 
further evidence for the averted aromatic ring discussed above was found based on the 
intensity of the cross-peak between SJG-H11 and the A5-H4’ proton. Unfortunately, in 
this study the cross-peak in question is situated under the large COSY peak arising from 
the scalar coupling of SJG-H11 to SJG-Hlla, so no such conclusions can be drawn. 
However, the methylene protons of the linker (SJG-H12a, HI2b, HI3a and HI3b) all 
exhibit expected NOESY connectivities that locate them firmly in the minor groove. 
(See Table 15 and Figure 79). As with DSB-120 the characteristic signal between 
SJG-H13a/b and C7-H4’ although overlaid, can be located as a strong cross-peak, while 
SJG-H12a and SJG-H12b show connectivities to A5-H2 and T6 -H1 ’ (See Figures 80 & 
81). Interestingly, evidence based on connectivities from the SJG-Hla and SJG-Hlb 
protons of SJG-136 to I8-H2 and I8-H1 ’ suggest that this drug is located more deeply in 
the minor groove than observed for DSB-120. In the study of the latter drug DSB-Hla 
and DSB-Hlb both show very weak NOESY cross-peaks to I8-H2 and I8-H1 ’ and from 
these reduced through-space connectivities it was deduced that DSB-120 was immersed 
rather shallowly in the minor groove. In the SJG-136 adduct of the current study the 
SJG-Hla and SJG-Hlb protons show moderate cross-peaks to I8-H2. Unfortunately, as 
with the A5-H4’ proton, the SJG-Hla and SJG-Hlb to I8 -H1 ’ resonance is too overlaid 
to be conclusive. However, the deeper location of SJG-136 in the minor groove is 
further supported by the probable absence of cross-peaks between SJG-Hla/b and A5- 
H17C7-H47 Three of these peak areas are overlaid but there is a clear absence of any 
connectivity between SJG-Hla and C7-H4’. This suggests that the SJG-136 adduct 
bears a greater resemblance to the tomamycin adduct in this respect than to DSB-120, 
where a bowing of the ends of the drug away from the floor of the minor groove 
resulted in weak peaks being observed between the protons discussed above.
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Figure 79: Representation of the 5W(CICGATCICG)2-SJG-136 inter-strand cross-linked adduct, showing NOE 
connectivities between SJG-136 and the DNA backbone. For increased clarity only one end of the symmetrical molecule
is labelled
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Figure 80: Expansion of 600 MHz NOESY spectrumof the 5’rf(CICGATCICG)2-SJG-136 








Figure 81: Expansion of 600 MHz NOESY spectrum of the 5 W(CICGATCICG)2-SJG-136 
adduct showing NOE cross-peak between SJG-H12a/b and C7-H1’(A) & T6-H1’ (B)
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3.7: Molecular modeling of the 5,d(CICGATCICG)2-SJG-136 adduct
The 5W(CICGATCICG)2-SJG-136 adduct was modelled using the SYBYL software 
suite. 197 This is a general molecular modeling package and was implemented due to 
reasons of availability and suitability for this type of study. The ligand-DNA complexes 
were first modelled using the HYPERCHEM package. 198 Both DNA and drug were 
drawn and docked within the package and subjected first to steepest descent energy 
optimisation and secondly to molecular dynamics in vacuo at 300 K. SJG-136 was 
isolated, minimised and then imported from HYPERCHEM into the SYBYL suite 
where it was re-docked onto a DNA duplex produced within SYBYL. This procedure 
ensured correct atom typing/charges within the final model.
The following procedures were then implemented to produce a refined structural model 
of the adduct.
1. Restraints were applied to the DNA H-bonds of the terminal bases to reduce end 
fraying during MD calculations.
2. The charges were recalculated for the modified bases and ligand using the 
Gasteiger Huckel method within the SYBYL package. Standard DNA charges 
were used for the rest of the DNA duplex.
3. The ligand molecule and modified bases were subjected to steepest descent 
energy minimization using minimization software supplied within the SYBYL 
package.
4. The entire adduct was then subjected to steepest descent energy minimization.
5. The adduct was solvated with 5 layers of Gasteiger Huckel charged water 
molecules within a droplet. A single sodium counter ion was associated with 
each end of the DNA backbone phosphates.
6 . Molecular mechanics calculations were then performed on the adduct. The 
temperature was ramped in stages/steps from OK to 300K over around 50 ps and 
then held at 300 K for 20 ps. All structure refinement utilised the Tripos force 
field and AMBER mechanics.
7. When a satisfactory model had been obtained steps 4-6 were repeated applying 
the restraints generated from the 2D NMR datasets (NOESY and COSY). Full 
restraints can be found in Appendix I. The additional restraints initially used
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were maintained on the terminal bases to reduce end fraying of the duplex 
during the final stages of the calculation.
8 . The final lOps of the rMD data (at 300 K) were averaged and the drug-DNA 
model was subjected to an energy minimization procedure in vacuo to produce 
the final NOE refined molecular model of the adduct.
3.7.1: The importance o f solvation and counter ions in molecular mechanics operations
Forces between charged atoms maintain the macromolecular tertiary structure in all
100nucleic acids. Westhof et al stated that p-helical structures were sustained by an 
equilibrium between several factors. These included electrostatic forces between 
negatively charged phosphates, hydrophobic interactions between aromatic rings of 
bases (promotes orderly base pair stacking) and energy of the sugar-phosphate 
backbone conformation.
Non-covalent bonds within the helix of DNA consist of electrostatic forces, hydrogen 
bonding and Van der Waals forces. These are all influenced greatly by water in all 
biological systems and Stryer16 stated that the addition of water could reduce the 
strength of electrostatic interactions by up to 80 times relative to those experienced by 
DNA in vacuo. Therefore it was deemed important to solvate the drug-DNA adduct in 
order to give an accurate representation of its structure in biological systems. Hence the 
inclusion of 5 layers of Gasteiger Huckel charged water molecules all subjected to 
calculations in the molecular mechanics of the refined model.
3.7.2: The refined molecular model o f the 5 ,d(ClCGATCICG)2-SJG-l 36 adduct
Molecular mechanics and dynamics calculations on the 5 W(CICGATCICG)2-SJG-136 
adduct were performed in aquo using the standard method outlined in this chapter. All 
figures are from the minimised averaged structure, the water and counter ions were 
removed for clarity.
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Figures 82 - 84 show the in aquo computer model of the SJG-136-5 V(CICGATCICG)2  
DNA duplex. SJG-136 is depicted in white, with the two DNA strands in green and 
purple. It is clear from this picture that Watson-Crick base pairing has been maintained. 
This is in agreement with the 2D NOESY NMR spectrum, which suggested the DNA 
had retained the p-helical structure required for the sequential assignment procedure to 
be successful. It can be seen that the drug is crescent shaped and fits snugly into the 
minor groove as expected, with minimal protrusion. This is in analogy to all other PBD 
drugs studied in this manner to date. Figure 85 shows the central region of the duplex 
with SJG-136 in situ. The central AT base pairs are shown in red and appear to have 
become slightly distorted in order to accommodate the drug. This is supported by the 
very weak A5-H8 to T6 -H6  cross-peak visible in the aromatic region of the spectrum. 
(See Figure 8 6 ). Figure 87 shows the T6-H4’ proton discussed in section 3.6.2. DNA 
strands are shown in green and purple with SJG-136 depicted in white. The T6-H4’ 
proton in question, as well as the drug aromatic ring are shown in red. NMR results 
suggested that the aromatic ring is partially averted from the wall of the minor groove 
resulting in an attenuation of the shielding received by T6-H4’.
3.8: Conclusions
In summary, a novel 5W(CICGATCICG)2-SJG-136 adduct has been produced and 
examined by high field NMR spectroscopy. The drug binds covalently in the minor 
groove to the exo-cyclic NH2 groups of guanines G4 on opposite strands of DNA, 
forming an inter-strand cross-link with SJG-C11 ‘S’ stereochemistry at both reaction 
sites.
Self-complementarity is maintained and minimal disruption to the DNA backbone is 
observed, allowing retention of a p-helical structure and subsequent assignment of all 
proton resonances using a sequential assignment procedure.
Molecular models of the 5’^ (CICGATCICG^-SJG-136 adduct have been generated 
using distance restraint data compiled from the 2D NMR experiments performed on the 
adduct. These show the drug fitting comfortably into the minor groove, following the 
contour of B-form DNA as a result of the ‘S’ stereochemistry seen at the SJG-Clla
1 2 2
chiral centre. Some distortion is evident in the central base pairs as a result of the 
accommodation of the drug in this fashion.
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K>4^
Figure 82: Cross-eye stereo view of 5V(CICGATCICG)2-SJG-136 adduct. DNA strands are shown in green and purple, 
SJG-136 is depicted in white. Model generated using SYBYL197 and pictured using UCSF CHIMERA193
K>L/i
Figure 83: Cross-eye stereo view of 5V(CICGATCICG)2-SJG-136 adduct., showing snug fit of SJG-136 into the minor groove
DNA strands are shown in green and purple, SJG-136 is depicted in white.
Model generated using SYBYL197 and pictured using CHIMERA193
Figure 84: Cross-eye stereo view of 5W(CICGATCICG)2-SJG-136 adduct. View from above showing maintenance of p-helical structure 
and fit of SJG-136 within the boundaries of the DNA. DNA strands are shown in green and purple, SJG-136 is depicted in white.
Model generated using SYBYL197 and pictured using UCSF CHIMERA193
Figure 85: Cross-eye stereo view of 5W(CICGATCICG)2-SJG-136 adduct. Central 
region only showing distortion of central bases. DNA strands are shown in green and 
purple, SJG-136 is depicted in white. Central A-T base pairs are shown in red. Model 
generated using SYBYL197 and pictured using UCSF CHIMERA193
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Figure 86: Expansion of the 600MHz 2D NOESY spectrum of 5’rf(CICGATCICG)2- 
SJG-136 showing the H8/H6 -  H8/H6 region. A very weak cross-peak between A5-H8 
and T6-H6 can be observed as a result of the distortion of the central A5 and T6 base
pairs
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Figure 87: Cross-eye stereo view of 5V(CICGATCICG)2-SJG-136 adduct.
Central region only showing proximity of T6-H4’ to the PBD aromatic ring. DNA strands are shown in green and purple, 
SJG-136 is depicted in white. Aromatic ring and H4’ proton are shown in red.
Model generated using SYBYL197 and pictured using CHIMERA193
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CHAPTER 4: RESULTS AND DISCUSSION
THE 5’rf(CTCATCAC).(GTGATGAG)-SJG-136 INTRA-STRAND ADDUCT 
4.1: Design and Synthesis of Duplex
The 5W(CTCATCAC).(GTGATGAG) duplex was designed to afford no reaction sites
react via direct attack or an SN2 type reaction mechanism through the cxo-cyclic NH2 
group of a guanine base. This means that the only possible reaction route for the drug 
with 5 ’ J(CT CAT C AC). (GT GAT GAG) is to react at guanine bases G il and G14 as 
shown in Figure 8 8 . SJG-136 has been shown to cover a three base pair region hence 
the DNA bases G9 and G14 are situated too far apart for a cross-linking reaction at 
these sites to be feasible, while the cytosine bases C3 and C6  contain no amino group at 
which reaction can occur.
_  „ 8 7  6  5 4 3 2 1
3 ' - C - A - C - T - A - C - T - C - 5
Figure 88: Representation of the 5’J(CTCATCAC).(GTGATGAG)-SJG-136 intra-strand 
cross-linked adduct showing the drug numbering system
on the ‘C’ strand, while providing two available sites on the ‘G’ strand in order to 
investigate the possibility of intra-strand cross-link formation. SJG-136 is known to
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The duplex was synthesised using methods discussed in Chapter 2. As for the 
5’c/(CICGATCICG)2-SJG-136 adduct, the duplex was allowed to react for 16 hours 
with 5 mg of SJG-136. From the ID NMR spectrum it was deduced that the reaction 
had proceeded to completion and 2D NOESY and COSY experiments were performed 
on the resulting adduct.
4.2: Confirmation of cross-link formation with two alkylation sites
The one-dimensional ^-N M R non-exchangeable spectra for both the duplex and the 
adduct can be seen in Figures 89 & 90. Once again the majority of signals are well- 
resolved - it is clear that the reaction has proceeded to completion, and a new species 
has been formed. An aromatic peak count is difficult due to the presence of overlaid 
signals towards the centre of the region, but an increase in the number of peaks can be 
observed, as would be expected with the addition of SJG-H9 and SJG-H6 , both of 
which may give rise to resonances in the aromatic region. In addition a new resonance is 
clearly discemable at around 6.4 ppm, while the methyl peak present at 1.2 ppm in the 
duplex spectrum is no longer visible -  suggesting that there is no remaining duplex 
DNA in the solution. A count of methyl peaks between 1-2 ppm yields a total of six as 
expected for a non-self-complementary DNA-SJG-136 adduct (four thymine methyl 
peaks plus two SJG-methyl peaks) in comparison with the duplex spectrum, where only 
four methyls corresponding to the four thymine bases can be discerned.
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Figure 89: 400 MHz ‘H NMR spectrum of the
5W(CTCATCAC).(GTGATGAG) duplex
5
Figure 90: 400 MHz *H NMR spectrum of the 
5V(CT CAT C AC).(GT GATGAG)-SJG-136 adduct
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For proton assignment of the 5’</(CTCATCAC).(GTGATGAG)-SJG-136 adduct once 
again COSY and NOESY NMR techniques were employed. An expansion of the 
H8/H6-H1’ region of the duplex and adduct NOESY spectra can be seen in Figure 91. 
It is clear when the two spectra are superimposed that there are no duplex resonances 
remaining in the adduct spectrum, confirming that the reaction has proceeded to 
completion as suggested by examination of the 1D spectra.
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Figure 91: 600 MHz NOESY spectra of the 5W(CTCATCAC).(GTGATGAG) duplex 
(black) and the 5’</(CTCATCAC).(GTGATGAG)-SJG-136 adduct (red), H6/H8 to H I’
region
Four strong COSY peaks can be identified in the H6/H8-H1’ region, confirming the 
presence of only one adduct. The region was fully assigned using the sequential 
assignment procedure outlined in Chapter 2, and can be seen in Figure 92. The 
presence of two complete ‘walks’ in this region confirms that the DNA strand is non­
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self-complementary as expected, and has retained its B-form character. In addition, two 
complete drug proton walks are possible across the whole spectrum, showing that the 
drug has reacted at both ends forming a non-self-complementary bis-adduct. Complete 
chemical shift assignments for the nucleotide and drug protons in the duplex and the 
adduct are listed in Tables 16 - 18.
4.3: Identification of the Covalent Linkage Site
As previously discussed, PBD ligands are known to react with the exo-cyclic NH2 group 
of a guanine base as shown in Figure 74 (Chapter 3). The 
5 ’J(CT CAT C AC). (GT GAT GAG) duplex as discussed previously was designed to 
afford no reaction sites on the ‘C’ strand, with two available sites on the ‘G’ strand in 
order to promote an intra-strand linkage.
As with the 5W(CICGATCICG)2-SJG-136 adduct, large changes in chemical shift at 
G14-H1 ’ and Gll-Hl* (0.85 ppm and 0.60 ppm respectively) as well as their Watson- 
Crick paired cytosines, help to confirm these bases as the sites of covalent modification. 
Large changes in chemical shift are also seen in the central protons A4-HT and T5-H1’ 
(‘C’ strand) and T13-H1’ and A12-H1’ (‘G’ strand). In addition, relatively large 
changes (> 0.20 ppm) are seen for several of the ‘G’ strand H2”  protons (G9-H2” , 
T10-H2” and T13-H2” ). This is suggestive of a greater association of the drug with the 
modified strand, and is not unexpected.
Connectivities between SJG-136 and the duplex were numerous and are listed in Tables 
19 <& 20 (section 4.6) A pictorial representation is shown in Figure 96. These 
connectivities, in conjunction once again with large changes in the chemical shift value 
throughout the central bases of the adduct when compared with the duplex, place the 
drug unequivocally within the minor groove of the DNA duplex. This, along with 
confirmation of the covalent linkage sites, confirms the presence of the first intra­
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Figure 92: 600 MHz NOESY spectrum of 5W(CTCATCAC).(GTGATGAG)-SJG-136, 
200ms mixing time, H6/H8 to H I’ region
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Figure 93: 600 MHz 2D NOESY and COSY spectra of the 
5’d(CTCATCAC).(GTGATGAG)-SJG-136 adduct. Black = NOESY, Blue = COSY.
NOESY mixing time 200 ms
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H8/H6 CH3/H2/H5 H I’ H2’ H2” H3’ H4’
Cl 7.70 7.76 0.06 5.76 5.84 0.08 5.67 5.80 0.13 2.04 2.08 0.02 2.38 2.44 0.06 4.46 4.55 0.09 3.90 3.98 0.08
T2 7.48 7.52 0.04 1.50 1.58 0.08 5.96 5.93 0.03 2.04 2.15 0.11 2.40 2.44 0.04 4.70 4.79 0.09 4.05 4.13 0.17
C3 7.42 7.45 0.05 5.56 5.65 0.09 5.34 5.99 0.65 1.98 2.12 0.14 2.26 2.55 0.29 4.40 4.82 0.42 3.96 4.18 0.22
A4 8.18 8.32 0.14 7.45 7.73 0.28 6.05 6.29 0.24 2.47 2.75 0.28 2.74 2.60 0.14 4.83 4.89 0.06 3.96 3.89 0.07
T5 7.00 6.89 0.11 1.24 1.15 0.09 5.66 5.55 0.11 1.84 2.18 0.34 2.24 1.76 0.48 4.64 4.51 0.13 3.96 3.56 0.40
C6 7.35 7.07 0.28 5.46 5.25 0.21 5.37 5.61 0.24 1.86 2.12 0.26 2.18 1.64 0.54 4.64 4.71* 0.07 3.90 3.94 0.04
A7 8.10 8.04 0.06 7.67 7.61 0.06 6.03 5.88 0.13 2.46 2.53 0.07 2.66 2.42 0.24 4.83 4.78 0.05 3.96 3.62 0.34
C8 7.19 7.30 0.11 5.20 5.21 0.01 5.86 5.97 0.11 1.90 1.97 0.07 2.64 2.02 0.62 4.60 4.71* 0.11 4.27 4.04 0.23
G9 7.77 7.83 0.07 - - 5.80 5.94 0.14 2.05 2.47 0.42 2.60 2.72 0.12 4.77 4.71* 0.06 3.90 4.13 0.23
T10 7.19 7.30 0.11 1.20 1.39 0.19 5.64 5.44 0.20 1.98 2.42 0.44 2.32 2.22 0.10 4.70 4.82 0.12 4.03 4.13 0.10
G il 7.73 7.78 0.05 - - - 5.48 6.08 0.60 2.51 2.84 0.33 2.62 2.60 0.02 4.83 4.97 0.14 4.16 4.35 0.19
A12 8.04 8.14 0.10 7.60 8.02 0.42 6.01 6.24 0.23 2.41 2.55 0.14 2.70 2.44 0.26 4.76 4.86 0.10 4.26 3.86 0.40
T13 6.86 7.01 0.15 1.19 1.26 0.07 5.46 5.40 0.06 1.68 2.15 0.47 2.04 2.10 0.06 4.83 4.60 0.23 3.89 3.45 0A4
G14 7.66 7.52 0.14 - - - 5.19 5.94 0.85 2.32 2.45 0.13 2.44 2.57 0.13 4.62 4.55 0.07 4.10 4.05 0.05
A15 7.92 7.83 0.09 7.60 7.71 0.11 5.92 5.77 0.15 2.44 2.44 0.00 2.68 2.55 0.13 4.76 4.87 0.11 4.23 4.05 0.18
G16 7.44 7.51 0.07 - - - 5.78 5.92 0.13 2.16 2.08 0.08 2.38 2.55 0.17 4.82 4.47 (131 ** 3.98 -
Table 16: Complete chemical shift assignments for the 5’rf(CTCATCAC).(GTGATGAG) duplex and 5’</(CTCATCAC).(GTGATGAG)-SJG-136 
adduct. Black = duplex, Red = adduct, Green = difference (greater than 0.2 ppm underlined). * = unfound, assigned as under residual water peak at 
4.71 ppm, ** = unfound.
H la Hlb H2a H2b H3a H3b H6 H9 HI 1 HI la H12a H12b H13b H13a H14
2.95 2.58 5.32 5.17 4.32 4.11 6.95 5.97 4.52 4.74 4.25 3.76 2.30 2.07 3.80
Table 17: Chemical shift assignments for SJG-136 protons in the 5’</(CTCATCAC).(GTGATGAG)-SJG-136 adduct, G-3’ end.
H la ’ H lb ’ H2a’ H2b’ H3a/b’ H6’ H9’ H IT HI la ’ HI 2a’ HI 2b’ H14’
3.22 2.64 5.24 5.22 4.09/4.14 7.06 6.58 5.76 3.91 4.20 4.30 3.78
Table 18: Chemical shift assignments for SJG-136 protons in the 5W(CTCATCAC).(GTGATGAG)-SJG-136 adduct, G-5’ end.
u>ON
4.4: Stereochemistry at alkylation sites
As discussed in Chapter 3, the proton attached at the C ll covalent linkage site has 
proved to be a useful diagnostic probe for the determination of ‘R’ or ‘S’
1 SIstereochemistry at this site. In an adduct with ‘S’ stereochemistry at SJG-C11 the 
SJG-H11 proton will be directed towards the 3’ side of the covalently modified guanine, 
with an ‘R’ isomer leading to a reversed situation with the SJG-H11 proton closer in 
space to the 5’ side (See Figure 95). In the case of the 
5’J(CTCATCAC).(GTGATGAG)-SJG-136 adduct the 5’ (Gil) end of the duplex 
shows a strong NOE between SJG-H11 and A12-H1\ (see Figure 94). This confirms 
that ‘S’ stereochemistry at SJG-C11 is present at this end of the molecule. This is not 
unexpected as both the previous adduct (Chapter 3) and the 5 ’t/(CICGATCICG)2- 
DSB-120 adduct181 displayed ‘S’ stereochemistry at this site. At the 3’ end of the duplex 
the PBD subunit is a mirror image of that at the 5’ end. A SJG-C11 centre with ‘S’ 
stereochemistry will therefore point toward the 3’ neighbour of G14’s Watson-Crick 
base paired cytosine on the opposite strand (A4). ‘R’ stereochemistry results in a 
connectivity with G14’s own 3’ neighbour, A15. When the 2D NOESY spectrum for 
the 5V(CTCATCAC).(GTGATGAG)-SJG-136 adduct is examined there is no 
connectivity between SJG-H11 and A15-H1’, however, a large NOE is seen between 
SJG-H11 and A4-H1 ’(Figure 94). This indicates that the 3’ end of the drug adduct also 




Figure 94: 600 MHz NOESY spectrum of the 5V(CTCATCAC).(GTGATGAG)-SJG-136 
adduct, 200 ms mixing time. Expansion showing NOE connectivities between 
SJG-H11/SJG-H11’ and A12-H17A4-H1’ as confirmation of stereochemistry at the SJG-
C ll  and SJG -C ir centres
‘S’ stereochemistry at SJG-C11. The SJG- 
H11- A4-H1’ connection is shown by a 
dotted line
‘S’ stereochemistry at SJG-C11. The SJG- 
HI 1- A12-H1’ connection is shown by a 
dotted line
Figure 95: Representation of part of the 5V(CTCATCAC).(GTGATGAG)-SJG-136 
adduct, showing NOE connectivities confirming ‘S’ stereochemistry at both ends. 
Model produced in UCSF Chimera193
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4.5: Nucleic Acid Proton Chemical Shifts
As discussed previously, 2D NOESY and COSY experiments were performed on the 
5 ’ d(GTGATGAG). (CTCATCAC)-SJG-13 6  adduct in order to determine the proton 
chemical shifts and intensity of cross-peaks for use in molecular modeling procedures. 
Figure 92 shows an expanded NOESY contour plot of the H6 /H8  to HI ’ region of the 
adduct spectrum. As discussed previously, two complete proton walks of approximately 
equal intensity can be seen in this region confirming the retention of right-handed 
B-form conformation of this non-self-complementary adduct.
4.5.1: Relative chemical shifts o f the DNA H2 * and H2 * ’protons
In general the H2’ protons resonate up-field of the H2” protons within the same 
nucleotide sequence. 181 On assignment of the 5’d(CICGATCICG)2-SJG-136 adduct in 
Chapter 3 it was noted that a reversal in the general pattern for H l’-H2’/H2” 
resonances had been observed for the 18 nucleotide, with the more intense H l’-H2’ 
resonance found down-field of the H l’-H2” . This was attributed to a conformational 
change within the internal nucleotide, with an additional perturbation of the structure of 
the nucleotide facing the covalently modified guanine. In the case of the 
5’J(CTCATCAC).(GTGATGAG)-SJG-136 adduct a similar reversal of the general 
pattern is seen in many of the nucleotides in the vicinity of the drug. This is, perhaps to 
be expected with the accommodation of SJG-136 in the minor groove as an intra-strand 
adduct, and perturbation of the surrounding nucleotides provides additional evidence in 
support of this.
4.5.2: Chemical shift changes o f the 5 ’d(CTCATCAC).(GTGATGAG)-SJG-136 adduct 
relative to the duplex
Chemical shifts for the oligonucleotide proton resonance signals of the SJG-136 adduct 
relative to the duplex are shown in Tables 16 - 18. Numerous large shifts in resonance 
can be seen, as would be expected on accommodation of the ligand in the minor groove 
in this way. The two central adenine H2 resonances (A4-H2 and A12-H2) of the duplex
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both experience large down-field shifts of 0.28 ppm & 0.42 ppm respectively, providing 
further evidence of some central perturbation as a result of formation of an intra-strand 
adduct. On examination of the H I’ and H2’ chemical shift data it can be seen that there 
is a slight majority of large shift changes from duplex to adduct found in nucleotides 
situated on the covalently modified DNA strand. This suggests that the drug is 
associating more closely with the modified strand, and as such supports the formation of 
the intra-strand adduct.
4.6: Intermolecular Drug-DNA Contacts
The proton resonances for SJG-136 have been identified and assigned using analysis of 
the 2D NOESY and COSY data as discussed in Chapter 2. The complete 2D spectra 
showing assignment of drug proton peaks can be seen in Figure 93. It is possible to 
trace two complete drug proton walks across the entire 2D NOESY spectrum and 
numerous contacts have been found between the drug protons and the C3, A4, T5, C6  
and A7 nucleotides on the non-covalently modified strand, and the G il, A12, T13, G14 
and A15 nucleotides on the covalently modified strand. These are shown in Tables 19 
& 20, as well as pictorially in Figure 96. The presence of the two complete drug proton 
walks (corresponding to the two ends of the drug) as well as the network of NOE 
contacts from the drug to specific DNA protons once again locates the drug 
unequivocally within the minor groove and confirms the presence of the intra-strand 
cross-linked adduct.
4.6.1: Distinction between the non-self-complementary ends o f the
5 ’d(CTCATCAC'). (GTGA TGA G) -SJG-13 6 adduct
The two different ends of the SJG-136 molecule were identified by use of a strong NOE 
contact between the SJG-H9 proton with the respective A-H2 protons of the central 
adenine nucleotides (A12-H2 and A4-H2) of the DNA duplex. These appear in the 
H6 /H8  -  HI ’ region of the spectrum, and can be seen in Figure 97. This assignment is 
confirmed by the presence of further NOE contacts between the SJG-H9/H9’ protons at 
the respective ends of the drug and the surrounding DNA protons. Examples are SJG- 
H9 -  T5-H1’ and SJG-H9’ -  A12-H1\ C6-H1 * and T13-H1’. These are shown in 
Figures 98 & 99.
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DNA Protons H lb’ H la’ H2a’ H2b’ H3a’ H3b’ H6’ H9’ h i t HI la ’ H12a’ H12b’ H13a/b H14’
A4H2 VW
C6H1’ M M/S S/M S/M
C8H1’ M W
A7H2 M S W W w M
A7H1’ M M W W S
A7H3’ M
A7H4’ M vw M/S
G11H1’ S S
G11H4’ M M
A12H2 S W/M W/M M
A12H1’ M/W
A12H4’ M M W M
T13H1’ MAV M M
T13H4’ W vw W
G14H4’ M/S
Table 19: Drug-DNA connectivities for the 5V(CTCATCAC).(GTGATGAG)-SJG-136 adduct, G-5’ end
DNA
Protons
Hla Hlb H2a H2b H3a H3b H6 H9 H ll Hl la H12a H12b H13a/b H14
C3H1’ W
A4H1’ M W M/S
A4H2 S M/S M/S
A4H4’ M M
T5HI’ M M M
T5H4’ S
A12H2 W/M W/M M
T13H1’ W M M
T13H4’ W




Table 20: Drug-DNA connectivities for the 5V(CTCATCAC).(GTGATGAG)-SJG-136 adduct, G-3’ end
5 '  -





Figure 96: Representation of the 5W(CTCATCAC).(GTGATGAG)-SJG-136 adduct showing NOE connectivities between
the drug and the DNA backbone
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Figure 97: 600 MHz 2D NOESY spectrum of 5’</(CTCATCAC).(GTGATGAG)-SJG-136,200 ms mixing time, 




Figure 98: 600 MHz 2D NOESY spectrum of 
5V(CTCATCAC).(GTGATGAG)-SJG-136, 200 ms mixing time, 









Figure 99: 600 MHz 2D NOESY spectrum of 
5V(CTCATCAC).(GTGATGAG)-SJG-136, 200 ms mixing time, 
expansion showing NOE connectivities between SJG-H9 and T5^H1’
4.6.2: Comparison o f the chemical shifts o f drug protons in the
5 ’d(CTCATCAC).(GTGATGAG)-SJG-136 intra-strand adduct relative to the 
5 ’d(CICGA TCICG)2-SJG-136 inter-strand adduct
A comparison of the drug chemical shifts for the inter-strand adduct discussed in 
Chapter 3 and the intra-strand adduct is shown in Tables 21 & 22. It can be seen that at 
the G-5’ end of the duplex the associated SJG-136 protons show a greater similarity in 
terms of chemical shift. With the exception of the SJG-H1 and SJG-H2 protons, there 
are no changes greater than 0.12 ppm. This is perhaps a result of a reaction mechanism 
as discussed in Chapter 1, with the alkylation proceeding in two stages. When the 
chemical shift values of the drug protons located at the 3’ end of the modified strand are 
compared with the inter-strand adduct however large discrepancies are encountered 
between the two shifts. The SJG-H11 proton resonance in particular has moved by more 
than 1 ppm, suggesting that the second step of the reaction has resulted in localised 
perturbation on accommodation of an intra-strand cross-link.
4.6.3: Distinction between ‘a ’ and ‘b ’protons
Figures 100 & 101 show pictorial representations of the adduct as a stereo-view, 
identifying protons ‘a’ and ‘b’ at positions HI, H2, H3, H12, and H I3. Distinction 
between ‘a* and ‘b’ protons was achieved using the NOE connectivities between the 
protons and their surrounding DNA protons.
The SJG-Hla/b and Hla/b’ protons were assigned on the basis of their respective 
proximity to the nearby adenine H2 (A7-H2 and A15-H2), as well as through the size of 
NOE cross-peaks to other drug resonances. When basic molecular models are examined 
it can be seen that the SJG-Hla proton is closer in space to the A-H2 than the SJG-Hlb 
proton is, and the two were therefore assigned using the size of the resulting NOE cross­
peak. In addition SJG-Hla gives rise to more intense cross-peaks than SJG-Hlb to 
SJG-H11 and SJG-H2a/b, reflecting the fact that the SJG-Hla proton is closer in space 
to these protons than the SJG-Hlb proton is.
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Hla Hlb H2a H2b H3a H3b H6 H9 H ll H lla H12a HI 2b H13a H13b H14
Inter­
strand
2.55 3.21 5.84 5.84 4.02/4.0
6
4.02/4.06 7.05 6.53 5.64 3.92 4.24 4.24 2.28 2.28 3.83
Intra­
strand
2.95 2.58 5.32 5.17 4.32 4.11 6.95 5.97 4.52 4.74 4.25 3.76 2.07 2.30 3.80
Diff
(+/-)
0.40 0.63 0.52 0.67 “ - ft 10 0.56 1.12 0.82 0.01 0.48 0.21 0.02 0.03
Table 21: Comparison of the chemical shifts of drug protons in the 5V(CICGATCICG>2-SJG-136 inter-strand adduct and the 
5W(CTCATCAC).(GTGATGAG)-SJG-136 intra-strand adduct -  G-3’ end. Differences greater than 0.25 ppm are underlined
H la’ H lb’ H2a’ m b ’ H3a’ H3b’ H6 ’ H9’ H l l ’ H l la ’ H12a’ HI 2 b’ H13a H13b H14’
Inter-
strand
2.55 3.21 5.84 5.84 4.02/4.06 4.02/4.06 7.05 6.53 5.64 3.92 4.24 4.24 2.28 2.28 3.83
Intra-
strand
3.22 2.64 5.24 5.22 4.09/4.14 4.09/4.14 7.06 6.58 5.76 3.91 4.20 4.30 2.07 2.30 3.78
Diff
(+/-)
0.67 0.57 0.60 0.62 - - 0.01 0.05 0.12 0.01 0.04 0.06 0.21 0.02 0.05
Table 22: Comparison of the chemical shifts of drug protons in the 5V(CICGATCICG>2-SJG-136 inter-strand adduct and the 
5V(CTCATCAC).(GTGATGAG)-SJG-136 intra-strand adduct -  G-5* end. Differences greater than 0.25 ppm are underlined
H2b H2a
H la
Figure 100: Cross-eye stereo view of an SJG-136-drug adduct, 
showing numbering of SJG-Hla/b, SJG-H2a/b and SJG-H3a/b protons. 







Figure 101: Cross-eye stereo view of an SJG-136-drug adduct, 
showing numbering of SJG-H12a/b, SJG-H12a/b’ and SJG-H13a/b protons. 
Model generated using USCF Chimera193
146
The SJG-H2a/b protons were similarly assigned based on their proximities to 
surrounding protons. Unfortunately in this case connectivities to the DNA backbone 
were too overlaid to be of use, so the SJG-H2a/H2a’ and SJG-H2b/H2b’ protons were 
distinguished by their NOE contacts to other drug resonances. When models of the 
5V(CTCATCAC).(GTGATGAG)-SJG-136 adduct are examined it can be seen that the 
SJG-H2a/H2a’ proton is closer in space to the SJG-H1/H1’ protons, whereas the SJG- 
H2b/H2b’ proton is closer to the SJG-H3/H3’ protons. When these NOE connectivities 
are examined it is observed that the cross-peak intensities vary significantly, and so the 
SJG-H2a/b/H2a/b’ protons were assigned on this basis. This was supported for the SJG- 
H2a/b by the NOE cross-peaks to the SJG-Hlla proton, in which the SJG-H2a proton 
displayed a slightly more intense resonance.
The SJG-H3a/b protons were distinguished as a result of small differences in spatial 
proximity to the SJG protons H6  and H2a/b. When distances are calculated from 
molecular models193 the SJG-H3a proton is slightly closer to the SJG-H2 protons than 
the SJG-H3b proton is. In addition the SJG-H3b proton is marginally closer (~ 0.5A 
according to models produced within UCSF Chimera ) in space to the SJG-H6  proton. 
When the 2D NOESY NMR spectrum is examined SJG-H3a shows a more intense 
cross-peak to SJG-H2a/b than SJG-H3b does. On examination of the SJG-H6  
connectivities it is observed that there exists a weak NOE to SJG-H3b, while there is no 
connectivity with SJG-H3a. On this basis a distinction was made between SJG-H3a and 
SJG-H3b. At the G-5’ end of the molecule the SJG-H3a/b’ protons were unfortunately 
too close together and too overlaid to allow a distinction to be made between them. 
Consequently they are reported as SJG-H3a/b\
The SJG-H12a/b and H12a/b’ protons were once again difficult to distinguish due to 
their resonance in the overcrowded H4’ region of the spectrum. However, they were 
tentatively assigned based on connectivities to SJG-H9’ and adenine H2 protons A12- 
H2 and A4-H2. The SJG-H12a’ proton shows a more intense cross-peak to SJG-H9’ 
than SJG-H12b’ does and so a distinction can be made between the two. At the 3’ end 
of the molecule the NOE connectivities of SJG-H12a/b to A4-H2 and A12-H2 show 
significant differences, with a more intense cross-peak seen due to connectivity with 
SJG-H12a in both cases.
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Finally the SJG-H13a/b protons were distinguished due to their NOE connectivity with 
SJG-H9’. The distance between SJG-H13b and SJG-H9’ is greater than for SJG-H13a, 
and on examination of the spectrum it can be seen that the cross-peak between SJG-H9’ 
and SJG-H13a is more intense.
4.6.4: Chemical Shifts ofT13-H4’ and T5-H4 ’
An interesting feature of the intra-strand 2D NOESY spectrum is the unusually low shift 
of T13-H4’ and T5-H4’. These nucleotides are situated at the centre of the duplex 
between the two sites of covalent modification. The increased shielding of the 4’ 
protons in these bases is probably due to the proximity of the aromatic PDB rings, and 
is indicative of some distortion around the SJG-C11 centre. As a two-step reaction has
A7been predicted for alkylation of DNA by PBD ligands this is probably the second 
centre to react, and some distortion would not be wholly unexpected in the case of 
accommodation of an intra-strand linkage. In support, there exist no analogous unusual 
shifts either in the inter-strand adduct reported in Chapter 3, or in the inter-strand DSB- 
120 adduct reported by Mountzouris et a / . 181
4.7: The refined molecular model of the 5V(CTCATCAC).(GTGATGAG)-SJG- 
136 adduct
The 5’J(CTCATCAC).(GTGATGAG)-SJG-136 intra-strand adduct was modelled using 
the SYBYL197 software suite as discussed in Chapter 3. Once again drug-DNA adducts 
were first modelled using a HYPERCHEM198 package. Both DNA and drug were 
drawn and docked within the package and subjected to steepest descent energy 
optimisation and secondly to molecular dynamics in vacuo at 300K. SJG-136 was then 
imported from HYPERCHEM into the SYBYL suite where it was docked with correct 
stereochemistry onto a DNA duplex produced within the SYBYL package. The model 
was then subjected to procedures identical to those discussed in Chapter 3. Complete 
restraints tables can be seen in Appendix II.
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Figures 102 - 104 show the in aquo computer model of the intra-strand adduct. SJG- 
136 is depicted in white, with the two DNA strands in magenta and green. As with the 
inter-strand adduct it is clear that Watson-Crick base pairing has been maintained. This 
is in agreement with the 2D NMR spectra, which as discussed, suggested that the p- 
helical structure of the DNA backbone had been maintained.
4.8: Conclusions
In summary, a 5 ’ d(CTCATCAC). (GTGATGAG)-SJG-136 adduct has been successfully 
produced and fully assigned. Covalent linkage sites have been confirmed to be the 
exocyclic NH2 groups of DNA-G11 and DNA-G14, making this the first positive 
identification of an intra-strand cross-linked DNA-PBD adduct.
The stereochemistry at the SJG-C11 alkylation sites have been confirmed as ‘S’ at both 
ends of the duplex, in agreement with molecular mechanics energy calculations, which 
predict the SJG-C11 ‘S’ stereochemistry to be energetically favoured. 42-44
Relative chemical shifts of the DNA-H2’ and H2” have been found to show a reversal 
in the usual pattern for duplex DNA, with the more intense DNA-H1’ -  DNA-H2’ 
resonance found down-field of the DNA-H1’ -  DNA-H2” resonance. This has been 
noted in previous studies of DNA-PBD adducts, both within this project (Chapter 3)
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and within studies of the DSB-120 adduct and is indicative of a conformational 
change within the internal nucleotide. As such it was not unexpected on accommodation 
of an intra-strand cross-linkage.
Intermolecular drug-DNA contacts confirm the presence of the drug located in the 
minor groove, and following the right-handed contour of the p-helical DNA helix. In 
addition, NOE connectivities suggest that the SJG-136 molecule associates more closely 




Figure 102: Stereoview of the 5W(CTCATCAC).(GTGATGAG)-SJG-136 intra-strand adduct. DNA strands are shown in green and
purple, SJG-136 is shown in white. Watson-Crick base pairing and the ^-helical structure of the DNA backbone have been maintained.
Models produced in the SYBYL software suite197 and pictured using UCSF Chimera193
Figure 103: Stereoview of the 5’</(CTCATCAC).(GTGATGAG)-SJG-136 intra-strand adduct. DNA strands are shown in green and
purple, SJG-136 is shown in white. The drug is seen to fit snugly into the minor groove with little protrusion beyond the periphery.
Models produced in the SYBYL software suite197 and pictured using UCSF Chimera193
Figure 104: Stereoview of the 5V(CTCATCAC).(GTGATGAG)-SJG-136 intra-strand adduct. DNA strands are shown in green and
purple, SJG-136 is shown in white. The p-helical structure of the DNA backbone has been maintained.
Models produced in the SYBYL software suite197 and pictured using UCSF Chimera193
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CHAPTER 5: RESULTS AND DISCUSSION
THE 5 V(CGATTAATCG)2-ADOZELESIN ADDUCT
As discussed in Chapter 1, adozelesin is a synthetic analogue of (+)-CC-1065, a 
cyclopropapyrroloindole (CPI) drug containing the DNA alkylating 
cyclopropa[c]pyrrolo[3,2-e]-indole-4[5H]one subunit (see Figure 105). Adozelesin 
(Figure 105) was synthesised in order to combat delayed lethality problems associated 
with (+)-CC-1065. It is an overall right-handed molecule, mimicking the pitch of 
B-fonn DNA and fitting snugly into the minor groove with a sequence preference of 


















A d o z e le s inO
Figure 105: Representation of the (+)-CC-1065 and adozelesin molecules, showing ‘A’, ‘B’ 
and (C’ subunits
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Reaction with double stranded DNA is through the N3 position of reactive adenine to
O O  Q A
form a covalent adduct that overlaps a 5 base pair region in the minor groove. ' The 
reaction is thought to be a multi-step process utilising non-covalent interaction by 
hydrophobic and Van der Waals forces between the three subunits and the minor groove 
followed by covalent bonding with the alkylating subunit. The most probable reaction 
mechanism is shown in Figure 107.
In previous work with the 5 ’<i(CGTAAGCGCTTACG)2-adozelesin adduct the 
adozelesin residues were found to bind to adenine (A 12) edge on in the minor groove, 
with the maintenance of Watson-Crick base pairing. A high degree of hydrogen bonding 
was found to exist between phenolic protons and the phosphate backbone104 and a 
strong hydrogen bond was formed between the amide linker and a thymine (T10) on the 
modified strand.
In addition to these observations, during molecular modeling experiments179,180 it was 
noted that a degree of ‘fish tailing’ could be observed at the aromatic ring of the ‘C’ 
subunit, with the benzofuran tail ‘bending’ towards the modified strand as depicted in 
Figure 106. As the sequence modelled in these studies was palindromic only half of the 
adduct was modelled, but it was thought possible that the ‘fish-tailing’ of the ‘C’ 
subunit could be a result of a slight overlap of the aromatic rings of the respective 
adozelesin molecules in the bis-adduct. In this case an increased proximity of the 
benzofuran tail to the modified strand would be observed as shown in Figure 106.
5 1 -C -G -T -A -A -G -C -G -C -T -T -A -C -G -3  '
P H SH,C
h2c
3 1- G - C - A - T - T - C - G - C - G - A - A - T - C - G - 5 '






Figure 107: Reaction mechanism of adozelesin with the adenine N3 of duplex DNA
5.1: Design and synthesis of the duplex
The 5 V(GCTAATTAGC)2  duplex was designed to investigate the possibility of an 
overlap of the aromatic rings of the ‘B’ and ‘C’ subunits in the DNA-adozelesin adduct. 
Adozelesin is known to span five base pairs so the new DNA sequence was designed to 
be four base pairs shorter than that used by Cameron and Thompson, 179,180 in order to 
attempt to force an overlap between drug molecules in the resulting adduct as shown in 
Figure 108.
3 ' - G - C - T - A - A - T - T - A - G - C - 3 '
5 1- C - G - A - T - T - A - A - T - C - G - 3 1
Figure 108: Possible overlap of adozelesin ‘B’ and ‘C’ subunits in the 
5V(CGATTAATCG>2-adozelesin adduct
The most feasible reaction site for adozelesin with this duplex would be through the N3 
position of the adenine residue A3. In order for a fo's-adduct to form significant overlap 
would be required between the ‘B’ and ‘C’ subunits of the respective adozelesin 
molecules.
As for previous duplexes the 5 ’^ (GCTAATTAGC^ duplex was synthesised using 
standard methods as discussed in Chapter 2. The duplex was then allowed to react with 
4 mg of adozelesin for 48 hours at room temperature. On observation of the ID *H 
NMR spectrum at this point the reaction appeared to be incomplete, and so the reaction
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was left to proceed for a further 1 0  days, at which point it was deduced that the reaction 
had proceeded to completion. The rate of this reaction was in contrast to that observed 
by Cameron and Thompson with the longer DNA duplex, in which the reaction was 
complete after 48 hours. 179 On completion of the drug-DNA reaction 2D NOESY and 
COSY experiments were performed on the resulting adduct. A diagram showing the 
numbering system for the duplex for the purposes of NMR assignment is shown in 
Figure 109.
5 1 - C l Gl A - T l T l A6- A 7- T l C9- G - 3  1
^  .  10 9 8 7 6  5 4 3  2 1
3 ' - G - C - T - A - A - T - T - A - G - C - 5 1
Figure 109: Numbering system for the 5W(CGATTAATCG)2 duplex
5.2: Symmetry of the 5V(CGATTAATCG)2-adozelesin adduct — identification of 
two symmetrical adducts.
The one-dimensional NMR non-exchangeable spectra for both the duplex and the 
adduct can be seen in Figures 110 & 111. The duplex signals are well-resolved, and a 
peak count in the aromatic region affords approximately 15 peaks — as would be 
expected for this duplex. This information, along with the three clear thymine methyl 
peaks that can be observed between 1 . 0 0  ppm and 1.60 ppm provides evidence for the 
purity of this duplex.
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8 7 6 5 4 3 2 1  p p
Figure 110: *H NMR spectrum of the 5V(CGATTAATCG)2 duplex
B 7 6 5 3 2 14
Figure 111: *H NMR spectrum of the 5W(CGATTAATCG)2-adozeIesin adduct
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The adduct spectrum is greatly increased in complexity and due to overlaid signals it is 
not possible to complete an accurate peak-count in the aromatic region. However on 
estimating the number of peaks it is apparent that the numbers in the aromatic region as 
well as the thymine methyl region have more than doubled, and it was deemed possible 
that more than one species was present in the reaction mixture.
The 5 W(CGATTAATCG)2-adozelesin adduct was further investigated using COSY and 
NOESY NMR techniques. An expansion of the 2D NOESY adduct and duplex spectra, 
H6/H8-H1’ region, are shown in Figure 112. On superimposition of the duplex 2D 
NOESY spectrum on the adduct spectrum it was deduced that the reaction had 
proceeded to completion as there was no evidence of remaining duplex cross-peaks. 
For example, the duplex cross-peak at coordinates (F1/F2) 6.96 ppm/5.97 ppm has 
completely disappeared while a new peak is evident at coordinates 8.15 ppm/6.24 ppm. 
However, the presence of four strong COSY resonances in the H6/H8-H1’ region 
confirms the presence of two separate species in the reaction mixture. Figure 113 shows 
the region completely assigned and it can be seen that two complete proton walks are 
possible using the sequential assignment method from HI* resonances to H6 /H8  
resonances. As there is no duplex DNA remaining in the mixture this confirms that two 
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Figure 112: 600 MHz 2D NOESY spectra of the 5’*/(CGATTAATCG)2-adozelesin adduct 
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Figure 113: 600 MHz 2D NOESY spectrum of the 5V(CGATTAATCG)2-adozelesin mixed 
adduct, 200 ms mixing time. Expansion of the H6/H8-H1’ region showing two complete 
walks. Green = Watson-Crick (denoted WC) Red = Hoogsteen (denoted Hg) X = COSY 
(unlabelled) and peaks due to drug interaction (labelled)
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5.3: Identification of the covalent sites in both DNA-adozelesin adducts
As discussed previously, adozelesin is known to react through the N3 position of a 
reactive adenine base, spanning a distance of five base pairs. As such, on reaction with 
the 5 V(CGATTAATCG) 2  duplex the adozelesin molecule has two possible reaction 
sites on each duplex strand - either at base A3 or base A6  as shown in Figure 114.
5 1 - C L G- A - T - T - A - A - T - C- G- 3 1
r ~
^  _ 10 9 8 7 6  5 4 3 2 1
3 1 - G - C - T - A - A - T - T - A - G - C - 5 1 
5 ' - C L G L A - T 1 T 1 A - A - T L C 9- G - 3 1
^  _ 10 9 8 7 6 5 4 3  2 1 _
3 ' - G - C - T - A - A - T - T - A - G - C - 5  '
Figure 114: Possible reaction sites for adozelesin on the 5V(CGATTAATCG)2 duplex
Reaction at base A6  is unlikely due to the hydrophobic nature of the adozelesin 
molecule. In the case of reaction at A6  the benzofuran tail (subunit ‘C ’) of the molecule 
would be left relatively exposed, as opposed to the snug fit in the minor groove afforded 
by reaction at A3. In addition large steric clashes would also occur between the ‘A’ 
subunits of the respective molecules and as such the A3 nucleotide is the most likely 
site of covalent modification.
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As previously discussed, alkylation of DNA has been observed to proceed through 
opening of the cyclopropyl ring and formation of a C8  methylene bridge. This is 
confirmed in this case by the observation of down-field shifts of the adozelesin 
cyclopropyl ring protons Ado-H8 A and Ado-H8 B. The shifts of Ado-H8 A and Ado- 
H8 B would be expected at 1.47 ppm and 2.02 ppm respectively.200 In the 
5 ’<i(CGATTAATCG)2-adozelesin adduct these proton resonances are shifted to the 
methylene region, at 5.50 ppm in the case of the first adduct and 5.35 ppm for the 
second. This is also in analogy with the 5 W(CGTAAGCGCTTACG)2-adozelesin 
adduct in which the Ado-H8 A and Ado-H8 B proton resonances were found at 5.06 ppm 
and 5.15 ppm respectively, 104 and confirms that the covalent bond with adenine has 
formed via the C8  methylene bridge.
Further evidence exists for DNA-A3 as the site of covalent modification in the 
observation of NOE connectivities from the A-H2 proton of the modified adenine into 
the CPI headunit NOEs can be found from A3-H2 into Ado-H8A2, and Ado-Hl A/B in 
the case of both adducts. A lack of any cross-peak between A3-H2 and the adozelesin 
H3 proton is in analogy with previous work on the 5 W(CGTAAGCGCTTACG)2- 
adozelesin adduct and indicates that the drug is bound in an edge-on orientation in the 
minor groove.
5.4: Possible adduct conformations
Analysis of the 2D NOESY and COSY spectra confirms the presence of two different 
DNA-drug adducts. There are four clear COSY cross peaks visible at FI/F2 coordinates 
7.44 ppm/5.70 ppm, 7.44 ppm/5.65 ppm, 7.31 ppm/5.45 ppm, and 6.98 ppm/5.18 ppm 
confirming the presence of four distinct cytosine resonances. In addition two complete 
proton ‘walks’ are possible in the H6 /H8  -  HI ’ region of the NOESY spectrum (Figure 
113). Comparison of the duplex NOESY spectrum with that of the adduct showed no 
evidence for residual duplex in the reaction mixture as shown in Figure 112, and two 
drug walks are present across the whole spectrum (seen in Figures 115 & 116). The 
drug resonances in both adducts display cross-peaks that confirm their close association 
with DNA duplex.
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Figure 115: 600 MHz 2D NOESY and COSY spectra of the 5V(CGATTAATCG)2-adozelesin 
mixed adduct. NOESY mixing time 200 ms. Black=NOESY, Blue = COSY.
Green lines = Watson-Crick assignments, Red lines = Hoogsteen assignments
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Figure 116: 600 MHz 2D NOESY and COSY spectra of the 5’d(CGATTAATCG)2-adozelesin mixed 
adduct. Black = NOESY, Blue= COSY. NOESY mixing time 200 ms. Expansion of the H6/H8-H6/H8 
region. Green lines = Watson-Crick assignments, Red lines = Hoogsteen assignments
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5.4.1: Possible mixed adduct species
Six possibilities exist to explain the presence of two separate proton walks in the 2D 
NOESY spectrum of the 5 ’c/(CGATTAATCG)2-adozelesin adduct. The first is that 
there is simply unreacted DNA duplex remaining in the reaction mixture. As discussed 
above this can be ruled out on the basis of a comparison between the 2D NOESY 
spectrum of the duplex and that of the mixture after reaction with adozelesin. When the 
two spectra are superimposed it is clear that no duplex peaks remain. (Figure 112)
The second possibility is that of alkylation at a different adenine residue -  namely A6  or 
A7. Once again this possibility is not feasible in the reaction of adozelesin with this 
duplex. The site of covalent modification in the case of both adducts has been 
confirmed to be at A3. In addition, reaction at A6  or A7 to form a bis-adduct would 
require an overlap of the ‘A’ and ‘B’ subunits of the drug. These units are not planar 
and any overlap would be subject to huge steric clashes and hence highly unfavourable.
A third possibility exists in the formation of a mono-adduct alongside the expected bis- 
adduct, such as that depicted in Figure 117.
5 1 - C LGLA - T - T LA6- A - T LCLG - 3  1
_  10 9 8 7 6  5 4 3 2 1
3 ' - G - C - T - A - A - T - T - A - G - C - 5 '
Figure 117: Representation of a 5W(CGATTAATCG)2-adozeIesin mono-adduct
Examination of the 2D NOESY spectrum of the reaction mixture again renders this 
possibility extremely unlikely. Observation of the two completed walks in the H6 /H8 - 
H l’ region confirms that both species present are symmetrical. In the case of a mono- 
adduct the symmetry of the species would be lost as the two DNA strands would no
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longer be equivalent. In addition, the unmodified DNA strand would closely resemble 
duplex DNA, particularly at the terminal ends of the strand. As discussed there is no 
evidence for duplex resonances in the spectrum so it is unlikely that anything 
resembling a duplex remains in the reaction mixture. In addition, the time taken for the 
reaction to complete is vastly greater than that observed in previous studies of CPI- 
DNA adduct formation. 104
There remain three possibilities for identification of the two adducts present. Firstly, the 
formation of a Watson-Crick bis-adduct with overlap of the ‘C’ subunits as predicted. 
Secondly formation of a base-paired overlapping adduct in which the central AT step 
displays Hoogsteen base pairing (See Figure 118) and finally formation of an 
overlapped 6 /s-adduct with open base pairs.
H
I
H oogsteen  A-T base pairing
HI
c; o
Watson-Crick A-T base pairing
Figure 118: Traditional Watson-Crick and Hoogsteen base pairing
As discussed in Chapter 1, previous work involving reaction of a 
5 ’d(CGTAATTACG) 2  duplex with die dimeric CPI bizelesin resulted in mixed adduct 
formation in which approximately 60 % consisted of an adduct in which both adenine
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residues of the central AT step were Hoogsteen base paired to thymines (see Figure 
119), while the remaining 40 % existed in an open conformation.115 It is suggested that 
the insertion of bizelesin into the minor groove provides impetus for reorientation of the 




Figure 119: Representation of a DNA duplex showing Hoogsteen base pairs. Hoogsteen 
bases are shown in white, with hydrogen bonds in green. It can be observed that the A-H8
proton is relocated into the minor groove
In the case of the 5’d(CGATTAATCG)2-adozelesin adduct the overlap of the ‘C’ 
subunits provides a similar shaped drug to the dimeric bizelesin as shown in Figure 
120, and it is feasible that the Hoogsteen adduct is ‘frozen’ out in the same way as 




Bizelesin molecule on reaction with DNA
Overlapped adozelesin molecules on reaction with DNA
Figure 120: Representation of bizelesin and overlapped adozelesin after reaction with
DNA, showing similarities in shape
The Hoogsteen rotation is a stable duplex answer to the steric stress associated with 
cross-linkage115 and as the overlapped region of the adozelesin drug moieties 
unquestionably result in a large increase in steric crowding at this region it is perhaps 
unsurprising that the duplex DNA should adopt this conformation as a solution. 
Quinoxaline intercalators have been shown to stabilise partially Hoogsteen base pairs to 
the 3’ side of intercalation201,202 but the intercalator insertion disrupts base stacking and 
base-backbone interactions in the Hoogsteen region. Overlapped adozelesin molecules 
however, like bizelesin, will not intrude into the base stacking of the Watson-Crick to 
Hoogsteen base pair transition region and therefore is capable of yielding stable duplex
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DNA in which the central base pairs show Hoogsteen pairing in a similar way to that 
observed in studies of bizelesin.
The possibility of open base pairs was investigated using 2D ROESY spectroscopy. As 
discussed in Chapter 2, ROESY experiments are used to determine conformational 
exchange on an NMR timescale. Exchange within a molecule is observed as peaks of an 
opposite sign in the NMR spectrum. The ROESY spectrum of the 
5,d(CGATTAATCG)2-adozelesin mixed adduct showed no evidence for 
conformational exchange and the possibility of open base pairs was ruled out as a result. 
It was therefore concluded that the mixed adozelesin adduct consisted of two adducts, 
one maintaining traditional Watson-Crick base pairing throughout, while the other 
exhibits formation of Hoogsteen base pairs at the central AT step in analogy with 
previous studies on bizelesin. The two species are denoted adozelesin-Watson-Crick 
(WC) and adozelesin-Hoogsteen (Hg) in all subsequent discussion.
5.4.2: Orientation o f the adozelesin molecules in the Watson-Crick and Hoogsteen 
adducts
There are two possible overlap orientations for both the Watson-Crick and the 
Hoogsteen adduct. A representation of these is shown in Figure 121 A & B. It can be 
confirmed by NOESY connectivities from the ‘B’ and ‘C’ subunits of the drug 
molecules to the modified DNA strand that a closer association is formed between the 
drug and the modified strand in both cases, and so the orientation can be confirmed to 
be that shown in Figure 121 B. Further discussion of this topic can be found in section
5.6.1.
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5 ' - C l Gl A3- T l T l A - A - T l Cl G - 3  '
_  10 9 8 7 6  5 4 3 2 1
3 ' - G - C - T - A - A - T - T - A - G - C - 5 '
Figure 121 A: Possible orientation for the 5’d(CGATTAATCG)2-adozelesin overlapped 
adduct -  each drug molecule associates more closely with the opposite strand
5 ' - C - G - A - T - T - $ - . $ - T >- C - G - 3 '
^  .  10  9 8 7 6 5 4 3 2  1 __ _
3 ' - G - C - T - A - A - T - T - A - G - C - 5 ’
Figure 121 B: Second possibility for orientation of the 5W(CGATTAATCG)2-adozelesin 
overlapped adduct — each drug molecule associates more closely with its own DNA strand
5.5: Nucleic Acid Proton Chemical Shifts -  Watson-Crick
The 5W(CGATTAATCG)2-adozelesin adduct was examined by 2D NOESY and COSY 
NMR and proton resonances were assigned using the assignment protocol discussed in 
Chapter 2. The complete spectra are shown in Figures 116 & 117 while Figure 113 
shows an expanded NOESY contour plot of the H6/H8 - HI ’ region of the spectrum. As 
discussed in section 5.2 two complete walks of approximately equal intensity are 
possible in this region, leading to the deduction of the presence of two 6/y-adducts with 
an overlap of the ‘C’ subunits of each adozelesin molecule. Both adducts retain self-
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complementarity and B-form DNA character, but whilst one adduct maintains Watson- 
Crick base pairing the second adduct displays a rotation of the adenine residue of the 
central AT step in each strand -  forming a Hoogsteen base pair. This is in analogy with 
previous studies on adducts of the dimeric CPI drug bizelesin115
Proton chemical shifts in the 5’d(CGATTAATCG)2-adozelesin adduct relative to 
duplex DNA can be found in Table 23. Down-field shifts of the adozelesin cyclopropyl 
ring protons Ado-H8A and Ado-H8B (5.50 ppm) relative to unbound adozelesin (1.47 
ppm and 2.02 ppm respectively200) confirms the site of covalent attachment as C8 of the 
adozelesin molecule as expected. Large up-field shifts are observed in the T8-H6 
nucleotide aromatic and T8-H1’ protons, which are situated directly opposite to the 
modified A3 base. The above-mentioned resonances can be seen in Figure 122 and it is 
noted that they are also extremely weak relative to other DNA aromatic and H I’ 
resonances. This suggests a degree of backbone distortion as a result of the overlapped 
region of the adozelesin molecules. It is possible that the drug molecules are required to 
‘push back’ in order to achieve tc stacking between the aromatic rings. This movement 
of drug molecules in the narrow minor groove causes distortion along the backbone of 
the DNA duplex, which centres on the T8 nucleotide. This is supported by further 
down-field shifts of 0.68 ppm at the aromatic proton of the C9 nucleotide (C9-H6), 
indicating T8 and C9 as the probable centre for any distortion. The presence of 
complete proton ‘walks’ indicates that the p-helical structure is maintained, but the 
weakness of resonances connected to the T8 nucleotide show that the molecular 
distance is at the limit of detection. Further molecular modeling with the inclusion of n- 












Figure 122: 600 MHz 2D NOESY spectrum of the 5W(CGATTAATCG)2-adozelesin 
adduct, 200 ms mixing time. Expansion showing T8-H6 Watson-Crick resonances, it can 
be observed that the T8-H6 -  HI* cross-peaks are very weak relative to other H I’ peaks
The 5’t/(CGATTAATCG)2-adozelesin Watson-Crick adduct displays a perhaps 
surprising lack of changes in chemical shift values at the central region of the duplex in 
the area of drug overlap. These central protons remain at a chemical shift very close to 
that found in the duplex. The ability of the minor groove to open by up to 17 A has been 
noted in the studies of lexitropsins.171 These are non-covalent minor groove binders that 
form overlapped adducts, and are discussed in C hapter 1. Presumably on widening in 
this manner the steric crowding and subsequent perturbation of the DNA backbone in 
this area is reduced sufficiently that the chemical shifts of these protons remain 
relatively unchanged.
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H6/H8 H r CH3/H5/H2 H2’ H2” H3’ H 4’ Imino
c
1
7.40 7.40 0 0 0 5.47 5.99 0.52 5.67 5.67 0 00 1.65 2.19 0.54 2.16 2.45 0 2 9 4.51 4.51 0.00 3.52 3.80 0.28 *
G
2
7.80 7.76 0 02 5.36 5.29 0 07 - - - 2.55 2.55 0 00 2.66 2.64 0.02 4.83 4.14 0.69 4.17 3.04 0.13 -
A
3
8.10 8.11 0.01 6.13 6.13 0.00 7.40 7.40 0 00 2.54 2.57 0 03 2.78 2.78 0 0 0 4.89 4.89 0.00 4.00 3.90 0.10 -
T
4
7.00 7.05 0.05 5.71 5.79 0  08 1.17 1.11 0.06 1.79 1.77 0 02 2.32 2.34 0 02 4.71** 4.03 - 4.00 3.49 0.51 12.80
T
5
7.16 7.29 0 1 3 5.52 5.34 0.18 1.43 1.49 0.06 1.93 2.09 0 1 6 2.28 2.41 0.13 4.71** 4.21 - 3.96 3.31 0.65 9.76
A
6
8.10 8.22 0 / 2 5.76 5.90 0.14 * 7.56 - 2.58 2.53 0 05 2.74 2.66 0.08 4.33 4.85 0.52 4.28 3.76 0.52 -
A
7
7.97 7.81 0.16 5.96 5.78 0 1 8 7.65 7.82 0.17 2.36 2.09 0.27 2.71 2.41 0.30 4.82 4.40 0.42 4.00 3.00 1.00 -
T
8
6.94 6.51 0 43 5.70 5.18 0.52 1.09 0.97 0 1 2 1.78 1.34 0  44 2.22 1.84 0.38 4.90 4.21 0.69 3.96 4.00 0.04 11.02
C
9




7.75 7.56 0.19 5.94 5.73 0 2 1 2.18 2.07 O i l 2.44 2.31 0.13 4.51 4.34 0.17 3.90 3.51 0.39
Table 23: Chemical shifts (ppm) for the 5V(CGATTAATCG)2 duplex and the 5’rf(CGATTAATCG)2-adozelesin Watson-Crick adduct, DNA 
resonances. Red = Duplex, Black = Adduct, Blue = difference, greater than 0.25 ppm underlined. * = peak not found ** =peak under residual water
peak at 4.71 ppm
CH3 H1A H1B H3 H6 H8A H8B H8A2 H3’l H4’l H6’l H7’l H3’2 H4’2 H5’2 | H6’2 H7’2
I 2.70 3.51 3.51 8.14 8.28 5.50 5.50 4.20 7.92 6.96 8.10 8.14 7.28 7.80 7.46 I 7.53 8.10
Table 24: Chemical shifts (ppm) for the 5V(CGATTAATCG)2-adozelesin Watson-Crick adduct, drug peaks
5.6: Intra-m olecular drug/DNA contacts -  W atson-C rick
The assignment of the complete 2D NOESY and COSY spectra for the 
5’d(CGATTAATCG)2-adozelesin mixed adduct provided many drug-DNA inter-proton 
connectivities to confirm the location of the drug in the minor groove of the DNA 
duplex. A table showing all drug-DNA connectivities can be found in Table 25, while a 
diagram depicting these connectivities is shown in Figure 124.
NOE cross-peaks between the DNA duplex and the ‘A’ subunit of adozelesin confirm 
the association of the drug molecule with the base protons at the site of covalent 
modification. In particular an intense NOE between A3-H2 and Ado-Hla/b provides 










Figure 123: 600 MHz 2D NOESY spectrum of the 5W(CGATTAATCG)2-adozelesin mixed 
adduct 300 ms mixing time. Expansion showing NOE cross-peaks between A3-H2(WC) 
and the CPI head unit confirming covalent link site
175
5.6.1: Association of the Watson-Crick adduct with the modified strand of DNA.
NOE connectivities between the protons of the ‘C’ subunit (Ado-H4’2, Ado-H5’2, Ado- 
H6’2 and Ado-H7’2) and bases A6, A7 and T8 as shown in Table 25 confirm a close 
association of the drug with its own modified strand as shown in Figure 121 B (section 
5.4.1). If the ‘C’ subunits were overlapped in such a way as to afford a closer 
association with the opposite strand (as in Figure 121 A) then these protons would be 
too spatially distant to exhibit NOE connectivities. Figure 125 shows an expansion of 
the 2D NOESY H6/H8-H1’ region, with cross-peaks from aromatic drug protons to 
DNA H I’ protons marked. A pictorial representation of this association can be viewed 
in the refined molecular model of the adduct in section 5.7.
5.6.2: Overlap o f the ‘C ’ subunits results in dipolar coupling o f ‘B ’ and C ’ subunit 
protons
NOE resonances between the Ado-H6’l and Ado-H3’l protons of the indole ‘B’ 
subunit and the aromatic protons of the benzofuran ‘C’ subunit such as Ado-H6’l to 
Ado-H4’2, and Ado-H6’l to Ado-H6’2 (Figure 126) confirm the overlap of the ‘B’ and 
‘C’ subunits. These connectivities can only arise from the overlap of the ‘B’ and ‘C’ 
subunits in the respective molecules of adozelesin in the bis-adduct, as the protons are 
too spatially separated from each other to exhibit connectivities within the same drug 
molecule. These observations provide evidence that the subunits are substantially 
overlapped, as depicted in Figure 108 in section 5.1. Once again, a pictorial 
representation can be viewed on observation of the refined molecular model in section 
5.7.
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A3-H2 S M(O) W(O)





A6-H1 ’ M W(O) 0
A6-H8 W
A6-H4’
A7-H2 M M/W 0 W 0 0 M




Table 25: NOE connectivities between the drug protons and the DNA duplex in the 5V(CGATTAATCG)2-adozelesin Watson-Crick adduct
S=Strong, M= Moderate, W= Weak, VW = Very weak, O = Overlaid
5' -  C - G-A- T- T -  A -A - T -  C -  G -  3
k
3 '  -G -C -T -A -A -T -T -A -G -C -5 '
Figure 124: Representation of one end of the 5V(CGATTAATCG)2-adozelesin Watson-Crick adduct, showing NOE connectivities between the drug
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Figure 125: 600 MHz 2D NOESY spectrum of 5 W(CGATTAATCG)2-adozelesin, mixing 
time 200ms. Expansion of the H6/H8-H1’ region . Peaks A, B, C, and D are cross-peaks 
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Figure 126: 600 MHz 2D NOESY and COSY spectra of the 5 V(CGATTAATCG)2- 
adozelesin mixed adduct. NOESY mixing time 200ms. Black=NOESY, BIue=COSY. 
Expansion of the H6/H8-H6/H8 region. Peaks A and B show connectivities arising from 
the overlap of the ‘C’ subunits. X = peaks due to sequential connectivities of the DNA
backbone
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5.7: The refined molecular model of the 5’rf(CGATTAATCG)2-adozelesin Watson-
Crick adduct
The 5’J(CGATTAATCG)2-adozelesin Watson-Crick adduct was modelled using the
|  QH
SYBYL software suite as described in Chapters 3 and 4. The drug-DNA adduct was 
modelled initially within HYPERCHEM198 and subjected to steepest descent energy 
minimization and molecular dynamics in vacuo at 300 K. On completion the overlapped 
adozelesin molecules were extracted as a pair and docked onto a Watson-Crick duplex 
produced within the SYBYL package. The model was then subjected to procedures 
identical to those discussed in Chapter 3. Complete restraints tables can be seen in 
Appendix III.
Figures 127 & 128 show the in aquo computer model of the adozelesin Watson-Crick 
adduct. Adozelesin is shown in white, with the two DNA strands in green and purple. 
As with previous adducts it is clear that Watson-Crick base pairing has been 
maintained, with retention of the p-helical structure that allows sequential assignment of 
the DNA duplex.
Figure 129 shows the central region of the duplex, with A7-H1’, Ado-H3’2 and Ado- 
H7’2 highlighted. NOE connectivities between the adozelesin aromatic protons and A7- 
H l’ are a clear indication of the drug association with its own covalently modified 
strand as discussed in section 5.6.1 as any other configuration would render these 
protons too spatially separated to exhibit NOE connectivities in this manner.
Figure 130 again shows the central region of the duplex. Ado-H4’2, Ado-H6’2 Ado- 
H4’2 and Ado-H6’l are highlighted in red. These protons were found to be dipolar 
coupled, exhibiting NOESY cross-peaks as discussed in section 5.6.2, This provides 
compelling evidence for the overlap of the ‘C’ subunits.
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Figure 127: Stereoview of the 5W(CGATTAATCG)2-adozelesin Watson-Crick adduct. DNA strands are shown in purple and green 
while the adozelesin molecules are shown in white. The duplex has maintained ^-helical structure and the adozelesin molecules are 
accommodated snugly following the contour of the minor groove. Models generated in the SYBYL software suite197 and pictured using 
UCSF Chimera193
OG Figure 128:_Stereoview of the 5V(CGATTAATCG)2-adozelesin Watson-Crick adduct. DNA strands are shown in purple and
green while the adozelesin molecules are shown in white. Models generated in the SYBYL software suite197 and pictured using
UCSF Chimera193
Figure 129: Stereoview of the 5’rf(CGATTAATCG)2-adozelesin Watson-Crick adduct, central region. A7-H1’, Ado-H3’2 and Ado-H7’2 
are shown in red. NOE connectivities between these protons confirm association of the adozelesin molecule with its own covalently 
modified DNA strand as pictured. Models produced in SYBYL software suite197 and pictured using UCSF Chimera193
Figure 130: Stereoview of the 5’*/(CGATTAATCG)2-adozelesin Watson-Crick adduct, central region. Ado-H6’l ,  Ado-H4’2 andAdo- 
H6’2 are shown in red. NOE connectivities between these protons confirm overlap of the ‘C’ subunits as pictured.Models produced 
in SYBYL software suite197 and pictured using UCSF Chimera193
5.8: Nucleic acid proton chemical shifts of the 5’</(CGATTAATCG)2-adozelesin 
Hoogsteen adduct
Proton chemical shifts in the 5’d(CGATTAATCG)2-adozelesin Hoogsteen adduct 
relative to duplex DNA can be found in Table 26. As found in the Watson-Crick 
adduct, down-field shifts of the adozelesin cyclopropyl ring protons Ado-H8A and Ado- 
H8B from the expected resonance of 1.47 ppm and 2.02 ppm respectively200 to 5.35 
ppm confirms the site of covalent attachment as Ado-C8 as discussed in section 5.3. 
As expected on accommodation of the adozelesin molecule in the minor groove some 
large shift changes can be observed.
A large up-field shift of 0.50 ppm can be observed in the HI ’ proton of the A3 residue. 
As discussed in section 5.3 this is the site of covalent modification and as such large 
shifts here are not unexpected. A significant up-field shift (0.45 ppm) was also seen in 
the 5’J(CGTAAGCGCTTACG)2-adozelesin adduct studied previously at the equivalent 
A12 site.104
Large changes in chemical shift of the T5-H8 proton as well as the A6-H1’ and A7-H1’ 
protons were also observed in the 5’c/(CGATTAATCG)2-adozelesin Hoogsteen adduct. 
The T5 and A6 nucleotides are the sites of the Hoogsteen base pair, and the large 
chemical shift changes lend support to a change of environment at this point as a result. 
In addition these central protons are all situated in the vicinity of the overlapping ‘C’ 
subunits of the adozelesin molecules so large changes in chemical shift could be 
indicative of some steric crowding at this point.
5.9: Intra-molecular drug/DNA contacts — Hoogsteen
Once again, careful assignment of the 2D NOESY and COSY spectra for the 
5’d(CGATTAATCG)2-adozelesin Hoogsteen adduct provided many inter-proton 
connectivities from drug to DNA, confirming the location of the drug in the minor 
groove. A table showing all drug-DNA connectivities can be found in Table 28 whilst a 
diagram depicting these connectivities is seen in Figure 131.
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H6/H8 H r CH3/H5/H2 H2’ H2” H3’ H4’ Imino |
c
1
7.40 7.41 0.01 5.47 5.51 0.04 5.67 5.68 0.01 1.65 1.63 0.02 2.16 2.22 0.06 4.51 4.69 0.20 3.52 3.89 0.37 *
G
2
7.80 7.79 0.01 5.36 5.34 0.02 - - - 2.55 2.60 0.05 2.66 2.70 0.04 4.83 4.23 0.60 4.17 * - -
A
3
8.10 8.15 0.05 6.13 5.63 0.50 7.40 7.28 0.12 2.54 2.24 0.30 2.78 2.62 0.16 4.89 4.97 0.08 4.00 3.91 0.09
T
4




7.16 6.92 0.24 5.52 5.58 0.06 1.43 1.32 0.11 1.93 1.62 0.31 2.28 1.83 0.45 4.71** 4.28 0.43 3.96 3.32 0.64 12.90
A
6
8.10 7.80 0.30 5.76 5.39 0.37 * 7.43 - 2.58 2.57 0.01 2.74 2.70 0.04 4.33 4.88 0.55 4.28 3.80 0.52
A
7
7.97 8.14 0.17 5.96 6.23 0.27 7.65 7.82 0.17 2.36 2.51 0.15 2.71 2.59 0.12 4.82 4.40 0.42 4.00 3.32 0.68 _
T
8








7.75 7.41 0.34 5.94 5.68 0.26 2.18 1.68 0.50 2.44 2.09 0.35 4.51 4.40 0.11 3.90 3.55 0.35
'
Table 26: Chemical shifts (ppm) for the 5’rf(CGATTAATCG)2 duplex and the 5V(CGATTAATCG)2-adozeIesin Hoogsteen adduct. Red = duplex, 
Black = adduct, Blue = difference, greater than ±0.25 ppm underlined. * = not found ** = situated under residual water peak at 4.71 ppm
1 CH3 H1A H1B H3 H6 H8A H8B H8A2 H3’l H4’ l H6’ l H7’ l H3’2 H4’2 H5’2 H6’2 H7’2
| 2.83 3.89 3.89 8.10 8.28 5.35 5.35 3.90 7.28 7.80 8.37 8.34 7.72 8.11 8.16 7.38 7.45
oo
Table 27: Chemical shifts (ppm) for the 5V(CGATTAATCG)2-adozelesin Hoogsteen adduct, drug peaks
Numerous connectivities between the drug and the ‘A’ subunit of adozelesin once again 
confirm the association of the drug molecule with the base protons surrounding the A3 
nucleotide. As expected, connectivities from the ‘A’ subunit are predominantly to bases 
A3 and T4 of the DNA duplex, owing to the close association of the head unit with the 
modified strand on formation of a covalent link.
5.9.1: NOE connectivities confirm an overlap o f the ‘C ’ subunits
Evidence for the overlap of the ‘B’ and ‘C’ subunits exists in the form of connectivities 
between the subunits. NOE connectivities can be seen between the Ado-H4’l proton of 
the indole (‘B’) subunit and the aromatic Ado-H4’2, Ado-H5’2 and Ado-H6’2 protons 
of the benzofuran (‘C’) subunit. In addition a cross-peak can be seen as a result of the 
spatial proximity of Ado-H6’2 to Ado-H6’l. (See Figure 132). As discussed in section
5.6.2, these connectivities can only arise from the overlap of these subunits in the 
respective molecules of adozelesin. Such cross-peaks are a firm indication of a 
substantial overlap of the ‘C’ subunits. A pictorial representation of the spatial 
separation of these protons can be found in the refined molecular model of the 
adozelesin-Hoogsteen adduct in section 5.10.
5.9.2: NOE connectivities confirm the association o f the adozelesin molecule with the 
covalently modified DNA strand.
When the NOE connectivities between the drug and the DNA backbone are examined it 
is evident that there are cross-peaks between the A7-H1’ base proton of the DNA 
backbone and the aromatic Ado-H5’2 and Ado-H6’2 protons of the adozelesin 
benzofuran subunit (see Figure 133). As discussed in section 5.6.1 such dipolar 
coupling of adozelesin aromatic protons with the base protons of the covalently 
modified strand provides unequivocal evidence for the close association of the drug 
molecule with the modified strand as depicted in Figure 121 B.
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Hla/b H8a/b H8A2 ch3 H6 H3 H3’l H4’l H6’l H7’l H3’2 H4’2 H5’2 H6’2 H7’2
A3-H8 VW
A3-H1’ O VW
A3-H4’ M/W w W
A3-H2 M W(O) M/W







A6-H1’ 0 W 0
A6-H8 0 W(O)
A6-H4’ W(O)
A7-H2 O {P) 0 0 M(O)
A7-H1’ M M(O) W(O) M M VW
A7-H3’ W(O) M(0)
A7-H4’ M/W W(O) W
T8-H1’ VW(O) M(O) VW
T8-H6 O
Table 28: NOE connectivities between the drug protons and the DNA duplex in the 5’rf(CGATTAATCG)2-adozelesin Hoogsteen adduct. S=Strong,
M= Moderate, W= Weak, VW = Very weak, O = Overlaid
5 ' -C -G -A -T -T -A -A -T -C -G -3
- T O
c -
3 ' -G -C -T -A -A -T -T -A -G -C -5 '
Figure 131:Representation of the 5W(CGATTAATCG)2-adozelesin Hoogsteen adduct, showing NOE connectivities between the drug and the DNA
3  duplex. One adozelesin molecule is shown only to aid clarity
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Figure 132: 600 MHz 2D NOESY and COSY spectra of the 5V(CGATTAATCG)2- 
adozelesin mixed adduct, NOESY 200 ms mixing time. Black=NOESY, blue=COSY. 
Expansion of the H6/H8-H6/H8 region. Peaks A, B, C and D show NOEs arising as a result 
of the ‘C’ subunit overlap, other assignments are omitted to aid clarity. X = peaks due to 
sequential connectivities of the DNA backbone
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Figure 133: 600 MHz 2D NOESY and COSY spectra of the 5V(CGATTAATCG)2- 
adozelesin mixed adduct. NOESY mixing time 200 ms, expansion of the H6/H8-H1’ region.
Black NOESY, Blue=COSY. Peaks A and B are NOE connectivities arising from the 
association of the ‘C* subunit with the covalently modified strand. Other assignments are
omitted to aid clarity.
192
5.9.3: Formation o f Hoogsteen base pairs in the central region o f the 
5 ’d(CGATTAATCG)2-adozelesin adduct
The most diagnostic cross-peaks for a Hoogsteen base pair come from A6-H2 and A8- 
H8 protons, as seen in previous studies involving assignment of Hoogsteen duplexes.115 
In a Watson-Crick duplex the A-H2 is found in the minor groove while the major 
groove houses the A-H8 proton. When a Hoogsteen base pair is formed anti to syn 
rotation around the glycosidic bond (C l’-N9) moves the A-H2 to a major groove 
position similar to that previously occupied by A-H8 and relocates A-H8 in the minor 
groove. (See Figure 119, section 5.4.1). The new minor groove position of the syn A- 
H8 results in the classical connectivities to major groove protons such as DNA H3’, 
H4’, H2’ and H2” becoming greatly weakened, while the NOE cross-peak A6-H8 -  
A6-H1’ is intensified due to the relatively shorter distance from the A6-H1’ proton to 
the syn A6-H8. The resonances resulting from the interaction of A6-H8 with the 
protons discussed are shown in Figure 135, while a pictorial representation showing 
relative distances DNA-H1’ to DNA syn A-H8 and DNA anti A-H8 can be seen in 
Figure 134.
Anti (Watson-Crick) A6-H8 Syn (Hoogsteen) A6-H8
Figure 134: Representation of the central region of the 5V(CGATTAATCG)2 duplex 
showing syn and anti A6-H8 (depicted in white). Lines show the A6-H8 -  A6-H1’
connectivity in each case
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Figure 135: 600 MHz 2D NOESY spectrum of the 5V(CGATTAATCG)2-adozelesin mixed 
adduct. 200 ms mixing time. Expansion showing NOE connectivities arising from the A6- 
H8 (Hg) resonance. Cross-peaks to protons in the minor groove are weakened while the 
cross-peak from A6-H8(Hg) to A 6-H l’(Hg) is intensified
In addition to weakened peaks associated with the A6-H8 proton NOE resonances can 
be observed between the A6-H2 proton and the H2’ and H2” protons of the 3’ 
neighbouring base (T5). As shown in Figure 136 in its new location in the major 
groove the syn A6-H2 proton is placed in the vicinity of these protons and so exhibits 
NOE connectivities with them (See Figure 137). This is in analogy to previous studies 
on a Hoogsteen adduct performed by Seaman and Hurley.115
Figure 136: Stereoview of a DNA duplex showing a hoogsteen base at A6. The A6-H2 and
T5-H2’/H2” protons are shown in white
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Figure 137: 600 MHz 2D NOESY spectrum of the 5W(CGATTAATCG)2-adozelesin mixed 
adduct. 200 ms mixing time. Expansion of the H6/H8-H2’/H2” region showing NOE 
connectivity of A6-H2(Hg) with T5-H2’(Hg) and T5-H2” (Hg) (peaks A and B). Other 
assignments have been omitted to aid clarity.
5.10: The refined molecular model of the 5V(CGATTAATCG)2-adozelesin 
Hoogsteen adduct.
The 5’c/(CGATTAATCG)2-adozelesin Hoogsteen adduct was modelled using the 
SYBYL software suite197 as described in Chapters 3 and 4. The Hoogsteen DNA 
duplex was produced within the SYBYL package and subjected to steepest descent 
energy minimisation prior to the docking of overlapped adozelesin molecules produced 
and energy-minimised using steepest descent and molecular dynamics at 300 K within 
HYPERCHEM.193 The model was then subjected to procedures identical to those 
discussed in Chapter 3. Complete restraints tables can be seen in Appendix IV.
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Figures 138 & 139 show the in aquo computer model of the adozelesin Hoogsteen 
adduct. Adozelesin is shown in white, with the two DNA strands in green and purple. 
With the exception of the central A6 Hoogsteen base pairs the duplex has retained p« 
helical structure. The central Hoogsteen pairs are slightly distorted but show minimal 
disruption to surrounding base pairs and accommodate the drug overlap by providing a 
widening of the minor groove.
Figure 140 shows the central region of the duplex, with A7-H1’, Ado-H5’2 and Ado- 
H6’2 highlighted. NOE connectivities between the adozelesin aromatic protons and A7- 
H l’ are a clear indication of the drug association with its own covalently modified 
strand as discussed in section 5.6.1 as any other configuration would render these 
protons too spatially separated to exhibit NOE connectivities in this manner.
Figure 141 again shows the central region of the duplex. Ado-H4’2, Ado-H5’2, Ado- 
H6’2 and Ado-H6’l are highlighted in red. These protons were found to be dipolar 
coupled, exhibiting NOESY cross-peaks as discussed in section 5.6.2, This provides 
compelling evidence for the overlap of the ‘C’ subunits as shown in Figure 121 B.
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Figure 138: Stereoview of the 5W(CGATTAATCG)2-adozelesin Hoogsteen adduct. Slight distortion can be seen at the
central Hoogsteen base pairs, but the disruption to the surrounding bases is minimal. Models generated in the SYBYL





Figure 139: Stereoview of the 5W(CGATTAATCG)2-adozelesin Hoogsteen adduct. The adozelesin molecule follows the contours
of the minor groove with minimal disruption to the DNA helix. Models generated in the SYBYL software suite197 and pictured
using UCSF Chimera193
Figure 140: Stereoview of the 5’</(CGATTAATCG)2-adozelesin Hoogsteen adduct central region. A7-H1* and Ado-H5’2 and 
H6’2 are shown in red. A close association is observed resulting in \O E  connectivities. Models generated in the SYBYL 
software suite197 and pictured using UCSF Chimera193
Figure 141: Stereoview of the 5W(CGATTAATCG)2-adozelesin Hoogsteen adduct central region. Ado-H4’2, Ado-H5’2, Ado- 
H6’2 and Ado-H6’l  are shown in red. Overlap of the ‘C’ subunit results in NOE connectivities. Models generated in the SYBYL 
software suite197 and pictured using UCSF Chimera193
CHAPTER 6 -  CONCLUSIONS
6.1: PBD Dimers
The covalent modification of two DNA sequences, 5 V(CICGATCICG)2  and 
5’d(CTCATCAC).(GTGATGAG), by SJG-136 has been investigated by high field 
NMR spectroscopy and a refined molecular model of each has been generated using 
distance-range restraints determined from the assignment of the 2D NOESY NMR 
spectra. The first adduct confirms the findings of previous studies of DSB-120 linkage 
with the same DNA sequence, while the second is the first example of a PBD-DNA 
intra-strand cross-linked adduct
6.1.1: The 5 ’&(CICGATCICG)2-SJG-136 adduct
As expected, an inter-strand cross-linked adduct was obtained from the reaction of SJG- 
136 within the minor groove of 5,d(CICGATCICG)2. This result compliments very well 
studies by Mountzouris et al on the 5W(CICGATCICG)2-DSB-120 adduct.181 The 
covalent reaction between the Cl 1 carbon of SJG-136 and the exocyclic NH2 group of 
the G4 nucleotide was confirmed. ‘S’ stereochemistry was assigned to C ll, again in 
direct agreement with studies on the DSB-120 adduct, and providing support for 
previous molecular mechanics calculations, which predicted that the ‘S’ configuration 
was the energetically preferred stereochemistry in PBD-DNA adducts 42,43,44
Other similarities with the DSB-120 adduct include the reversal of the established 
chemical shift pattern of the DNA-H2’ and H2” protons. Typically, the H2’ resonance 
is found up-field of the H2” proton, located by the NOE cross-peak between DNA-H1 ’ 
and DNA-H2’/H2’\  In the case of both the DSB-120 adduct and the SJG-136 adduct 
this pattern is reversed and the more intense DNA-H1’ -  DNA-H2’ coupling is found 
down-field of the DNA-H1’ -  DNA-H2” . This feature is indicative of conformational 
change within the internal nucleotide and confirms that, like DSB-120, SJG-136 induces 
additional perturbation of the DNA-C7 nucleotide, which faces the covalently modified 
G4 nucleotide in the minor groove. A further similarity between the DSB-120 and SJG-
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136 adducts is the probable inversion of the aromatic rings of the drug, resulting in an 
attenuated up-field shift of the T6-H4’ proton in each case, when compared with a 
DNA-tomamycin adduct.
As expected, differences between the SJG-136 and DSB-120 adducts can be mainly 
attributed to the presence of the ethylidene functionality in SJG-136. The shielding 
effect of this functional group causes up-field shifts of protons within the DNA-I8, 
DNA-C9 and DNA-C1 nucleotides. Interestingly, in the case of the SJG-136 adduct, 
evidence is present to support the location of SJG-136 as deeper within the minor 
groove than DSB-120, which was reported as shallowly immersed. This feature can also 
be attributed to the ethylidene group, with unsaturation at C2 leading to a better 
isohelical fit in the minor groove as discussed in Chapter l .73 In addition, there is no 
evidence for de-stacking of the I2-C3 step as observed with the DSB-120 adduct. It is 
possible that the superior fit of the SJG-136 molecule in the minor groove renders such 
perturbation of the DNA structure unnecessary in order to accommodate the drug.
6.1.2: The 5 ’d(CTCATCAC). (GTGATGAG)-SJG-136 adduct
The 5W(CTCATCAC).(GTGATGAG)-SJG-136 adduct has been successfully made and 
represents a novel intra-strand cross-linking duplex adduct. The reaction sites are 
confirmed to be between the SJG-C11 centre and the erocyclic NH2 group of the G11 
and G14 nucleotides. SJG-C11 stereochemistry is assigned as ‘S’ at both C ll reaction 
sites, in accordance with previous studies of PBD-DNA adducts both within this thesis 
(Chapter 3) and elsewhere,45’181 and as expected the drug displays a greater association 
with the modified DNA strand.
As observed in both the DSB-120181 and SJG-136 inter-strand adducts (Chapter 3), a 
reversal in the typical relative pattern of DNA-H2’ and H2” protons is noted, with the 
DNA-H2 ’ proton resonating down-field o f the DNA-H2” proton. However, whilst in 
the inter-strand adducts this reversal was limited to nucleotides in the vicinity of the 
covalent modification site, the intra-strand adduct displays a pattern reversal throughout 
numerous nucleotides across the centre of the duplex, at nucleotides in the vicinity of 
the drug. This is attributed to some perturbation of the DNA structure on
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accommodation of an intra-strand cross-linking drug, and as such is not wholly 
unexpected.
When chemical shift data are examined relative to those obtained on assignment of the 
inter-strand adduct it is noted that chemical shifts at the G-5’ end of the intra-strand 
adduct show a greater similarity to those found in the inter-strand adduct. This provides 
support for the two-step reaction mechanism postulated by Thurston et al, which 
involved an initial alkylation at the one end of the strand, with a secondary alkylation 
following in the second reaction step. Presumably the G-5’ end of the duplex has 
reacted first in this case, with the second reaction step producing perturbation on 
accommodation of the intra-strand cross-link.
The formation of a novel intra-strand cross-link in this manner offers the potential for 
targeting the human telomere repeat sequence with PBD covalent minor groove binders. 
Telomeres are the ends of the chromosomes of eukaryotic cells and consist of GT rich 
repeats in telomere sequence. Normal mortal cells shorten their telomeres during each 
round of cellular replication, due to an inability of DNA to replicate the last few bases 
of a sequence. In cancer cells however, the telomerase enzyme is active, and responsible 
for regenerating the telomere ends, presumably to counteract the rapid cell division that 
is a feature of cancerous cells. For these reasons telomerase and the telomere repeat 
sequence have been recognised as an important target for the development of new anti­
cancer drugs. Several strategies based on the inhibition of telomerase exist, but it has 
also been suggested that some classes of DNA damaging drugs might interact 
preferentially with telomeric sequences. Cis-platin for example, is a G-G cross-linking 
agent that has been shown to shorten telomeres and inhibit telomerase. The human 
telomere sequence is -GATTG- and so it is feasible that it could present a potential 
binding site for an intra-strand cross-linker such as SJG-136 as shown in Figure 142, 
with possibilities for alternative length linkers to bind at different sites.
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-GGGATTGGG-
Figure 142: Potential intra-strand cross-link sites on the human telomere repeat sequence
As discussed in Chapter 1, previous studies on linker lengths in dimeric PBDs showed 
the most effective linker units to be those where the number of CH2 groups (n) was odd 
(especially 3 or 5).73,74 Furthermore, the n=5 ligand displayed around lOx greater 
potency with respect to the n=3 (DSB-120) analogue.74 The binding of the telomeric 
repeat sequence is a plausible explanation for the greater potency of the ligand with 
n=5, as it is possible that this longer sequence, in addition to the inter-strand links 
reported, could also bind to the telomere repeat sequence via an intra-strand cross-link 
such as that discussed in relation to the SJG-136 adduct. With the considerable current 
interest in telomeric targeting drugs this possible binding sequence could have major 
repercussions in anti-cancer drug design.
6.1.3: Future work
Telomere structures are complex and involve the folding of the single stranded DNA 
into quadruplex formations. It is unlikely that a PBD such as SJG-136 would bind 
successfully to a quadruplex structure, due to large differences in the shape and size of 
the grooves. The suggested target site then, is the duplex DNA/RNA hybrid site formed 
during transcription at the telomerase active site. Binding of PBD drugs to DNA/RNA 
hybrids has not been assessed, hence future work on PBD adducts will involve the 
synthesis of DNA/RNA hybrids in order to confirm the possibility of SJG-136 intra- 
strand adducts with a DNA/RNA hybrid duplex.
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6.2: The 5’d(CGATTAATCG)2-adozelesm adduct
Reaction of the 5V(CGATTAATCG)2 duplex with adozelesin has been successfully 
carried out and has resulted in two adducts in approximately equal proportions. Both 
adducts were identified and fully assigned using sequential assignment techniques as 
discussed in Chapter 2. One adduct displays a retention of Watson-Crick base pairing 
throughout the duplex, with minimal disruption of the P-helical structure. The other 
adduct, however, exhibits Hoogsteen base pairing at the central AT nucleotides, in 
analogy with previous studies of the symmetrical CPI analogue, bizelesin.115 Evidence 
exists for the significant overlap of the benzofuran subunit in both adducts, as shown in 
Figure 143 and similarities between the structure of bizelesin compared to overlapped 
adozelesin molecules have been suggested. There has however, been no evidence to 
support formation of open base pairing, as seen in the 5 ’ d(GTATTAATC G)2-bizelesin 
adduct.
3 ' - G - C - T - A - A - T - T - A - G - C - 3 1
H,C
5 ' - C - G - A - T - T - A - A - T - C - G - 3 '
Figure 143: Significant overlap of the benzofuran subunits in an adozelesin ‘stacked’
adduct
The discovery of novel ‘stacked’ adducts for CPI ligands suggests an alternative model 
for minor groove drug interactions. Similarities can be drawn between the adozelesin
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stacked molecules and analogous stacking in the non-covalent minor groove binding 
lexitropsin drugs, which have been found to stack in 1:1, 2:1 and 4:1 ratios with the 
DNA duplex, resulting in a widening of up to 17 A of the minor groove,171
6.2.1: Future work
Possible developments in the area of CPI drug design as a result of discoveries in this 
project include the synthesis of bulkier DNA interactive ligands. Previous assumptions 
of a requirement for a planar ligand and a tight fit into the minor groove have been 
brought into question in light of both these studies, and reports of stacked lexitropsin 
adducts. It appears that the minor groove is much more accommodating that previously 
supposed, allowing significant widening to in order to react with bulkier molecules.
Similarities in the shape of the overlapped adozelesin molecules in this study with the 
shape of the dimeric interstrand cross-linking drug bizelesin also suggest the possibility 
that stacked adducts may behave as pseudo cross-linkers. This would provide an 
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Appendix I












1 I2-H8 C3-H6 8.28 7.34 W 4.50 3.50
2 C3-H6 G4-H8 7.34 7.80 W 4.50 3.50
3 G4-H8 A5-H8 7.80 8.15 W 4.50 3.50
4 A5-H8 T6-H6 8.15 7.05 W 4.50 3.50
5 C7-H6 I8-H8 7.14 8.12 W 4.50 3.50
6 I8-H8 C9-H8 8.12 7.20 W 4.50 3.50
7 C1-H6 Cl-Hl* 7.90 5.52 M 3.50 2.00
8 I2-H8 I2-H1’ 8.28 6.15 M 3.50 2.00
9 C3-H6 C3-HF 7.34 5.47 M 3.50 2.00
10 G4-H8 G4-H1’ 7.80 6.08 M 3.50 2.00
11 A5-H8 A5-H1’ 8.15 6.30 W 4.50 3.50
12 T6-H6 T6-H1’ 7.05 5.71 W/M 4.00 3.00
13 C7-H6 C7-H1’ 7.14 5.44 W 4.50 3.50
14 I8-H8 I8-H1’ 8.12 5.84 M 3.50 2.00
15 C9-H8 C9-H1’ 7.20 5.77 M 3.50 2.00
16 G10-H8 G10-HF 7.90 6.06 M 3.50 2.00
17 c i - H r I2-H8 5.52 8.28 W 4.50 3.50
18 I2-H1’ C3-H6 6.15 7.34 M 3.50 2.00
19 C3-H1’ G4-H8 5.47 7.80 W/M 4.00 3.00
20 G4-H1’ A5-H8 6.08 8.15 M 3.50 2.00
21 A5-H1’ T6-H6 6.30 7.05 M 3.50 2.00
22 T6-H1’ C7-H6 5.71 7.14 M/W 4.00 3.00
23 C7-H1' I8-H8 5.44 8.12 W 4.50 3.50
24 I8-H1’ C9-H8 5.84 7.20 M 3.50 2.00
25 C9-H1’ G10-H8 5.77 7.90 W 4.50 3.50
26 C1-H6 C1-H2’ 7.60 2.28 M 3.50 2.00
27 C1-H6 C1-H2” 7.60 1.82 S 1.00 2.00
28 C1-H2’ I2-H8 2.28 8.28 M 3.50 2.00
29 C1-H2” I2-H8 1.82 8.28 M 3.50 2.00
30 I2-H8 I2-H2* 8.28 2.82 S 1.00 2.00
31 I2-H8 I2-H2” 8.28 2.66 S 1.00 2.00
32 I2-H2’ C3-H6 2.82 7.34 M 3.50 2.00
33 I2-H2” C3-H6 2.66 7.34 M 3.50 2.00
34 C3-H6 C3-H2’ 7.34 2.27 M 3.50 2.00
35 C3-H6 C3-H2” 7.34 1.86 S 1.00 2.00
36 C3-H2’ G4-H8 2.27 7.80 M 3.50 2.00
37 C3-H2” G4-H8 1.86 7.80 M 3.50 2.00
38 G4-H8 G4-H2’ 7.80 2.94 M 3.50 2.00
39 G4-H8 G4-H2” 7.80 2.66 S 1.00 2.00
40 G4-H2’ A5-H8 2.94 8.15 S 1.00 2.00
41 G4-H2” A5-H8 2.66 8.15 S 1.00 2.00
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42 A5-H8 A5-H2’ 8.15 2.66 S 1.00 2.00
43 A5-H8 A5-H2” 8.15 2.46 S 1.00 2.00
44 A5-H2’ T6-H6 2.66 7.05 M 3.50 2.00
45 A5-H2” T6-H6 2.46 7.05 M 3.50 2.00
46 T6-H6 T6-H2’ 7.05 2.17 M 3.50 2.00
47 T6-H6 T6-H2” 7.05 1.94 S 1.00 2.00
48 T6-H2’ C7-H6 2.17 7.14 M 3.50 2.00
49 T6-H2” C7-H6 1.94 7.14 M 3.50 2.00
50 C7-H6 C7-H2’ 7.14 2.09 M 3.50 2.00
51 C7-H6 C7-H2” 7.14 1.65 M 3.50 2.00
52 C7-H2’ I8-H8 2.09 8.12 M 3.50 2.00
53 C7-H2” I8-H8 1.65 8.12 M/W 4.00 3.00
54 I8-H8 I8-H2” 8.12 2.10 M 3.50 2.00
55 I8-H2’ C9-H6 2.57 7.20 M 3.50 2.00
56 I8-H2” C9-H6 2.10 7.20 M 3.50 2.00
57 C9-H6 C9-H2’ 7.20 2.13 M 3.50 2.00
58 C9-H6 C9-H2” 7.20 1.46 S 1.00 2.00
59 C9-H2’ G10-H8 2.13 7.90 M 3.50 2.00
60 C9-H2” G10-H8 1.46 7.90 M 3.50 2.00
61 G10-H8 G10-H2’ 7.90 2.55 S 1.00 2.00
62 G10-H8 G10-H2” 7.90 2.26 S 1.00 2.00
63 C1-H6 C1-H3’ 7.60 4.61 w 4.50 3.50
64 I2-H8 I2-H3’ 8.28 4.91 M 3.50 2.00
65 C3-H6 C3-H3’ 7.34 4.92 v w 5.00 4.00
66 G4-H8 G4-H3* 7.80 4.95 M 3.50 2.00
67 A5-H8 A5-H3’ 8.15 4.88 M/W 4.00 3.00
68 T6-H6 T6-H3’ 7.05 4.55 M 3.50 2.00
69 I8-H8 I8-H3’ 8.12 4.83 W 4.50 3.50
70 G10-H8 G10-H3’ 7.90 4.58 M 3.50 2.00
71 C3-H3’ G4-H8 4.92 7.80 W 4.50 3.50
72 G4-H3* A5-H8 4.95 8.15 M/W 4.00 3.00
73 A5-H3’ T6-H6 4.88 7.05 VW 5.00 4.00
74 C1-H6 C1-H4’ 7.60 3.63 M 3.50 2.00
75 I2-H8 I2-H4’ 8.28 4.32 w 4.50 3.50
76 C3-H6 C3-H4’ 7.34 4.06 M 3.50 2.00
77 G4-H8 G4-H4’ 7.80 4.06 M 3.50 2.00
78 A5-H8 A5-H4’ 8.15 3.94 W 4.50 3.50
79 T6-H6 T6-H4’ 7.05 3.98 M 3.50 2.00
80 C7-H6 C7-H4’ 7.14 4.02 W 4.50 3.50
81 C9-H8 C9-H4’ 7.20 3.94 W 4.50 3.50
82 G10-H8 G10-H4’ 7.90 3.96 M 3.50 2.00
83 C l-H l’ C1-H3’ 5.52 8.28 W 4.50 3.50
84 I2-H1’ I2-H3’ 6.15 7.34 M 3.50 2.00
85 G4-H1’ G4-H3’ 6.08 8.15 M 3.50 2.00
86 A5-H1* A5-H3’ 6.30 7.05 M 3.50 2.00
87 I8-H1’ I8-H3’ 5.84 7.20 M 3.50 2.00
88 G10-H1’ G10-H3’ 6.06 4.58 M 3.50 2.00
89 C l-H l’ C1-H4’ 5.52 3.63 W 4.50 3.50
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90 I2-H1’ I2-H4’ 6.15 4.32 M 3.50 2.00
91 C3-H1 ’ C3-H4’ 5.47 4.06 M 3.50 2.00
92 G4-H1’ G4-H4’ 6.08 4.06 S 1.00 2.00
93 A5-H1’ A5-H4’ 6.30 3.94 M 3.50 2.00
94 T6-H1’ T6-H4’ 5.71 3.98 M 3.50 2.00
95 C7-H1’ C7-H4* 5.44 4.02 M 3.50 2.00
96 I8-H1’ I8-H4’ 5.84 3.82 M/S 3.00 1.00
97 C9-H1’ C9-H4’ 5.77 3.94 M 3.50 2.00
98 G10-H1’ G10-H4’ 6.06 3.96 M 3.50 2.00
99 C1-H4’ C1-H2’ 3.63 2.28 W 4.50 3.50
100 I2-H4’ I2-H2’ 4.32 2.82 W 4.50 3.50
101 C3-H4’ C3-H2’ 4.06 2.27 M 3.50 2.00
102 G4-H4’ G4-H2’ 4.06 2.94 M 3.50 2.00
103 A5-H4’ A5-H2’ 3.94 2.66 M 3.50 2.00
104 T6-H4’ T6-H2’ 3.98 2.17 M 3.50 2.00
105 C7-H4’ C7-H2’ 4.02 2.09 W/M 4.00 3.00
106 I8-H4’ I8-H2’ 3.82 2.57 M 3.50 2.00
107 C9-H4* C9-H2’ 3.94 2.13 M 3.50 2.00
108 G10-H4’ G10-H2’ 3.96 2.55 M 3.50 2.00
109 C1-H4* C1-H2” 3.63 1.82 M 3.50 2.00
110 I2-H4’ I2-H2” 4.32 2.66 W 4.50 3.50
111 C3-H4’ C3-H2” 4.06 1.86 M 3.50 2.00
112 G4-H4’ G4-H2” 4.06 2.66 M 3.50 2.00
113 A5-H4’ A5-H2” 3.94 2.46 M 3.50 2.00
114 T6-H4’ T6-H2” 3.98 1.94 M 3.50 2.00
115 C7-H4’ C7-H2” 4.02 1.65 W/M 4.00 3.00
116 I8-H4’ I8-H2” 3.82 2.10 M 3.50 2.00
117 C9-H4’ C9-H2” 3.94 1.46 M 3.50 2.00
118 G10-H4’ G10-H2” 3.96 2.26 M 3.50 2.00
119 C1-H3’ C1-H4’ 5.52 3.63 W 4.50 3.50
120 I2-H3’ I2-H4’ 6.15 4.32 M 3.50 2.00
121 C3-H3’ C3-H4’ 5.47 4.06 M 3.50 2.00
122 G4-H3’ G4-H4’ 6.08 4.06 M 3.50 2.00
123 A5-H3’ A5-H4’ 6.30 3.94 M 3.50 2.00
124 I8-H3’ I8-H4’ 5.84 3.82 M 3.50 2.00
125 G10-H3’ G10-H4’ 6.06 3.96 W/M 4.00 3.00
126 T6-CH3 A5-H8 1.20 8.15 S 1.00 2.00
127 T6-CH3 T6-H6 1.20 7.05 s 1.00 2.00
128 T6-CH3 A5-H1’ 1.20 6.30 M 3.50 2.00
129 T6-CH3 C7-H5 1.20 5.26 W 4.50 3.50
130 T6-CH3 A5-H3’ 1.20 4.88 M/W 4.00 3.00
131 T6-CH3 A5-H2’ 1.20 2.66 S 1.00 2.00
132 T6-CH3 A5-H2” 1.20 2.46 s 1.00 2.00
133 I2-H2 I8-H2 7.82 7.38 w 4.50 3.50
134 I2-H2 G10-H1’ 7.82 6.06 M 3.50 2.00
135 I2-H2 C9-H1’ 7.82 5.77 w 4.50 3.50
136 I2-H2 I2-H1 * 7.82 6.15 M 3.50 2.00
137 I8-H2 I8-H1’ 7.38 5.84 M 3.50 2.00
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138 I8-H2 C9-H4’ 7.38 3.94 M 3.50 2.00
139 I2-H2 C3-H1’ 7.82 5.47 M 3.50 2.00
140 I8-H2 C9-H1’ 7.38 5.77 M 3.50 2.00
141 A5-H2 T6-H1’ 8.11 5.71 W 4.50 3.50
142 A5-H2 C7-H1’ 8.11 5.44 W 4.50 3.50
143 C1-H5 C1-H4’ 5.80 3.63 VW 5.00 4.00
144 C1-H5 C1-H2’ 5.80 2.28 W 4.50 3.50
145 C1-H5 C1-H2” 5.80 1.82 M 3.50 2.00
146 C3-H5 I2-H2’ 5.29 2.82 M 3.50 2.00
147 C3-H5 I2-H2” 5.29 2.66 M 3.50 2.00
148 C3-H5 C3-H2’ 5.29 2.27 M 3.50 2.00
149 C3-H5 C3-H2” 5.29 1.86 M 3.50 2.00
150 C7-H5 C7-H2’ 5.27 2.09 M 3.50 2.00
151 C7-H5 C7-H2” 5.27 1.65 M 3.50 2.00
152 C9-H5 I8-H2’ 5.26 2.57 M 3.50 2.00
153 C9-H5 I8-H2” 5.26 2.10 M 3.50 2.00
154 C9-H5 C9-H2’ 5.26 2.13 M 3.50 2.00
155 C9-H5 C9-H2” 5.26 1.46 M 3.50 2.00








1 H la I8-H3’ 2.55 4.83 M 3.50 2.00
2 H la I8-H2 2.55 7.38 M 3.50 2.00
3 Hlb I8-H3’ 3.21 4.83 M/W 4.00 3.00
4 H lb C7-H1’ 3.21 5.44 W 4.50 3.50
5 Hlb I8-H2 3.21 7.38 M 3.50 2.00
6 H2a/b A5-H4’ 5.84 3.94 M 3.50 2.00
7 H2a/b C9-H4’ 5.84 3.94 M 3.50 2.00
8 H2a/b G4-H4’ 5.84 4.06 W 4.50 3.50
9 H2a/b I8-H2 5.84 7.38 W 4.50 3.50
10 H3a/b I8-H1’ 4.02/4.06 5.84 W 4.50 3.50
11 H3a/b A5-H3’ 4.02/4.06 4.88 M 3.50 2.00
12 H3a/b A5-H1’ 4.02/4.06 6.30 W 4.50 3.50
13 H3a/b C9-H1 ’ 4.02/4.0 6 5.77 W 4.50 3.50
14 H6 T6-H4’ 7.05 3.98 W/M 4.00 3.00
15 H9 C7-H1’ 7.05 5.44 W 4.50 3.50
16 H9 C7-H4’ 6.53 4.02 w 4.50 3.50
17 H9 A5-H2 6.53 8.11 s 2.00 1.00
18 H9 T6-H1’ 6.53 5.71 M 3.50 2.00
19 H ll I8-H2 5.64 7.38 w 4.50 3.50
20 H ll G4-H1 ’ 5.64 6.28 M 3.50 2.00
21 H ll A5-H1’ 5.64 6.30 M 3.50 2.00
22 H lla I8-H2 3.92 7.38 M 3.50 2.00
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23 H lla I8-H1’ 3.92 5.84 M 3.50 2.00
24 HI la C7-H r 3.92 5.44 W 4.50 3.50
25 H12a/b C7-H1’ 4.24 5.44 M/W 4.00 3.00
26 H12a/b T6-H1 ’ 4.24 5.71 M 3.50 2.00
27 H12a/b A5-H2 4.24 8.11 M 3.50 2.00
28 H13a/b C7-H1’ 2.28 5.44 M 3.50 2.00
29 H13a/b C7-H4’ 2.28 4.02 S 2.00 1.00
30 H13a/b T6-H1’ 2.28 5.71 M 3.50 2.00
31 H14 C7-H1' 3.83 5.44 W 4.50 3.50
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Appendix II
Master Table Showing All DNA-DNA Connections for the 
5 V-CTCATCAC.GTGATGAG-SJG-136 Intra-strand Adduct.
Peak
Number








1 C1-H6 T2-H6 7.76 7.52 M/S 3.00 1.00
2 T2-H6 C3-H6 7.52 7.45 M/S 3.00 1.00
3 C3-H6 A4-H8 7.45 8.32 M 3.50 2.00
4 A4-H8 T5-H6 8.32 6.89 W 4.50 3.50
5 T5-H6 C6-H6 6.89 7.07 M 3.50 2.00
6 C6-H6 A7-H8 7.07 8.04 M 3.50 2.00
7 A7-H8 C8-H6 8.04 7.30 M 3.50 2.00
8 G9-H8 T10-H6 7.83 7.30 W 4.50 3.50
9 T10-H6 G11-H8 7.30 7.78 W/M 4.00 3.00
10 G11-H8 A12-H8 7.78 8.14 M 3.50 2.00
11 A12-H8 T13-H6 8.14 7.01 W 4.50 3.50
12 T13-H6 G14-H8 7.01 7.52 M 3.50 2.00
13 G14-H8 A15-H8 7.52 7.83 M 3.50 2.00
14 A15-H8 G16-H8 7.83 7.51 M 3.50 2.00
15 C1-H6 C l-H l’ 7.76 5.80 S 2.00 1.00
16 T2-H6 T2-H1’ 7.52 5.93 M 3.50 2.00
17 C3-H6 C3-H1’ 7.45 5.99 M 3.50 2.00
18 A4-H8 A4-H1’ 8.32 6.29 W 4.50 3.50
19 T5-H6 T5-H1’ 6.89 5.55 M/W 4.00 3.00
20 C6-H6 C6-H1’ 7.07 5.61 M 3.50 2.00
21 A7-H8 A7-H1 ’ 8.04 5.88 M 3.50 2.00
22 C8-H6 C8-H1’ 7.30 5.97 M 3.50 2.00
23 G9-H8 G9-H1’ 7.83 5.94 W 4.50 3.50
24 T10-H6 T10-H1’ 7.30 5.44 M 3.50 2.00
25 G11-H8 G ll-H l’ 7.78 6.08 W/M 4.00 3.00
26 A12-H8 A12-H1’ 8.14 6.24 W 4.50 3.50
27 T13-H6 T13-H1’ 7.01 5.40 M 3.50 2.00
28 G14-H8 G14-H1’ 7.52 5.94 W 4.50 3.50
29 A15-H8 A15-H1’ 7.83 5.77 W 4.50 3.50
30 G16-H8 G16-H1’ 7.51 5.92 M 3.50 2.00
31 T2-H1’ C1-H6 7.52 7.76 M 3.50 2.00
32 C3-H1’ T2-H6 7.45 7.52 M 3.50 2.00
33 A4-HF C3-H6 8.32 7.45 M 3.50 2.00
34 T5-H1’ A4-H8 6.89 8.32 M 3.50 2.00
35 C6-H1 ’ T5-H6 7.07 6.89 M 3.50 2.00
36 A7-H1’ C6-H6 8.04 7.07 M 3.50 2.00
37 C8-H1’ A7-H8 7.30 8.04 M 3.50 2.00
38 T10-H1’ G9-H8 7.83 7.83 M 3.50 2.00
39 G ll-H l’ T10-H6 7.30 7.30 M 3.50 2.00
40 A12-H1’ G11-H8 7.78 7.78 M 3.50 2.00
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41 T13-H1’ A12-H8 8.14 8.14 M 3.50 2.00
42 G14-H1’ T13-H6 7.01 7.01 M/S 3.00 1.00
43 A15-H1’ G14-H8 7.52 7.52 M 3.50 2.00
44 G16-H1’ A15-H8 7.83 7.83 M 3.50 2.00
45 C1-H6 C1-H2’ 7.51 2.44 M/S 3.00 1.00
46 T2-H6 T2-H2’ 7.52 2.44 S 2.00 1.00
47 C3-H6 C3-H2’ 7.45 2.55 s 2.00 1.00
48 A4-H8 A4-H2’ 8.32 2.75 s 2.00 1.00
49 T5-H6 T5-H2’ 6.89 2.18 s 2.00 1.00
50 C6-H6 C6-H2’ 7.07 2.12 s 2.00 1.00
51 A7-H8 A7-H2’ 8.04 2.53 M 3.50 2.00
52 C8-H6 C8-H2’ 7.30 2.02 S 2.00 1.00
53 G9-H8 G9-H2’ 7.83 2.72 S 2.00 1.00
54 T10-H6 T10-H2’ 7.30 2.42 S 2.00 1.00
55 G11-H8 G11-H2’ 7.78 2.84 s 2.00 1.00
56 A12-H8 A12-H2’ 8.14 2.55 s 2.00 1.00
57 T13-H6 T13-H2’ 7.01 2.15 s 2.00 1.00
58 G14-H8 G14-H2’ 7.52 2.57 s 2.00 1.00
59 A15-H8 A15-H2’ 7.83 2.55 s 2.00 1.00
60 G16-H8 G16-H2’ 7.51 2.25 s 2.00 1.00
61 C1-H6 C1-H2” 7.76 2.08 M 3.50 2.00
62 T2-H6 T2-H2” 7.52 2.15 S 2.00 1.00
63 C3-H6 C3-H2” 7.45 2.12 s 2.00 1.00
64 A4-H8 A4-H2” 8.32 2.60 M 3.50 2.00
65 T5-H6 T5-H2” 6.89 1.76 M 3.50 2.00
66 C6-H6 C6-H2” 7.07 1.64 s 2.00 1.00
67 A7-H8 A7-H2” 8.04 2.42 S 2.00 1.00
68 C8-H6 C8-H2” 7.30 1.97 M 3.50 2.00
69 G9-H8 G9-H2” 7.83 2.47 M 3.50 2.00
70 T10-H6 T10-H2” 7.30 2.22 S 2.00 1.00
71 G11-H8 G11-H2” 7.78 2.60 M/S 3.00 1.00
72 A12-H8 A12-H2” 8.14 2.44 S 2.00 1.00
73 T13-H6 T13-H2” 7.01 2.10 s 2.00 1.00
74 G14-H8 G14-H2” 7.52 2.45 s 2.00 1.00
75 A15-H8 A15-H2” 7.83 2.44 s 2.00 1.00
76 G16-H8 G16-H2” 7.51 2.08 s 2.00 1.00
77 T2-H6 C1-H2’ 7.52 2.44 s 2.00 1.00
78 C3-H6 T2-H2’ 7.45 2.44 s 2.00 1.00
79 A4-H8 C3-H2’ 8.32 2.55 M 3.50 2.00
80 T5-H6 A4-H2’ 6.89 2.75 M 3.50 2.00
81 C6-H6 T5-H2’ 7.07 2.18 M 3.50 2.00
82 A7-H8 C6-H2’ 8.04 2.12 M 3.50 2.00
83 C8-H6 A7-H2’ 7.30 2.53 S 2.00 1.00
84 T10-H6 G9-H2’ 7.30 2.72 M 3.50 2.00
85 G11-H8 T10-H2’ 7.78 2.42 M 3.50 2.00
86 A12-H8 G11-H2’ 8.14 2.84 S 2.00 1.00
87 T13-H6 A12-H2’ 7.01 2.55 M/S 3.00 1.00
88 G14-H8 T13-H2’ 7.52 2.15 S 2.00 1.00
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89 A15-H8 G14-H2’ 7.83 2.57 M/S 3.00 1.00
90 G16-H8 A15-H2’ 7.51 2.55 S 2.00 1.00
91 T2-H6 C1-H2” 7.52 2.08 s 2.00 1.00
92 C3-H6 T2-H2” 7.45 2.15 M 3.50 2.00
93 A4-H8 C3-H2” 8.32 2.12 S 2.00 1.00
94 T5-H6 A4-H2” 6.89 2.60 M/S 3.00 1.00
95 C6-H6 T5-H2” 7.07 1.76 S 2.00 1.00
96 A7-H8 C6-H2” 8.04 1.64 M/S 3.00 1.00
97 C8-H6 A7-H2” 7.30 2.42 M/S 3.00 1.00
98 T10-H6 G9-H2” 7.30 2.47 S 2.00 1.00
99 G11-H8 T10-H2” 7.78 2.22 s 2.00 1.00
100 A12-H8 G11-H2” 8.14 2.60 s 2.00 1.00
101 T13-H6 A12-H2” 7.01 2.44 s 2.00 1.00
102 G14-H8 T13-H2” 7.52 2.10 s 2.00 1.00
103 A15-H8 G14-H2” 7.83 2.45 s 2.00 1.00
104 G16-H8 A15-H2” 7.51 2.44 s 2.00 1.00
105 C1-H6 C1-H3’ 7.76 4.55 M 3.50 2.00
106 T2-H6 T2-H3* 7.52 4.79 W 4.50 3.50
107 C3-H6 C3-H3’ 7.45 4.82 W 4.50 3.50
108 A4-H8 A4-H3’ 8.32 4.89 W 4.50 3.50
109 T5-H6 T5-H3’ 6.89 4.51 M 3.50 2.00
110 A7-H8 A7-H3’ 8.04 4.78 W 4.50 3.50
111 G9-H8 G9-H3’ 7.83 4.71 W 4.50 3.50
112 T10-H6 T10-H3’ 7.30 4.82 W 4.50 3.50
113 G11-H8 G11-H3’ 7.7 8 4.97 M 3.50 2.00
114 A12-H8 A12-H3’ 8.14 4.86 W 4.50 3.50
115 T13-H6 T13-H3’ 7.01 4.60 W 4.50 3.50
116 G14-H8 G14-H3’ 7.52 4.55 M/W 4.00 3.00
117 A15-H8 A15-H3’ 7.83 4.87 W 4.50 3.50
118 G16-H8 G16-H3’ 7.51 4.47 M 3.50 2.00
119 T2-H6 C1-H3’ 7.52 4.55 M 3.50 2.00
120 C3-H6 T2-H3’ 7.45 4.79 W 4.50 3.50
121 A4-H8 C3-H3’ 8.32 4.82 W 4.50 3.50
122 T5-H6 A4-H3’ 6.89 4.89 W 4.50 3.50
123 C6-H6 T5-H3’ 7.07 4.51 W 4.50 3.50
124 G11-H8 T10-H3’ 7.78 4.82 VW 5.00 4.00
125 A12-H8 G11-H3’ 8.14 4.97 W 4.50 3.50
126 T13-H6 A12-H3’ 7.01 4.86 W 4.50 3.50
127 G14-H8 T13-H3’ 7.52 4.60 VW 5.00 4.00
128 A15-H8 G14-H3’ 7.83 4.55 W 4.50 3.50
129 G16-H8 A15-H3’ 7.51 4.87 VW 5.00 4.00
130 C1-H6 C1-H4’ 7.76 3.98 M/W 4.00 3.00
131 T2-H6 T2-H4’ 7.52 4.13 M/W 4.00 3.00
132 C3-H6 C3-H4’ 7.45 4.18 M/W 4.00 3.00
133 A4-H8 A4-H4’ 8.32 3.64 W 4.50 3.50
134 T5-H6 T5-H4, 6.89 3.56 VW 5.00 4.00
135 A7-H8 A7-H4’ 8.04 3.62 vw 5.00 4.00
136 C8-H6 C8-H4’ 7.30 4.04 M/W 4.00 3.00
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137 G9-H8 G9-H4’ 7.83 4.13 W 4.50 3.50
138 T10-H6 T10-H4’ 7.30 4.13 M/W 4.00 3.00
139 G11-H8 G11-H4’ 7.78 4.35 W 4.50 3.50
140 A12-H8 A12-H4’ 8.14 3.86 w 4.50 3.50
141 T13-H6 T13-H4’ 7.01 3.30 w 4.50 3.50
142 G14-H8 G14-H4’ 7.52 4.05 M 3.50 2.00
143 A15-H8 A15-H4’ 7.83 4.05 M/W 4.00 3.00
144 G16-H8 G16-H4’ 7.51 3.98 M 3.50 2.00
145 C l-H I’ C1-H3’ 5.80 4.55 M 3.50 2.00
146 T2-H1’ T2-H3’ 5.93 4.79 M 3.50 2.00
147 C3-H1’ C3-H3’ 5.99 4.82 M 3.50 2.00
148 A4-H1’ A4-H3’ 6.29 4.89 M 3.50 2.00
149 T5-H1’ T5-H3’ 5.55 4.51 M 3.50 2.00
150 A7-H1 ’ A7-H3’ 5.88 4.78 M 3.50 2.00
151 G9-H1’ G9-H3’ 5.94 4.71 W 4.50 3.50
152 T10-H1’ T10-H3’ 5.44 4.82 M/W 4.00 3.00
153 G ll-H l’ G11-H3’ 6.08 4.97 M 3.50 2.00
154 A12-H1’ A12-H3’ 6.24 4.86 M 3.50 2.00
155 T13-H1’ T13-H3’ 5.40 4.60 W 4.50 3.50
156 G14-H1’ G14-H3’ 5.94 4.55 M 3.50 2.00
157 A15-H1’ A15-H3’ 5.77 4.87 M 3.50 2.00
158 G16-H1’ G16-H3’ 5.92 4.47 M 3.50 2.00
159 C l-H I’ C1-H4’ 5.80 3.98 M 3.50 2.00
160 T2-H1 ’ T2-H4’ 5.93 4.13 M 3.50 2.00
161 C3-H1 ’ C3-H4’ 5.99 4.18 M 3.50 2.00
162 A4-H1’ A4-H4’ 6.29 3.64 M 3.50 2.00
163 T5-H1’ T5-H4’ 5.55 3.56 M 3.50 2.00
164 C6-H1 ’ C6-H4’ 5.61 3.04 M 3.50 2.00
165 A7-H1’ A7-H4’ 5.88 3.62 M/S 3.00 1.00
166 C8-H1’ C8-H4’ 5.97 4.04 M 3.50 2.00
167 G9-H1’ G9-H4’ 5.94 4.13 S 2.00 1.00
168 T10-H1’ T10-H4’ 5.44 4.13 M 3.50 2.00
169 G ll-H l’ G11-H4’ 6.08 4.35 M/S 3.00 1.00
170 A12-H1’ A12-H4’ 6.24 3.86 M/S 3.00 1.00
171 T13-H1’ T13-H4’ 5.40 3.30 VW 5.00 4.00
172 G14-H1’ G14-H4’ 5.94 4.05 M 3.50 2.00
173 A15-H1’ A15-H4’ 5.77 4.05 M 3.50 2.00
174 G16-H1’ G16-H4’ 5.92 3.98 S 2.00 1.00
175 C1-H2’ C1-H4’ 2.44 3.98 S 2.00 1.00
176 T2-H2’ T2-H4’ 2.44 4.13 M 3.50 2.00
177 C3-H2’ C3-H4’ 2.55 4.18 M 3.50 2.00
178 A4-H2’ A4-H4’ 2.75 3.64 W 4.50 3.50
179 T5-H2’ T5-H4’ 2.18 3.56 W 4.50 3.50
180 C6-H2’ C6-H4’ 2.12 3.04 M 3.50 2.00
181 A7-H2’ A7-H4’ 2.53 3.62 M 3.50 2.00
182 C8-H2’ C8-H4’ 2.02 4.04 M 3.50 2.00
183 G9-H2’ G9-H4’ 2.72 4.13 S 2.00 1.00
184 T10-H2’ T10-H4’ 2.42 4.13 M 3.50 2.00
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185 G11-H2’ G11-H4’ 2.84 4.35 M/S 3.00 1.00
186 A12-H2’ A12-H4’ 2.55 3.86 M 3.50 2.00
187 T13-H2’ T13-H4’ 2.15 3.30 W 4.50 3.50
188 G14-H2’ G14-H4’ 2.57 4.05 M 3.50 2.00
189 A15-H2’ A15-H4’ 2.55 4.05 S 2.00 1.00
190 G16-H2’ G16-H4’ 2.25 3.98 S 2.00 1.00
191 C1-H2” C1-H4’ 2.08 3.98 S 2.00 1.00
192 T2-H2” T2-H4’ 2.15 4.13 S 2.00 1.00
193 C3-H2” C3-H4’ 2.12 4.18 M 3.50 2.00
194 A4-H2” A4-H4’ 2.60 3.64 M 3.50 2.00
195 T5-H2” T5-H4’ 1.76 3.56 M 3.50 2.00
196 C6-H2” C6-H4’ 1.64 3.04 M 3.50 2.00
197 A7-H2” A7-H4’ 2.42 3.62 M 3.50 2.00
198 C8-H2” C8-H4’ 1.97 4.04 M 3.50 2.00
199 G9-H2” G9-H4’ 2.47 4.13 M 3.50 2.00
200 T10-H2” T10-H4’ 2.22 4.13 S 2.00 1.00
201 G11-H2” G11-H4’ 2.60 4.35 M 3.50 2.00
202 A12-H2” A12-H4’ 2.44 3.86 S 2.00 1.00
203 T13-H2” T13-H4’ 2.10 3.30 W 4.50 3.50
204 G14-H2” G14-H4’ 2.45 4.05 M/S 3.00 1.00
205 A15-H2” A15-H4* 2.44 4.05 M 3.50 2.00
206 G16-H2” G16-H4’ 2.08 3.98 M 3.50 2.00
207 T2-CH3 C1-H6 1.58 7.76 S 2.00 1.00
208 T2-CH3 T2-H6 1.58 7.52 S 2.00 1.00
209 T2-CH3 C1-H5 1.58 5.84 M 3.50 2.00
210 T2-CH3 C l-H l’ 1.58 5.80 W 4.50 3.50
211 T2-CH3 C3-H5 1.58 5.65 M 3.50 2.00
212 T2-CH3 T2-H3’ 1.58 4.79 VW 5.00 4.00
213 T2-CH3 C1-H3’ 1.58 4.55 s 2.00 1.00
214 T2-CH3 T2-H4’ 1.58 4.13 w 4.50 3.50
215 T2-CH3 C1-H4’ 1.58 3.98 w 4.50 3.50
216 T2-CH3 T2-H2” 1.58 2.15 M 3.50 2.00
217 T2-CH3 C1-H2” 1.58 2.08 M 3.50 2.00
218 T2-CH3 T2-H2’ 1.58 2.44 M 3.50 2.00
219 T2-CH3 C1-H2’ 1.58 2.44 M 3.50 2.00
220 T10-CH3 G9-H8 1.39 7.83 M 3.50 2.00
221 T10-CH3 T10>H6 1.39 7.30 s 2.00 1.00
222 T10-CH3 G9-H1’ 1.39 5.94 M 3.50 2.00
223 T10-CH3 G9-H2* 1.39 2.72 S 2.00 1.00
224 T10-CH3 G9-H2” 1.39 2.47 S 2.00 1.00
225 T10-CH3 T10-H2’ 1.39 2.42 M 3.50 2.00
226 T13-CH3 A12-H8 1.26 8.14 S 2.00 1.00
227 T13-CH3 T13-H6 1.26 7.01 s 2.00 1.00
228 T13-CH3 A12-H1’ 1.26 6.24 M 3.50 2.00
229 T13-CH3 T13-H1’ 1.26 5.40 W 4.50 3.50
230 T13-CH3 A12-H3" 1.26 4.86 M 3.50 2.00
231 T13-CH3 A12-H2’ 1.26 2.55 S 2.00 1.00






































T13-CH3 T13-H2’ 1.26 2.15 M/W 4.00 3.00
T13-CH3 T13-H2” 1.26 2 .1 0 M/W 4.00 3.00
T5-CH3 A4-H8 1.15 8.32 2 .0 0 1 .0 0
T5-CH3 T5-H6 1.15 6.89 2 .0 0 1.00
T5-CH3 A4-H1’ 1.15 6.29 M 3.50 2 .0 0
T5-CH3 T5-H1’ 1.15 5.55 W 4.50 3.50
T5-CH3 C6-H5 1.15 5.25 M/W 4.00 3.00
T5-CH3 A4-H3’ 1.15 4.89 M 3.50 2.00
T5-CH3 A4-H2’ 1.15 2.75 2.00 1.00
T5-CH3 A4-H2” 1.15 2.60 2.00 1.00
T5-CH3 T5-H2’ 1.15 2.18 W 4.50 3.50
A4-H2 A4-H1’ 7.73 6.29 VW 5.00 4.00
A4-H2 T13-H1’ 7.73 5.40 M 3.50 2.00
A7-H2 A7-H1’ 7.61 5.88 M 3.50 2.00
A7-H2 T10-H1’ 7.61 5.44 W 4.50 3.50
A12-H2 A12-H1’ 8.02 6.24 W 4.50 3.50
A12-H2 T5-H1’ 8.02 5.55 M 3.50 2.00
A12-H2 C6-H1 ’ 8.02 5.61 M 3.50 2.00
A12-H2 T13-H1’ 8.02 5.40 W 4.50 3.50
A15-H2 A15-H1’ 7.71 5.77 M/W 4.00 3.00
A12-H2 T2-H1’ 8.02 5.93 W 4.50 3.50
A15-H2 C3-H1’ 7.71 5.99 W 4.50 3.50
T2-H4’ C l-H l’ 4.13 6.29 M 3.50 2.00
C3-H4’ T2-H1’ 4.18 5.55 M 3.50 2.00
A4-H4’ C3-H1’ 3.64 5.61 2.00 1.00
T5-H4’ A4-H1’ 3.56 5.88 M 3.50 2.00
C6-H4’ T5-H1’ 3.04 5.97 M 3.50 2.00
A7-H4’ C6-H1’ 3.62 5.94 M 3.50 2.00
C8-H4’ A7-H1’ 4.04 5.44 M 3.50 2.00
T10-H4’ G9-H1’ 4.13 6.08 2.00 1.00
G11-H4’ T10-H1’ 4.35 6.24 M/W 4.00 3.00
A12-H4’ G ll-H l’ 3.86 5.40 M 3.50 2.00
T13-H4’ A12-H1’ 3.30 5.94 M 3.50 2.00
G14-H4’ T13-H1’ 4.05 5.77 M 3.50 2.00
A15-H4’ G14-H1’ 4.05 5.92 2.00 1.00
G16-H4’ A15-H1’ 3.98 5.77 2.00 1.00
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1 H la’ A7-H2 3.22 7.61 S 2.00 1.00
2 H la’ A7-H1’ 3.22 5.88 M 3.50 2.00
3 H la’ A12-H4’ 3.22 3.86 M 3.50 2.00
4 H lb’ C8-H1’ 2.64 5.97 M 3.50 2.00
5 H lb’ A7-H1’ 2.64 5.88 M 3.50 2.00
6 H lb’ A12-H4’ 2.64 3.86 M 3.50 2.00
7 H lb’ A7-H2 2.64 7.61 M 3.50 2.00
8 H2a’ C8-H1’ 5.24 5.97 W 4.50 3.50
9 H2a’ A7-H2 5.24 7.61 W 4.50 3.50
10 H2a’ G ll-H l’ 5.24 6.08 S 2.00 1.00
11 H2a’ G11-H4’ 5.24 4.35 M 3.50 2.00
12 H2a’ A12-H4’ 5.24 3.86 W 4.50 3.50
13 H2b’ A7-H2 5.22 7.61 W 4.50 3.50
14 H2b’ G ll-H l’ 5.22 6.08 s 2.00 1.00
15 H2b’ G11-H4’ 5.22 4.35 M 3.50 2.00
16 H2b’ A12-H4’ 5.22 3.86 M 3.50 2.00
17 H3a’ A7-H1’ 4.09/4.14 5.88 W 4.50 3.50
18 H3b’ A7-H1’ 4.09/4.14 5.88 W 4.50 3.50
19 H6’ A7-H4’ 7.06 3.62 M 3.50 2.00
20 H6’ T13-H4’ 7.06 3.30 W 4.50 3.50
21 H9’ C6-H1’ 6.58 5.61 M 3.50 2.00
22 H9’ A12-H2 6.58 8.02 S 2.00 1.00
23 H9’ A12-H1’ 6.58 6.24 M/W 4.00 3.00
24 H9’ T13-H1’ 6.58 5.40 M/W 4.00 3.00
25 H9’ T13-H4’ 6.58 3.30 VW 5.00 4.00
26 H ll’ A7-H2 5.76 7.61 W 4.50 3.50
27 H ll’ A7-H4’ 5.76 3.62 v w 5.00 4.00
28 HI la ’ C6-H1’ 3.91 5.61 M/S 3.00 1.00
29 HI la ’ A7-H2 3.91 7.61 M 3.50 2.00
30 HI la ’ A7-H1’ 3.91 5.88 S 2.00 1.00
31 H12a’ C6-H1’ 4.20 5.61 M/S 3.00 1.00
32 H12a’ A12-H2 4.20 8.02 M/W 4.00 3.00
33 HI 2a’ T13-H1’ 4.20 5.40 M 3.50 2.00
34 HI 2b’ A4-H2 4.30 7.73 VW 5.00 4.00
35 HI 2b’ C6-H1’ 4.30 5.61 M/S 3.00 1.00
36 HI 2b’ A12-H2 4.30 8.02 M/W 4.00 3.00
37 H12b’ T13-H1’ 4.30 5.40 M 3.50 2.00
38 H13a/b’ A12-H2 2.30/2.07 8.02 M 3.50 2.00
39 H13a/b’ T13-H4’ 2.30/2.07 3.30 W 4.50 3.50
40 H13a/b’ G14-H4’ 2.30/2.07 4.05 M/S 3.00 1.00






















































































































































































































1 C1-H6 G2-H8 7.40 7.76 W 4.50 3.50
2 G2-H8 A3-H8 7.76 8.11 W 4.50 3.50
3 A3-H8 T4-H6 8.11 7.05 W 4.50 3.50
4 T4-H6 T5-H6 7.05 7.29 W 4.50 3.50
5 T5-H6 A6-H8 7.29 8.22 W 4.50 3.50
6 A6-H8 A7-H8 8.22 7.81 W 4.50 3.50
7 A7-H8 T8-H6 7.81 6.51 W 4.50 3.50
8 T8-H6 C9-H6 6.51 7.96 M/W 4.00 3.00
9 C9-H6 G10-H8 7.96 7.56 W 4.50 3.50
10 C1-H6 C l-H l’ 7.40 5.99 w 4.50 3.50
11 G2-H8 G2-H1’ 7.76 5.29 M 3.50 2.00
12 A3-H8 A3-H1’ 8.11 6.13 M 3.50 2.00
13 T4-H6 T4-H1’ 7.05 5.79 M/W 4.00 3.00
14 T5-H6 T5-H1’ 7.29 5.34 M/W 4.00 3.00
15 A6-H8 A 6-H r 8.22 5.90 W 4.50 3.50
16 A7-H8 A7-H1’ 7.81 5.78 w 4.50 3.50
17 T8-H6 T8-H1’ 6.51 5.18 vw 5.00 4.00
18 C9-H6 C9-H1’ 7.96 5.38 w 4.50 3.50
19 G10-H8 G10-H1’ 7.56 5.73 M 3.50 2.00
20 G2-H8 C l-H l’ 7.76 5.99 M/S 3.00 1.00
21 A3-H8 G2-H1 ’ 8.11 5.29 M 3.50 2.00
22 T4-H6 A3-H1’ 7.05 6.13 M 3.50 2.00
23 T5-H6 T4-H1’ 7.29 5.79 M/W 4.00 3.00
24 A6-H8 T5-H1’ 8.22 5.34 M/W 4.00 3.00
25 A7-H8 A6-H1’ 7.81 5.90 M/W 4.00 3.00
26 T8-H6 A7-H1’ 6.51 5.78 W 4.50 3.50
27 C9-H6 T8-H1’ 7.96 5.18 M 3.50 2.00
28 G10-H8 C9-H1 ’ 7.56 5.38 W 4.50 3.50
29 C1-H6 C1-H3’ 7.40 4.51 M 3.50 2.00
30 G2-H8 G2-H3’ 7.76 4.14 W 4.50 3.50
31 A3-H8 A3-H3’ 8.11 4.89 M/W 4.00 3.00
32 T4-H6 T4-H3’ 7.05 4.03 W 4.50 3.50
33 T5-H6 T5-H3’ 7.29 4.21 w 4.50 3.50
34 A6-H8 A6-H3’ 8.22 4.85 w 4.50 3.50
35 A7-H8 A7-H3’ 7.81 4.40 M/W 4.00 3.00
36 T8-H6 T8-H3’ 6.51 4.21 w 4.50 3.50
37 C9-H6 C9-H3’ 7.96 4.29 w 4.50 3.50
38 G10-H8 G10-H3’ 7.56 4.34 M 3.50 2.00
39 G2-H8 C1-H3’ 7.76 4.51 M 3.50 2.00
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40 A3-H8 G2-H3’ 8.11 4.14 W 4.50 3.50
41 T4-H6 A3-H3’ 7.05 4.89 W 4.50 3.50
42 T5-H6 T4-H3’ 7.29 4.03 M 3.50 2.00
43 A6-H8 T5-H3’ 8.22 4.21 W 4.50 3.50
44 A7-H8 A6-H3’ 7.81 4.85 W 4.50 3.50
45 T8-H6 A7-H3’ 6.51 4.40 VW 5.00 4.00
46 C9-H6 T8-H3’ 7.96 4.21 W 4.50 3.50
47 G10-H8 C9-H3’ 7.56 4.29 W 4.50 3.50
48 C1-H6 G2-H4’ 7.40 3.04 M 3.50 2.00
49 G2-H8 A3-H4’ 7.76 3.90 M/W 4.00 3.00
50 A3-H8 A3-H4’ 8.11 3.90 M/W 4.00 3.00
51 T4-H6 T4-H4’ 7.05 3.49 M 3.50 2.00
52 T5-H6 T5-H4’ 7.29 3.31 W 4.50 3.50
53 A6-H8 A6-H4’ 8.22 3.76 W 4.50 3.50
54 A7-H8 A7-H4’ 7.81 3.00 M/W 4.00 3.00
55 T8-H6 T8-H4’ 6.51 4.00 VW 5.00 4.00
56 C9-H6 C9-H4’ 7.96 3.80 M/W 4.00 3.00
57 G10-H8 G10-H4’ 7.56 3.51 w 4.50 3.50
58 C1-H6 C1-H2’ 7.40 2.19 M 3.50 2.00
59 G2-H8 G2-H2’ 7.76 2.55 S 2.00 1.00
60 A3-H8 A3-H2’ 8.11 2.57 S 2.00 1.00
61 T4-H6 T4-H2’ 7.05 1.77 M/S 3.00 1.00
62 T5-H6 T5-H2’ 7.29 2.79 M/S 3.00 1.00
63 A6-H8 A6-H2’ 8.22 2.53 M/S 3.00 1.00
64 A7-H8 A7-H2’ 7.81 2.79 M/S 3.00 1.00
65 T8-H6 T8-H2’ 6.51 1.34 W 4.50 3.50
66 C9-H6 C9-H2’ 7.96 1.49 M 3.50 2.00
67 G10-H8 G10-H2’ 7.56 2.07 S 2.00 1.00
68 C1-H6 C1-H2” 7.40 2.42 s 2.00 1.00
69 G2-H8 G2-H2” 7.76 2.64 s 2.00 1.00
70 A3-H8 A3-H2” 8.11 2.78 s 2.00 1.00
71 T4-H6 T4-H2” 7.05 2.34 s 2.00 1.00
72 T5-H6 T5-H2” 7.29 2.41 M 3.50 2.00
73 A6-H8 A6-H2” 8.22 2.66 M 3.50 2.00
74 A7-H8 A7-H2” 7.81 2.41 M/S 3.00 1.00
75 T8-H6 T8-H2” 6.51 1.84 M/W 4.00 3.00
76 C9-H6 C9-H2” 7.96 1.89 M 3.50 2.00
77 G10-H8 G10-H2” 7.56 2.31 M/S 3.00 1.00
78 G2-H8 C1-H2* 7.76 2.19 S 2.00 1.00
79 A3-H8 G2-H2’ 8.11 2.55 s 2.00 1.00
80 T4-H6 A3-H2’ 7.05 2.57 M/S 3.00 1.00
81 T5-H6 T4-H2’ 7.29 1.77 M 3.50 2.00
82 A6-H8 T5-H2’ 8.22 2.79 M 3.50 2.00
83 A7-H8 A6-H2’ 7.81 2.53 S 2.00 1.00
84 T8-H6 A7-H2’ 6.51 2.79 M/W 4.00 3.00
85 C9-H6 T8-H2’ 7.96 1.34 M/S 3.00 1.00
86 G10-H8 C9-H2’ 7.56 1.49 M 3.50 2.00
87 G2-H8 C1-H2” 7.76 2.42 S 2.00 1.00
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88 A3-H8 G2-H2” 8.11 2.64 S 2.00 1.00
89 T4-H6 A3-H2” 7.05 2.78 M/S 3.00 1.00
90 T5-H6 T4-H2” 7.29 2.34 M 3.50 2.00
91 A 6-H8 T5-H2” 8.22 2.41 M 3.50 2.00
92 A7-H8 A6-H2” 7.81 2.66 S 2.00 1.00
93 T8-H6 A7-H2” 6.51 2.41 W 4.50 3.50
94 C9-H6 T8-H2” 7.96 1.84 M/S 3.00 1.00
95 G10-H8 C9-H2” 7.56 1.89 M/W 4.00 3.00
96 C l-H l’ C1-H3’ 7.76 7.40 M 3.50 2.00
97 G2-H1’ G2-H3’ 8.11 7.76 M 3.50 2.00
98 A3-H1’ A3-H3’ 7.05 8.11 W 4.50 3.50
99 T4-H1’ T4-H3’ 7.29 7.05 M/W 4.00 3.00
100 T5-H1’ T5-H3’ 8.22 7.29 M 3.50 2.00
101 A6-H1’ A6-H3’ 7.81 8.22 M 3.50 2.00
102 A7-H1’ A7-H3’ 6.51 7.81 M/W 4.00 3.00
103 T8-H1’ T8-H3’ 7.96 6.51 W 4.50 3.50
104 C9-H1’ C9-H3’ 7.56 7.96 w 4.50 3.50
105 G10-HV G10-H3’ 5.73 7.56 M 3.50 2.00
106 C l-H l’ C1-H4’ 7.76 3.80 M 3.50 2.00
107 G2-H1’ G2-H4’ 8.11 3.04 M 3.50 2.00
108 A3-H1’ A3-H4’ 7.05 3.90 M 3.50 2.00
109 T4-H1’ T4-H4’ 7.29 3.90 M/W 4.00 3.00
110 T5-H1’ T5-H4’ 8.22 3.49 M 3.50 2.00
111 A6-H1’ A6-H4’ 7.81 3.31 M 3.50 2.00
112 A7-H1* A7-H4’ 6.51 3.76 M 3.50 2.00
113 C9-H1’ C9-H4’ 7.56 4.00 M 3.50 2.00
114 G10-H1’ G10-H4’ 5.73 3.51 M/S 3.00 1.00
115 C1-H3’ C1-H4’ 7.40 3.80 M 3.50 2.00
116 G2-H3’ G2-H4’ 7.76 3.04 M 3.50 2.00
117 A3-H3’ A3-H4’ 8.11 3.90 M 3.50 2.00
118 T4-H3’ T4-H4’ 7.05 3.90 M 3.50 2.00
119 T5-H3’ T5-H4’ 7.29 3.49 M 3.50 2.00
120 A6-H3’ A6-H4’ 8.22 3.31 M 3.50 2.00
121 A7-H3’ A7-H4’ 7.81 3.76 M 3.50 2.00
122 T8-H3’ T8-H4’ 6.51 3.00 M 3.50 2.00
123 C9-H3’ C9-H4’ 7.96 4.00 W 4.50 3.50
124 G10-H3’ G10-H4’ 7.56 3.51 M/S 3.00 1.00
125 C1-H2’ C1-H3’ 2.19 7.40 W 4.50 3.50
126 G2-H2’ G2-H3’ 2.55 7.76 M 3.50 2.00
127 A3-H2’ A3-H3’ 2.57 8.11 M 3.50 2.00
128 T4-H2’ T4-H3’ 1.77 7.05 M 3.50 2.00
129 A6-H2’ A6-H3’ 2.53 8.22 M 3.50 2.00
130 A7-H2’ A7-H3’ 2.79 7.81 W 4.50 3.50
131 T8-H2’ T8-H3’ 1.34 6.51 M 3.50 2.00
132 C9-H2’ C9-H3’ 1.49 7.96 M 3.50 2.00
133 G10-H2’ G10-H3’ 2.07 7.56 M 3.50 2.00
134 C1-H2” C1-H3’ 2.42 7.40 M 3.50 2.00
135 G2-H2” G2-H3’ 2.64 7.76 M 3.50 2.00
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136 A3-H2” A3-H3’ 2.78 8.11 M 3.50 2.00
137 T4-H2” T4-H3’ 2.34 7.05 M 3.50 2.00
138 T5-H2” T5-H3’ 2.41 7.29 W 450 3.50
139 A6-H2” A6-H3’ 2.66 8.22 M 3.50 2.00
A7-H2” A7-H3’ 2.41 7.81 W 4.50 3.50
141 T8-H2” T8-H3’ 1.84 6.51 M 3.50 2.00
142 C9-H2” C9-H3’ 1.89 7.96 M 3.50 2.00
143 G10-H2” G10-H3’ 2.31 7.56 M 3.50 2.00
144 C1-H2’ C1-H4’ 2.19 3.80 M 3.50 2.00
145 G2-H2’ G2-H4’ 2.55 3.04 M 3.50 2.00
146 A3-H2’ A3-H4’ 2.57 3.90 M/W 4.00 3.00
147 T4-H2’ T4-H4’ 1.77 3.90 W 4.50 3.50
148 T5-H2’ T5-H4’ 2.79 3.49 M/W 4.00 3.00
149 A6-H2’ A6-H4’ 2.53 3.31 M/W 4.00 3.00
150 A7-H2’ A7-H4* 2.79 3.76 M/W 4.00 3.00
151 T8-H2’ T8-H4’ 1.34 3.00 W 4.50 3.50
152 C9-H2’ C9-H4’ 1.49 4.00 M/W 4.00 3.00
153 G10-H2’ G10-H4’ 2.07 3.51 M 3.50 2.00
154 C1-H2” C1-H4’ 2.42 3.80 M 3.50 2.00
155 G2-H2” G2-H4* 2.64 3.04 M 3.50 2.00
156 A3-H2” A3-H4’ 2.78 3.90 M/W 4.00 3.00
157 T4-H2” T4-H4’ 2.34 3.90 W 4.50 3.50
158 T5-H2” T5-H4’ 2.41 3.49 M/W 4.00 3.00
159 A6-H2” A6-H4’ 2.66 3.31 M/W 4.00 3.00
160 A7-H2” A7-H4’ 2.41 3.76 M/W 4.00 3.00
161 T8-H2” T8-H4’ 1.84 3.00 W 4.50 3.50
162 C9-H2” C9-H4* 1.89 4.00 M/W 4.00 3.00
163 G10-H2” G10-H4’ 2.31 3.51 M 3.50 2.00
164 T8-CH3 A7-H3’ 0.97 4.40 W 4.50 3.50
165 T8-CH3 T8-H1’ 0.97 5.18 v w 5.00 4.00
166 T8-CH3 T8-H6 0.97 6.51 M/S 3.00 1.00
167 T8-CH3 A7-H8 0.97 7.81 M 3.50 2.00
168 T8-CH3 T8-H3’ 0.97 4.21 VW 5.00 4.00
169 T8-CH3 A7-H2’ 0.97 2.09 M 3.50 2.00
170 T8-CH3 A7-H2” 0.97 2.41 M 3.50 2.00
171 T8-CH3 A7-H1’ 0.97 5.78 W 4.50 3.50
172 T4-CH3 T4-H6 7.05 M/S 3.00 1.00
173 T4-CH3 A3-H8 8.11 S 2.00 1.00
174 T4-CH3 T4-H1’ 5.79 w 4.50 3.50
175 T4-CH3 A3-H1’ 6.13 M 3.50 2.00
176 T4-CH3 A3-H3’ 4.89 M 3.50 2.00
177 T4-CH3 A3-H2’ 2.57 S 2.00 1.00
178 T4-CH3 A3-H2” 2.78 S 2.00 1.00
179 T4-CH3 T4-H3’ 4.03 w 4.50 3.50
180 T4-CH3 T4-H2’ 1.77 w 4.50 3.50
181 T4-CH3 T4-H2” 2.34 M 3.50 2.00
182 T5-CH3 T5-H6 1.49 7.29 M/S 3.00 1.00
183 T5-CH3 T4-H6 1.49 7.05 M/S 3.00 1.00
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184 T5-CH3 T4-H1’ 1.49 5.79 M 3.50 2.00
185 T5-CH3 T4-H3’ 1.49 4.03 VW 5.00 4.00
186 T5-CH3 T4-H2’ 1.49 1.77 M/S 3.00 1.00
187 T5-CH3 T4-H2” 1.49 2.34 M 3.50 2.00
188 C1-H5 C1-H6 5.67 7.40 S 2.00 1.00
189 C9-H5 C9-H6 5.18 7.96 S 2.00 1.00
190 A3-H2 A3-H1’ 7.40 6.13 VW 5.00 4.00
191 A7-H2 A7-H1’ 7.82 5.78 w 4.50 3.50
192 A7-H2 T4-H1’ 7.82 5.79 w 4.50 3.50
193 A7-H2 T5-H1’ 7.82 5.34 w 4.50 3.50










1 Ado-H6 Ado-CH3 8.28 2.70 M 3.50 2.00
2 Ado-CH3 Ado-H8A/B 2.70 5.50 M 3.50 2.00
3 Ado-H8A/B Ado-HIA/B 5.50 3.51 W 4.50 3.50
4 Ado-H8A/B Ado-H8A2 5.50 4.20 S 2.00 1.00
5 Ado-H8A2 T4-H1’ 4.20 5.79 M/W 4.00 3.00
6 Ado-H8A2 A3-H2 4.20 7.40 M 3.50 2.00
7 Ado-H8A2 A7-H2 4.20 7.82 M 3.50 2.00
8 Ado-HIA/B A7-H2 3.51 7.82 M 3.50 2.00
9 Ado-HIA/B A3-H2 3.51 7.40 S 2.00 1.00
10 Ado-H5’2 A7-H1’ 7.46 5.78 M 3.50 2.00
11 Ado-H5’2 A6-H8 7.46 8.22 W 4.50 3.50
12 Ado-H5’2 T8-H5’ 7.46 W 4.50 3.50
13 Ado-H5’2 T8-H5” 7.46 W 4.50 3.50
14 Ado-H6’2 A7-H1’ 7.53 5.78 W 4.50 3.50
15 Ado-H6’2 A7-H2 7.53 7.82 M 3.50 2.00
16 Ado-H6’2 T8-H4’ 7.53 4.00 W 4.50 3.50
17 Ado-H6’2 T8-H5’ 7.53 W 4.50 3.50
18 Ado-H3’l T4-H3 7.92 12.80 M/W 4.00 3.00
19 Ado-H3’l T8-H3 7.92 11.02 M/W 4.00 3.00
20 Ado-H3’l A3-H2 7.92 7.40 M 3.50 2.00
21 Ado-H3’l T4-H1’ 7.92 5.79 W 4.50 3.50
22 Ado-H3’l T5-H1’ 7.92 5.34 VW 5.00 4.00
23 Ado-H3 T4-H1’ 8.14 5.79 VW 5.00 4.00
24 Ado-H4’l T5-H3 6.96 9.76 M/W 4.00 3.00
25 Ado-H4’2 T5-H3 7.80 9.76 M/W 4.00 3.00
26 Ado-H4’2 A6-H1’ 7.80 5.90 VW 5.00 4.00
27 Ado-H4’2 T8-H5’ 7.80 vw 5.00 4.00
28 Ado-H4’2 T8-H5” 7.80 vw 5.00 4.00
29 Ado-H7’2 T8-H5’ 8.10 M 3.50 2.00
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30 Ado-H7’2 T8-H5” 8.10 VW 5.00 4.00
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Appendix IV




Proton 1 Proton 2 Shift
1




1 C1-H6 G2-H8 7.41 7.79 W 4.50 3.50
2 G2-H8 A3-H8 7.79 8.15 W 4.50 3.50
3 A3-H8 T4-H6 8.15 6.90 W 4.50 3.50
4 T4-H6 T5-H6 6.90 6.92 W 4.50 3.50
5 T5-H6 A6-H8 6.92 7.80 W 4.50 3.50
6 A6-H8 A7-H8 7.80 8.14 W 4.50 3.50
7 A7-H8 T8-H6 8.14 6.90 W 4.50 3.50
8 T8-H6 C9-H6 6.90 7.29 W 4.50 3.50
9 C9-H6 G10-H8 7.29 7.41 W 4.50 3.50
10 C1-H6 C l-H l’ 7.41 5.51 M 3.50 2.00
11 G2-H8 G2-HF 7.79 5.34 M/W 4.00 3.00
12 A3-H8 A3-H1’ 8.15 5.63 W 4.50 3.50
13 T4-H6 T4-H1’ 6.90 5.58 M/W 4.00 3.00
14 T5-H6 T5-H1’ 6.92 5.58 M/W 4.00 3.00
15 A6-H8 A6-H1’ 7.80 5.39 M 3.50 2.00
16 A7-H8 A7-H1’ 8.14 6.23 M/W 4.00 3.00
17 T8-H6 T8-H1’ 6.90 5.74 M 3.50 2.00
18 C9-H6 C9-H1’ 7.29 5.51 M 3.50 2.00
19 G10-H8 G10-H1’ 7.41 5.68 M 3.50 2.00
20 G2-H8 C l-H l’ 7.79 5.51 M 3.50 2.00
21 A3-H8 G2-H1’ 8.15 5.34 W 4.50 3.50
22 T4-H6 A3-H1’ 6.90 5.63 M/W 4.00 3.00
23 T5-H6 T4-H1’ 6.92 5.58 M 3.50 2.00
24 A6-H8 T5-H1’ 7.80 5.58 M 3.50 2.00
25 A7-H8 A6-H1’ 8.14 5.39 M 3.50 2.00
26 T8-H6 A7-H1’ 6.90 6.23 M 3.50 2.00
27 C9-H6 T8-H1’ 7.29 5.74 M 3.50 2.00
28 G10-H8 C9-H1 ’ 7.41 5.51 M 3.50 2.00
29 C1-H6 C1-H3’ 7.41 4.69 W 4.50 3.50
30 G2-H8 G2-H3’ 7.79 4.23 W 4.50 3.50
31 A3-H8 A3-H3’ 8.15 4.97 W 4.50 3.50
32 T4-H6 T4-H3’ 6.90 4.91 W 4.50 3.50
33 T5-H6 T5-H3’ 6.92 4.28 M 3.50 2.00
34 A6-H8 A6-H3’ 7.80 4.88 W 4.50 3.50
35 A7-H8 A7-H3’ 8.14 4.40 W 4.50 3.50
36 T8-H6 T8-H3’ 6.90 4.09 W 4.50 3.50
37 C9-H6 C9-H3’ 7.29 3.96 M 3.50 2.00
38 G10-H8 G10-H3’ 7.41 4.40 W 4.50 3.50
39 G2-H8 C1-H3’ 7.79 4.69 W 4.50 3.50
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40 A3-H8 G2-H3’ 8.15 4.23 VW 5.00 4.00
41 T4-H6 A3-H3’ 6.90 4.97 W 4.50 3.50
42 T5-H6 T4-H3’ 6.92 4.91 W 4.50 3.50
43 A6-H8 T5-H3’ 7.80 4.28 W 4.50 3.50
44 A7-H8 A6-H3’ 8.14 4.88 W 4.50 3.50
45 C9-H6 T8-H3’ 7.29 4.09 M 3.50 2.00
46 G10-H8 C9-H3’ 7.41 3.96 W 4.50 3.50
47 C1-H6 CI-H4’ 7.41 3.89 M 3.50 2.00
48 A3-H8 A3-H4’ 8.15 3.91 W 4.50 3.50
49 T4-H6 T4-H4’ 6.90 3.50 W 4.50 3.50
50 T5-H6 T5-H4’ 6.92 3.32 VW 5.00 4.00
51 T8-H6 T8-H4’ 6.90 4.01 W 4.50 3.50
52 C9-H6 C9-H4’ 7.29 3.89 M/W 4.00 3.00
53 G10-H8 G10-H4’ 7.41 3.55 W 4.50 3.50
54 C1-H6 C1-H2’ 7.41 1.63 s 2.00 1.00
55 G2-H8 G2-H2’ 7.79 2.60 s 2.00 1.00
56 A3-H8 A3-H2’ 8.15 2.24 s 2.00 1.00
57 T4-H6 T4-H2* 6.90 1.25 M 3.50 2.00
58 T5-H6 T5-H2’ 6.92 1.62 M 3.50 2.00
59 A6-H8 A6-H2’ 7.80 2.57 S 2.00 1.00
60 A7-H8 A7-H2’ 8.14 2.51 S 2.00 1.00
61 T8-H6 T8-H2* 6.90 1.82 S 2.00 1.00
62 C9-H6 C9-H2’ 7.29 1.84 S 2.00 1.00
63 G10-H8 G10-H2’ 7.41 1.68 S 2.00 1.00
64 C1-H6 C1-H2” 7.41 2.22 S 2.00 1.00
65 G2-H8 G2-H2” 7.79 2.70 s 2.00 1.00
66 A3-H8 A3-H2” 8.15 2.62 M 3.50 2.00
67 T4-H6 T4-H2” 6.90 1.40 M 3.50 2.00
68 T5-H6 T5-H2” 6.92 2.08 S 2.00 1.00
69 A6-H8 A6-H2” 7.80 2.70 S 2.00 1.00
70 A7-H8 A7-H2” 8.14 2.59 s 2.00 1.00
71 T8-H6 T8-H2” 6.90 2.12 s 2.00 1.00
72 C9-H6 C9-H2” 7.29 2.22 s 2.00 1.00
73 G10-H8 G10-H2” 7.41 2.09 s 2.00 1.00
74 G2-H8 C1-H2’ 7.79 1.63 s 2.00 1.00
75 A3-H8 G2-H2* 8.15 2.60 s 2.00 1.00
76 T4-H6 A3-H2’ 6.90 2.24 M 3.50 2.00
77 T5-H6 T4-H2’ 6.92 1.25 M 3.50 2.00
78 A6-H8 T5-H2’ 7.80 1.62 M 3.50 2.00
79 A7-H8 A6-H2’ 8.14 2.57 M/S 3.00 1.00
80 T8-H6 A7-H2’ 6.90 2.51 M 3.50 2.00
81 C9-H6 T8-H2’ 7.29 1.82 M 3.50 2.00
82 G10-H8 C9-H2’ 7.41 1.84 M/S 3.00 1.00
83 G2-H8 C1-H2” 7.79 2.22 M 3.50 2.00
84 A3-H8 G2-H2” 8.15 2.70 S 2.00 1.00
85 T4-H6 A3-H2” 6.90 2.62 S 2.00 1.00
86 T5-H6 T4-H2” 6.92 1.40 M 3.50 2.00
87 A6-H8 T5-H2” 7.80 2.08 M 3.50 2.00
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88 A7-H8 A6-H2” 8.14 2.70 S 2.00 1.00
89 T8-H6 A7-H2” 6.90 2.59 M 3.50 2.00
90 C9-H6 T8-H2” 7.29 2.12 S 2.00 1.00
91 G10-H8 C9-H2” 7.41 2.22 M/S 3.00 1.00
92 C l-H l’ C1-H3’ 5.51 4.69 W 4.50 3.50
93 G2-HF G2-H3’ 5.34 4.23 M 3.50 2.00
94 A3-H1’ A3-H3’ 5.63 4.97 W 4.50 3.50
95 T5-H1’ T5-H3’ 5.58 4.28 M/W 4.00 3.00
96 A6-H1’ A6-H3’ 5.39 4.88 W 4.50 3.50
97 A7-H1 ’ A7-H3’ 6.23 4.40 w 4.50 3.50
98 T8-H1’ T8-H3’ 5.74 4.09 M 3.50 2.00
99 C9-H1’ C9-H3’ 5.51 3.96 W 4.50 3.50
100 G10-H1’ G10-H3’ 5.68 4.40 W 4.50 3.50
101 C l-H l’ C1-H4’ 5.51 3.89 M 3.50 2.00
102 A3-H1’ A3-H4’ 5.63 3.91 M 3.50 2.00
103 T4-H1’ T4-H4’ 5.58 3.50 W 4.50 3.50
104 A6-H1’ A6-H4’ 5.39 3.80 M 3.50 2.00
105 A7-H1’ A7-H4’ 6.23 3.32 W 4.50 3.50
106 T8-H1’ T8-H4’ 5.74 4.01 M 3.50 2.00
107 C9-H1’ C9-H4’ 5.51 3.89 M 3.50 2.00
108 G10-H1’ G10-H4’ 5.68 3.55 W 4.50 3.50
109 A3-H3’ A3-H4’ 4.97 3.91 W 4.50 3.50
110 T4-H3’ T4-H4’ 4.91 3.50 W 4.50 3.50
111 T5-H3’ T5-H4’ 4.28 3.32 M 3.50 2.00
112 A6-H3’ A6-H4’ 4.88 3.80 M/W 4.00 3.00
113 A7-H3’ A7-H4’ 4.40 3.32 M/W 4.00 3.00
114 T8-H3’ T8-H4’ 4.09 4.01 M 3.50 2.00
115 C9-H3’ C9-H4’ 3.96 3.89 M 3.50 2.00
116 C1-H2’ C1-H3’ 1.63 4.69 W 4.50 3.50
117 G2-H2’ G2-H3’ 2.60 4.23 M 3.50 2.00
118 A3-H2’ A3-H3’ 2.24 4.97 M 3.50 2.00
119 T4-H2’ T4-H3’ 1.25 4.91 M 3.50 2.00
120 T5-H2’ T5-H3’ 1.62 4.28 M 3.50 2.00
121 A6-H2’ A6-H3’ 2.57 4.88 M 3.50 2.00
122 A7-H2’ A7-H3’ 2.51 4.40 W 4.50 3.50
123 T8-H2’ T8-H3’ 1.82 4.09 W 4.50 3.50
124 C9-H2* C9-H3’ 1.84 3.96 M 3.50 2.00
125 G10-H2’ G10-H3’ 1.68 4.40 M 3.50 2.00
126 C1-H2” C1-H3’ 2.22 4.69 VW 5.00 4.00
127 G2-H2” G2-H3’ 2.70 4.23 M 3.50 2.00
128 A3-H2” A3-H3’ 2.62 4.97 M 3.50 2.00
129 T4-H2” T4-H3’ 1.40 4.91 M 3.50 2.00
130 T5-H2” T5-H3’ 2.08 4.28 M 3.50 2.00
131 A6-H2” A6-H3’ 2.70 4.88 M 3.50 2.00
132 A7-H2” A7-H3’ 2.59 4.40 M 3.50 2.00
133 T8-H2” T8-H3’ 2.12 4.09 M 3.50 2.00
134 C9-H2” C9-H3’ 2.22 3.96 M 3.50 2.00
135 G10-H2” G10-H3’ 2.09 4.40 M 3.50 2.00
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136 C1-H2’ C1-H4’ 1.63 3.89 M 3.50 2.00
137 A3-H2’ A3-H4’ 2.24 3.91 M 3.50 2.00
138 T4-H2’ T4-H4’ 1.25 3.50 W 4.50 3.50
139 T5-H2’ T5-H4’ 1.62 3.32 M 3.50 2.00
140 A6-H2’ A6-H4’ 2.57 3.80 M 3.50 2.00
141 A7-H2’ A7-H4’ 2.51 3.32 W 4.50 3.50
142 T8-H2’ T8-H4’ 1.82 4.01 M 3.50 2.00
143 C9-H2’ C9-H4’ 1.84 3.89 M 3.50 2.00
144 G10-H2’ G10-H4* 1.68 3.55 M 3.50 2.00
145 C1-H2” C1-H4’ 2.22 3.89 M 3.50 2.00
146 A3-H2” A3-H4’ 2.62 3,91 M 3.50 2.00
147 T4-H2” T4-H4’ 1.40 3.50 W 4.50 3.50
148 T5-H2” T5-H4’ 2.08 3.32 W 4.50 3.50
149 A6-H2” A6-H4’ 2.70 3.80 M 3.50 2.00
150 A7-H2” A7-H4’ 2.59 3.32 W 4.50 3.50
151 T 8-H2” T8-H4’ 2.12 4.01 M 3.50 2.00
152 C9-H2” C9-H4’ 2.22 3.89 M 3.50 2.00
153 G10-H2” G10-H4’ 2.09 3.55 M 3.50 2.00
154 T8-CH3 A7-H3’ 1.13 4.40 W 4.50 3.50
155 T8-CH3 T8-H6 1.13 6.90 S 2.00 1.00
156 T8-CH3 A7-H8 1.13 8.14 M/S 3.00 1.00
157 T8-CH3 T8-H2’ 1.13 1.82 W 4.50 3.50
158 T8-CH3 T8-H2” 1.13 2.12 M 3.50 2.00
159 T8-CH3 A7-H2’ 1.13 2.51 S 2.00 1.00
160 T8-CH3 A7-H2” 1.13 2.59 s 2.00 1.00
161 T8-CH3 A 7-H r 1.13 6.23 M 3.50 2.00
162 T4-CH3 T4-H6 1.16 6.90 S 2.00 1.00
163 T4-CH3 A3-H8 1.16 8.15 M/S 3.00 1.00
164 T4-CH3 T4-H1’ 1.16 5.58 W 4.50 3.50
165 T4-CH3 A3-H1 ’ 1.16 5.63 M 3.50 2.00
166 T4-CH3 A3-H3’ 1.16 4.97 W 4.50 3.50
167 T4-CH3 A3-H2’ 1.16 2.24 M/S 3.00 1.00
168 T4-CH3 A3-H2” 1.16 2.62 M/S 3.00 1.00
169 T4-CH3 T4-H3’ 1.16 4.91 W 4.50 3.50
170 T5-CH3 T5-H6 1.32 6.92 s 2.00 1.00
171 T5-CH3 T4-H6 1.32 6.90 s 2.00 1.00
172 T5-CH3 T4-HF 1.32 5.58 M 3.50 2.00
173 T5-CH3 T4-H2’ 1.32 1.25 M 3.50 2.00
174 T5-CH3 T4-H2” 1.32 1.40 M 3.50 2.00
175 C1-H5 C1-H6 5.68 7.41 S 2.00 1.00
176 C9-H5 C9-H6 5.45 7.29 S 2.00 1.00
177 C9-H5 T8-CH3 5.45 1.13 M 3.50 2.00
178 A7-H2 A7-H1’ 7.82 6.23 W 4.50 3.50
179 A7-H2 T5-H1’ 7.82 5.58 W 4.50 3.50
180 A3-H2 T8-H3 7.28 10.13 w 4.50 3.50
181 A3-H2 T4-H3 7.28 11.17 w 4.50 3.50
182 A6-H2 A7-H2 7.43 7.82 M 3.50 2.00
183 A6-H2 T5-H2’ 7.43 1.62 M 3.50 2.00
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1 Ado-H6 Ado-CH3 8.28 2.83 M/S 3.00 1.00
2 Ado-H6 A3-H4’ 8.28 3.91 W 4.50 3.50
3 Ado-CH3 A3-H8 2.83 8.15 VW 5.00 4.00
4 Ado-CH3 Ado-H8A/B 2.83 5.35 M 3.50 2.00
5 Ado-H8A/B Ado-H8A2 5.35 3.90 M 3.50 2.00
6 Ado-H8A/B Ado-HIA/B 5.35 3.89 M 3.50 2.00
7 Ado-H8A2 A3-H1’ 3.90 5.63 W 4.50 3.50
8 Ado-H8A2 A3-H2 3.90 7.28 M 3.50 2.00
9 Ado-HIA/B A3-H2 3.89 7.28 M 3.50 2.00
10 Ado-HIA/B T8-H1’ 3.89 5.74 VW 5.00 4.00
11 Ado-H6’2 Ado-H4’ 1 7.38 7.80 M 3.50 2.00
12 Ado-H5’2 T5-H3 8.16 12.90 W 4.50 3.50
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